

#10/ATTACH

Exp Mail EV347011622US
USAN 10/010,742

10/010742

180

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 July 2001 (19.07.2001)

PCT

(10) International Publication Number
WO 01/51638 A2(51) International Patent Classification⁷: C12N 15/52,
9/00, 15/63, 5/10, A01K 67/027, C12P 21/00, C07K
16/40, C12Q 1/68, A61K 38/43, C12Q 1/00, G01N 33/573

(21) International Application Number: PCT/US01/01174

(22) International Filing Date: 12 January 2001 (12.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/176,139 14 January 2000 (14.01.2000) US
60/177,443 21 January 2000 (21.01.2000) US
60/178,574 28 January 2000 (28.01.2000) US(71) Applicant (for all designated States except US): INCYTE
GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo
Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YANG, Jun-
ming [CN/US]; 7125 Bark Lane, San Jose, CA 95129
(US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago
Road, San Leandro, CA 94577 (US). BURFORD, Neil
[GB/US]; 105 Wildwood Circle, Durham, CT 06422
(US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle
Lane, Brisbane, CA 94005 (US). LU, Dyung, Aina, M.
[US/US]; 233 Coy Drive, San Jose, CA 95123 (US).
REDDY, Roopa [IN/US]; 1233 W. McKinley Avenue #3,
Sunnyvale, CA 94086 (US). RING, Huijun, Z. [US/US];
625 Orange Avenue, Los Altos, CA 94022 (US). HILL-
MAN, Jennifer, L. [US/US]; 230 Monroe Drive #17,
Mountain View, CA 94040 (US). YUE, Henry [US/US];
826 Lois Avenue, Sunnyvale, CA 94087 (US). AZIMZAI,Yalda [US/US]; 5518 Boulder Canyon Drive, Castro
Valley, CA 94552 (US). YAO, Monique, G. [US/US];
111 Frederick Court, Mountain View, CA 94043 (US).
GANDHI, Ameena, R. [US/US]; 837 Roble Avenue #1,
Menlo Park, CA 94025 (US). NGUYEN, Dannel, B.
[US/US]; 1403 Ridgewood Drive, San Jose, CA 95118
(US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court,
San Jose, CA 95118 (US). LAL, Preeti [IN/US]; 2382
Lass Drive, Santa Clara, CA 95054 (US). BANDMAN,
Olga [US/US]; 366 Anna Avenue, Mountain View, CA
94043 (US).(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics,
Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/51638 A2

(54) Title: DRUG METABOLIZING ENZYMES

(57) Abstract: The invention provides human drug metabolizing enzymes (DME) and polynucleotides which identify and encode DME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of DME.

DRUG METABOLIZING ENZYMES

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of drug metabolizing enzymes and to the use of these sequences in the diagnosis, treatment, and prevention of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of drug metabolizing enzymes.

BACKGROUND OF THE INVENTION

The metabolism of a drug and its movement through the body (pharmacokinetics) are important in determining its effects, toxicity, and interactions with other drugs. The three processes governing pharmacokinetics are the absorption of the drug, distribution to various tissues, and elimination of drug metabolites. These processes are intimately coupled to drug metabolism, since a variety of metabolic modifications alter most of the physicochemical and pharmacological properties of drugs, including solubility, binding to receptors, and excretion rates. The metabolic pathways which modify drugs also accept a variety of naturally occurring substrates such as steroids, fatty acids, prostaglandins, leukotrienes, and vitamins. The enzymes in these pathways are therefore important sites of biochemical and pharmacological interaction between natural compounds, drugs, carcinogens, mutagens, and xenobiotics.

It has long been appreciated that inherited differences in drug metabolism lead to drastically different levels of drug efficacy and toxicity among individuals. For drugs with narrow therapeutic indices, or drugs which require bioactivation (such as codeine), these polymorphisms can be critical. Moreover, promising new drugs are frequently eliminated in clinical trials based on toxicities which may only affect a segment of the patient group. Advances in pharmacogenomics research, of which drug metabolizing enzymes constitute an important part, are promising to expand the tools and information that can be brought to bear on questions of drug efficacy and toxicity (See Evans, W. E. and R. V. Relling (1999) *Science* 286:487-491).

Drug metabolic reactions are categorized as Phase I, which functionalize the drug molecule and prepare it for further metabolism, and Phase II, which are conjugative. In general, Phase I reaction products are partially or fully inactive, and Phase II reaction products are the chief excreted species. However, Phase I reaction products are sometimes more active than the original administered drugs; this metabolic activation principle is exploited by pro-drugs (e.g. L-dopa). Additionally, some nontoxic compounds (e.g. aflatoxin, benzo[a]pyrene) are metabolized to toxic

intermediates through these pathways. Phase I reactions are usually rate-limiting in drug metabolism. Prior exposure to the compound, or other compounds, can induce the expression of Phase I enzymes however, and thereby increase substrate flux through the metabolic pathways. (See Klaassen, C. D., Amdur, M. O. and J. Doull (1996) Casarett and Doull's Toxicology: The Basic Science of Poisons, McGraw-Hill, New York, NY, pp. 113-186; B. G. Katzung (1995) Basic and Clinical Pharmacology, Appleton and Lange, Norwalk, CT, pp. 48-59; G. G. Gibson and P. Skett (1994) Introduction to Drug Metabolism, Blackie Academic and Professional, London.)

Drug metabolizing enzymes (DMEs) have broad substrate specificities. This can be contrasted to the immune system, where a large and diverse population of antibodies are highly specific for their antigens. The ability of DMEs to metabolize a wide variety of molecules creates the potential for drug interactions at the level of metabolism. For example, the induction of a DME by one compound may affect the metabolism of another compound by the enzyme.

DMEs have been classified according to the type of reaction they catalyze and the cofactors involved. The major classes of Phase I enzymes include, but are not limited to, cytochrome P450 and flavin-containing monooxygenase. Other enzyme classes involved in Phase I-type catalytic cycles and reactions include, but are not limited to, NADPH cytochrome P450 reductase (CPR), the microsomal cytochrome b5/NADH cytochrome b5 reductase system, the ferredoxin/ferredoxin reductase redox pair, aldo/keto reductases, and alcohol dehydrogenases. The major classes of Phase II enzymes include, but are not limited to, UDP glucuronyltransferase, sulfotransferase, glutathione S-transferase, N-acyltransferase, and N-acetyl transferase.

Cytochrome P450 and P450 catalytic cycle-associated enzymes

Members of the cytochrome P450 superfamily of enzymes catalyze the oxidative metabolism of a variety of substrates, including natural compounds such as steroids, fatty acids, prostaglandins, leukotrienes, and vitamins, as well as drugs, carcinogens, mutagens, and xenobiotics. Cytochromes P450, also known as P450 heme-thiolate proteins, usually act as terminal oxidases in multi-component electron transfer chains, called P450-containing monooxygenase systems. Specific reactions catalyzed include hydroxylation, epoxidation, N-oxidation, sulfoxidation, N-, S-, and O-dealkylations, desulfation, deamination, and reduction of azo, nitro, and N-oxide groups. These reactions are involved in steroidogenesis of glucocorticoids, cortisols, estrogens, and androgens in animals; insecticide resistance in insects; herbicide resistance and flower coloring in plants; and environmental bioremediation by microorganisms. Cytochrome P450 actions on drugs, carcinogens, mutagens, and xenobiotics can result in detoxification or in conversion of the substance to a more toxic product. Cytochromes P450 are abundant in the liver, but also occur in other tissues; the enzymes are located in microsomes. (See ExPASy ENZYME EC 1.14.14.1; Prosite PDOC00081 Cytochrome P450 cysteine heme-iron ligand signature; PRINTS EP450I E-Class P450 Group I

signature; Graham-Lorence, S. and Peterson, J.A. (1996) FASEB J. 10:206-214.)

Four hundred cytochromes P450 have been identified in diverse organisms including bacteria, fungi, plants, and animals (Graham-Lorence, supra). The B-class is found in prokaryotes and fungi, while the E-class is found in bacteria, plants, insects, vertebrates, and mammals. Five subclasses or groups are found within the larger family of E-class cytochromes P450 (PRINTS EP450I E-Class P450 Group I signature).

All cytochromes P450 use a heme cofactor and share structural attributes. Most cytochromes P450 are 400 to 530 amino acids in length. The secondary structure of the enzyme is about 70% alpha-helical and about 22% beta-sheet. The region around the heme-binding site in the C-terminal part of the protein is conserved among cytochromes P450. A ten amino acid signature sequence in this heme-iron ligand region has been identified which includes a conserved cysteine involved in binding the heme iron in the fifth coordination site. In eukaryotic cytochromes P450, a membrane-spanning region is usually found in the first 15-20 amino acids of the protein, generally consisting of approximately 15 hydrophobic residues followed by a positively charged residue. (See Prosite PDOC00081, supra; Graham-Lorence, supra.)

Cytochrome P450 enzymes are involved in cell proliferation and development. The enzymes have roles in chemical mutagenesis and carcinogenesis by metabolizing chemicals to reactive intermediates that form adducts with DNA (Nebert, D.W. and Gonzalez, F.J. (1987) Ann. Rev. Biochem. 56:945-993). These adducts can cause nucleotide changes and DNA rearrangements that lead to oncogenesis. Cytochrome P450 expression in liver and other tissues is induced by xenobiotics such as polycyclic aromatic hydrocarbons, peroxisomal proliferators, phenobarbital, and the glucocorticoid dexamethasone (Dogra, S.C. et al. (1998) Clin. Exp. Pharmacol. Physiol. 25:1-9). A cytochrome P450 protein may participate in eye development as mutations in the P450 gene CYP1B1 cause primary congenital glaucoma (Online Mendelian Inheritance in Man (OMIM) *601771 Cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1; CYP1B1).

Cytochromes P450 are associated with inflammation and infection. Hepatic cytochrome P450 activities are profoundly affected by various infections and inflammatory stimuli, some of which are suppressed and some induced (Morgan, E.T. (1997) Drug Metab. Rev. 29:1129-1188). Effects observed in vivo can be mimicked by proinflammatory cytokines and interferons. Autoantibodies to two cytochrome P450 proteins were found in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), a polyglandular autoimmune syndrome (OMIM *240300 Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy).

Mutations in cytochromes P450 have been linked to metabolic disorders, including congenital adrenal hyperplasia, the most common adrenal disorder of infancy and childhood; pseudovitamin D-deficiency rickets; cerebrotendinous xanthomatosis, a lipid storage disease characterized by

progressive neurologic dysfunction, premature atherosclerosis, and cataracts; and an inherited resistance to the anticoagulant drugs coumarin and warfarin (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, Inc. New York, NY, pp. 1968-1970; Takeyama, K. et al. (1997) *Science* 277:1827-1830; Kitanaka, S. et al. (1998) *N. Engl. J. Med.* 338:653-661; OMIM *213700 Cerebrotendinous xanthomatosis; and OMIM #122700 Coumarin resistance). Extremely high levels of expression of the cytochrome P450 protein aromatase were found in a fibrolamellar hepatocellular carcinoma from a boy with severe gynecomastia (feminization) (Agarwal, V.R. (1998) *J. Clin. Endocrinol. Metab.* 83:1797-1800).

The cytochrome P450 catalytic cycle is completed through reduction of cytochrome P450 by NADPH cytochrome P450 reductase (CPR). Another microsomal electron transport system consisting of cytochrome b5 and NADPH cytochrome b5 reductase has been widely viewed as a minor contributor of electrons to the cytochrome P450 catalytic cycle. However, a recent report by Lamb, D. C. et al. (1999; *FEBS Lett.* 462:283-8) identifies a Candida albicans cytochrome P450 (CYP51) which can be efficiently reduced and supported by the microsomal cytochrome b5/NADPH cytochrome b5 reductase system. Therefore, there are likely many cytochromes P450 which are supported by this alternative electron donor system.

Cytochrome b5 reductase is also responsible for the reduction of oxidized hemoglobin (methemoglobin, or ferrihemoglobin, which is unable to carry oxygen) to the active hemoglobin (ferrohemoglobin) in red blood cells. Methemoglobinemia results when there is a high level of oxidant drugs or an abnormal hemoglobin (hemoglobin M) which is not efficiently reduced. Methemoglobinemia can also result from a hereditary deficiency in red cell cytochrome b5 reductase (Reviewed in Mansour, A. and Lurie, A. A. (1993) *Am. J. Hematol.* 42:7-12).

Members of the cytochrome P450 family are also closely associated with vitamin D synthesis and catabolism. Vitamin D exists as two biologically equivalent prohormones, ergocalciferol (vitamin D₂), produced in plant tissues, and cholecalciferol (vitamin D₃), produced in animal tissues. The latter form, cholecalciferol, is formed upon the exposure of 7-dehydrocholesterol to near ultraviolet light (i.e., 290-310 nm), normally resulting from even minimal periods of skin exposure to sunlight (reviewed in Miller, W.L. and Portale, A.A. (2000) *Trends in Endocrinology and Metabolism* 11:315-319).

Both prohormone forms are further metabolized in the liver to 25-hydroxyvitamin D (25(OH)D) by the enzyme 25-hydroxylase. 25(OH)D is the most abundant precursor form of vitamin D which must be further metabolized in the kidney to the active form, 1 α ,25-dihydroxyvitamin D (1 α ,25(OH)₂D), by the enzyme 25-hydroxyvitamin D 1 α -hydroxylase (1 α -hydroxylase). Regulation of 1 α ,25(OH)₂D production is primarily at this final step in the synthetic pathway. The activity of 1 α -hydroxylase depends upon several physiological factors including the circulating level of the

enzyme product ($1\alpha,25(\text{OH})_2\text{D}$) and the levels of parathyroid hormone (PTH), calcitonin, insulin, calcium, phosphorus, growth hormone, and prolactin. Furthermore, extrarenal 1α -hydroxylase activity has been reported, suggesting that tissue-specific, local regulation of $1\alpha,25(\text{OH})_2\text{D}$ production may also be biologically important. The catalysis of $1\alpha,25(\text{OH})_2\text{D}$ to

- 5 $24,25$ -dihydroxyvitamin D ($24,25(\text{OH})_2\text{D}$), involving the enzyme 25-hydroxyvitamin D 24-hydroxylase (24-hydroxylase), also occurs in the kidney. 24-hydroxylase can also use $25(\text{OH})\text{D}$ as a substrate (Shinki, T. *et al.* (1997) *Proc. Natl. Acad. Sci. U.S.A.* 94:12920-12925; Miller, W.L. and Portale, A.A. *supra*; and references within).

- Vitamin D 25-hydroxylase, 1α -hydroxylase, and 24-hydroxylase are all NADPH-dependent, type I (mitochondrial) cytochrome P450 enzymes that show a high degree of homology with other members of the family. Vitamin D 25-hydroxylase also shows a broad substrate specificity and may also perform 26-hydroxylation of bile acid intermediates and 25, 26, and 27-hydroxylation of cholesterol (Dilworth, F.J. *et al.* (1995) *J. Biol. Chem.* 270:16766-16774; Miller, W.L. and Portale, A.A. *supra*; and references within).

- 15 The active form of vitamin D ($1\alpha,25(\text{OH})_2\text{D}$) is involved in calcium and phosphate homeostasis and promotes the differentiation of myeloid and skin cells. Vitamin D deficiency resulting from deficiencies in the enzymes involved in vitamin D metabolism (e.g., 1α -hydroxylase) causes hypocalcemia, hypophosphatemia, and vitamin D-dependent (sensitive) rickets, a disease characterized by loss of bone density and distinctive clinical features, including bandy or bow leggedness accompanied by a waddling gait. Deficiencies in vitamin D 25-hydroxylase cause cerebrotendinous xanthomatosis, a lipid-storage disease characterized by the deposition of cholesterol and cholestanol in the Achilles' tendons, brain, lungs, and many other tissues. The disease presents with progressive neurologic dysfunction, including postpubescent cerebellar ataxia, atherosclerosis, and cataracts. Vitamin D 25-hydroxylase deficiency does not result in rickets, suggesting the
- 20 existence of alternative pathways for the synthesis of $25(\text{OH})\text{D}$ (Griffin, J.E. and Zerwekh, J.E. (1983) *J. Clin. Invest.* 72:1190-1199; Gamblin, G.T. *et al.* (1985) *J. Clin. Invest.* 75:954-960; and W.L. and Portale, A.A. *supra*).

- Ferredoxin and ferredoxin reductase are electron transport accessory proteins which support at least one human cytochrome P450 species, cytochrome P450c27 encoded by the CYP27 gene (Dilworth, F. J. *et al.* (1996) *Biochem. J.* 320:267-71). A *Streptomyces griseus* cytochrome P450, CYP104D1, was heterologously expressed in *E. coli* and found to be reduced by the endogenous ferredoxin and ferredoxin reductase enzymes (Taylor, M. *et al.* (1999) *Biochem. Biophys. Res. Commun.* 263:838-42), suggesting that many cytochrome P450 species may be supported by the ferredoxin/ferredoxin reductase pair. Ferredoxin reductase has also been found in a model drug
- 35 metabolism system to reduce actinomycin D, an antitumor antibiotic, to a reactive free radical species

(Flitter, W. D. and Mason, R. P. (1988) Arch. Biochem. Biophys. 267:632-9).

Flavin-containing monooxygenase (FMO)

Flavin-containing monooxygenases oxidize the nucleophilic nitrogen, sulfur, and phosphorus heteroatom of an exceptional range of substrates. Like cytochromes P450, FMOs are microsomal and
5 use NADPH and O₂; there is also a great deal of substrate overlap with cytochromes P450. The tissue distribution of FMOs includes liver, kidney, and lung.

There are five different known isoforms of FMO in mammals (FMO1, FMO2, FMO3, FMO4, and FMO5), which are expressed in a tissue-specific manner. The isoforms differ in their substrate specificities and other properties such as inhibition by various compounds and
10 stereospecificity of reaction. FMOs have a 13 amino acid signature sequence, the components of which span the N-terminal two-thirds of the sequences and include the FAD binding region and the FATGY motif which has been found in many N-hydroxylating enzymes (Stehr, M. et al. (1998) Trends Biochem. Sci. 23:56-57; PRINTS FMOXYGENASE Flavin-containing monooxygenase signature).

Specific reactions include oxidation of nucleophilic tertiary amines to N-oxides, secondary amines to hydroxylamines and nitrones, primary amines to hydroxylamines and oximes, and sulfur-containing compounds and phosphines to S- and P-oxides. Hydrazines, iodides, selenides, and boron-containing compounds are also substrates. Although FMOs appear similar to cytochromes P450 in their chemistry, they can generally be distinguished from cytochromes P450 in vitro based on, for
20 example, the higher heat lability of FMOs and the nonionic detergent sensitivity of cytochromes P450; however, use of these properties in identification is complicated by further variation among FMO isoforms with respect to thermal stability and detergent sensitivity.

FMOs play important roles in the metabolism of several drugs and xenobiotics. FMO (FMO3 in liver) is predominantly responsible for metabolizing (S)-nicotine to (S)-nicotine N-1'-
25 oxide, which is excreted in urine. FMO is also involved in S-oxygenation of cimetidine, an H₂-antagonist widely used for the treatment of gastric ulcers. Liver-expressed forms of FMO are not under the same regulatory control as cytochrome P450. In rats, for example, phenobarbital treatment leads to the induction of cytochrome P450, but the repression of FMO1.

Endogenous substrates of FMO include cysteamine, which is oxidized to the disulfide, cystamine, and trimethylamine (TMA), which is metabolized to trimethylamine N-oxide. TMA
30 smells like rotting fish, and mutations in the FMO3 isoform lead to large amounts of the malodorous free amine being excreted in sweat, urine, and breath. These symptoms have led to the designation fish-odor syndrome (OMIM 602079 Trimethylaminuria).


Lysyl oxidase:

35 Lysyl oxidase (lysine 6-oxidase, LO) is a copper-dependent amine oxidase involved in the

formation of connective tissue matrices by crosslinking collagen and elastin. LO is secreted as a N-glycosylated precursor protein of approximately 50 kDa and cleaved to the mature form of the enzyme by a metalloprotease, although the precursor form is also active. The copper atom in LO is involved in the transport of electron to and from oxygen to facilitate the oxidative deamination of lysine residues in these extracellular matrix proteins. While the coordination of copper is essential to LO activity, insufficient dietary intake of copper does not influence the expression of the apoenzyme. However, the absence of the functional LO is linked to the skeletal and vascular tissue disorders that are associated with dietary copper deficiency. LO is also inhibited by a variety of semicarbazides, hydrazines, and amino nitrites, as well as heparin. Beta-aminopropionitrile is a commonly used inhibitor. LO activity is increased in response to ozone, cadmium, and elevated levels of hormones released in response to local tissue trauma, such as transforming growth factor-beta, platelet-derived growth factor, angiotensin II, and fibroblast growth factor. Abnormalities in LO activity have been linked to Menkes syndrome and occipital horn syndrome. Cytosolic forms of the enzyme have been implicated in abnormal cell proliferation (reviewed in Rucker, R.B. et al. (1998) *Am. J. Clin. Nutr.* 67:996S-1002S and Smith-Mungo, L.I. and Kagan, H.M. (1998) *Matrix Biol.* 16:387-398).

Dihydrofolate reductases

Dihydrofolate reductases (DHFR) are ubiquitous enzymes that catalyze the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate, an essential step in the de novo synthesis of glycine and purines as well as the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). The basic reaction is as follows:



The enzymes can be inhibited by a number of dihydrofolate analogs, including trimethoprim and methotrexate. Since an abundance of TMP is required for DNA synthesis, rapidly dividing cells require the activity of DHFR. The replication of DNA viruses (i.e., herpesvirus) also requires high levels of DHFR activity. As a result, drugs that target DHFR have been used for cancer chemotherapy and to inhibit DNA virus replication. (For similar reasons, thymidylate synthetases are also target enzymes.) Drugs that inhibit DHFR are preferentially cytotoxic for rapidly dividing cells (or DNA virus-infected cells) but have no specificity, resulting in the indiscriminate destruction of dividing cells. Furthermore, cancer cells may become resistant to drugs such as methotrexate as a result of acquired transport defects or the duplication of one or more DHFR genes (Stryer, L (1988) Biochemistry. W.H Freeman and Co., Inc. New York. pp. 511-5619).

Aldo/keto reductases

Aldo/keto reductases are monomeric NADPH-dependent oxidoreductases with broad

substrate specificities (Bohren, K. M. et al. (1989) J. Biol. Chem. 264:9547-51). These enzymes catalyze the reduction of carbonyl-containing compounds, including carbonyl-containing sugars and aromatic compounds, to the corresponding alcohols. Therefore, a variety of carbonyl-containing drugs and xenobiotics are likely metabolized by enzymes of this class.

- 5 One known reaction catalyzed by a family member, aldose reductase, is the reduction of glucose to sorbitol, which is then further metabolized to fructose by sorbitol dehydrogenase. Under normal conditions, the reduction of glucose to sorbitol is a minor pathway. In hyperglycemic states, however, the accumulation of sorbitol is implicated in the development of diabetic complications (OMIM *103880 Aldo-keto reductase family 1, member B1). Members of this enzyme family are
10 also highly expressed in some liver cancers (Cao, D. et al. (1998) J. Biol. Chem. 273:11429-35).

Alcohol dehydrogenases

Alcohol dehydrogenases (ADHs) oxidize simple alcohols to the corresponding aldehydes. ADH is a cytosolic enzyme, prefers the cofactor NAD⁺, and also binds zinc ion. Liver contains the highest levels of ADH, with lower levels in kidney, lung, and the gastric mucosa.

- 15 Known ADH isoforms are dimeric proteins composed of 40 kDa subunits. There are five known gene loci which encode these subunits (a, b, g, p, c), and some of the loci have characterized allelic variants (b₁, b₂, b₃, g₁, g₂). The subunits can form homodimers and heterodimers; the subunit composition determines the specific properties of the active enzyme. The holoenzymes have therefore been categorized as Class I (subunit compositions aa, ab, ag, bg, gg), Class II (pp), and
20 Class III (cc). Class I ADH isozymes oxidize ethanol and other small aliphatic alcohols, and are inhibited by pyrazole. Class II isozymes prefer longer chain aliphatic and aromatic alcohols, are unable to oxidize methanol, and are not inhibited by pyrazole. Class III isozymes prefer even longer chain aliphatic alcohols (five carbons and longer) and aromatic alcohols, and are not inhibited by pyrazole.

- 25 The short-chain alcohol dehydrogenases include a number of related enzymes with a variety of substrate specificities. Included in this group are the mammalian enzymes D-beta-hydroxybutyrate dehydrogenase, (R)-3-hydroxybutyrate dehydrogenase, 15-hydroxyprostaglandin dehydrogenase, NADPH-dependent carbonyl reductase, corticosteroid 11-beta-dehydrogenase, and estradiol 17-beta-dehydrogenase, as well as the bacterial enzymes acetoacetyl-CoA reductase, glucose 1-
30 dehydrogenase, 3-beta-hydroxysteroid dehydrogenase, 20-beta-hydroxysteroid dehydrogenase, ribitol dehydrogenase, 3-oxoacyl reductase, 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase, sorbitol-6-phosphate 2-dehydrogenase, 7-alpha-hydroxysteroid dehydrogenase, cis-1,2-dihydroxy-3,4-cyclohexadiene-1-carboxylate dehydrogenase, cis-toluene dihydrodiol dehydrogenase, cis-benzene glycol dehydrogenase, biphenyl-2,3-dihydro-2,3-diol dehydrogenase, N-acylmannosamine 1-
35 dehydrogenase, and 2-deoxy-D-gluconate 3-dehydrogenase (Krozowski, Z. (1994) J. Steroid

Biochem. Mol. Biol. 51:125-130; Krozowski, Z. (1992) Mol. Cell Endocrinol. 84:C25-31; and Marks, A.R. et al. (1992) J. Biol. Chem. 267:15459-15463).

UDP glucuronyltransferase

Members of the UDP glucuronyltransferase family (UGTs) catalyze the transfer of a
5 glucuronic acid group from the cofactor uridine diphosphate-glucuronic acid (UDP-glucuronic acid) to a substrate. The transfer is generally to a nucleophilic heteroatom (O, N, or S). Substrates include xenobiotics which have been functionalized by Phase I reactions, as well as endogenous compounds such as bilirubin, steroid hormones, and thyroid hormones. Products of glucuronidation are excreted in urine if the molecular weight of the substrate is less than about 250 g/mol, whereas larger
10 glucuronidated substrates are excreted in bile.

UGTs are located in the microsomes of liver, kidney, intestine, skin, brain, spleen, and nasal mucosa, where they are on the same side of the endoplasmic reticulum membrane as cytochrome P450 enzymes and flavin-containing monooxygenases, and therefore are ideally located to access products of Phase I drug metabolism. UGTs have a C-terminal membrane-spanning domain which
15 anchors them in the endoplasmic reticulum membrane, and a conserved signature domain of about 50 amino acid residues in their C terminal section (Prosite PDOC00359 UDP-glycosyltransferase signature).

UGTs involved in drug metabolism are encoded by two gene families, UGT1 and UGT2. Members of the UGT1 family result from alternative splicing of a single gene locus, which has a
20 variable substrate binding domain and constant region involved in cofactor binding and membrane insertion. Members of the UGT2 family are encoded by separate gene loci, and are divided into two families, UGT2A and UGT2B. The 2A subfamily is expressed in olfactory epithelium, and the 2B subfamily is expressed in liver microsomes. Mutations in UGT genes are associated with hyperbilirubinemia (OMIM #143500 Hyperbilirubinemia I); Crigler-Najjar syndrome, characterized
25 by intense hyperbilirubinemia from birth (OMIM #218800 Crigler-Najjar syndrome); and a milder form of hyperbilirubinemia termed Gilbert's disease (OMIM *191740 UGT1).

Sulfotransferase

Sulfate conjugation occurs on many of the same substrates which undergo O-glucuronidation to produce a highly water-soluble sulfuric acid ester. Sulfotransferases (ST) catalyze this reaction by
30 transferring SO_3^- from the cofactor 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to the substrate. ST substrates are predominantly phenols and aliphatic alcohols, but also include aromatic amines and aliphatic amines, which are conjugated to produce the corresponding sulfamates. The products of these reactions are excreted mainly in urine.

STs are found in a wide range of tissues, including liver, kidney, intestinal tract, lung,
35 platelets, and brain. The enzymes are generally cytosolic, and multiple forms are often co-expressed.

For example, there are more than a dozen forms of ST in rat liver cytosol. These biochemically characterized STs fall into five classes based on their substrate preference: arylsulfotransferase, alcohol sulfotransferase, estrogen sulfotransferase, tyrosine ester sulfotransferase, and bile salt sulfotransferase.

5 ST enzyme activity varies greatly with sex and age in rats. The combined effects of developmental cues and sex-related hormones are thought to lead to these differences in ST expression profiles, as well as the profiles of other DMEs such as cytochromes P450. Notably, the high expression of STs in cats partially compensates for their low level of UDP glucuronyltransferase activity.

10 Several forms of ST have been purified from human liver cytosol and cloned. There are two phenol sulfotransferases with different thermal stabilities and substrate preferences. The thermostable enzyme catalyzes the sulfation of phenols such as para-nitrophenol, minoxidil, and acetaminophen; the thermolabile enzyme prefers monoamine substrates such as dopamine, epinephrine, and levodopa. Other cloned STs include an estrogen sulfotransferase and an N-
15 acetylglucosamine-6-O-sulfotransferase. This last enzyme is illustrative of the other major role of STs in cellular biochemistry, the modification of carbohydrate structures that may be important in cellular differentiation and maturation of proteoglycans. Indeed, an inherited defect in a sulfotransferase has been implicated in macular corneal dystrophy, a disorder characterized by a failure to synthesize mature keratan sulfate proteoglycans (Nakazawa, K. et al. (1984) J. Biol. Chem.
20 259:13751-7; OMIM *217800 Macular dystrophy, corneal).

Galactosyltransferases

Galactosyltransferases are a subset of glycosyltransferases that transfer galactose (Gal) to the terminal N-acetylglucosamine (GlcNAc) oligosaccharide chains that are part of glycoproteins or glycolipids that are free in solution (Kolbinger, F. et al. (1998) J. Biol. Chem. 273:433-440; Amado,
25 M. et al. (1999) Biochim. Biophys. Acta 1473:35-53). Galactosyltransferases have been detected on the cell surface and as soluble extracellular proteins, in addition to being present in the Golgi. β 1,3-galactosyltransferases form Type I carbohydrate chains with Gal (β 1-3)GlcNAc linkages. Known human and mouse β 1,3-galactosyltransferases appear to have a short cytosolic domain, a single transmembrane domain, and a catalytic domain with eight conserved regions. (Kolbinger, F. supra
30 and Hennet, T. et al. (1998) J. Biol. Chem. 273:58-65). In mouse UDP-galactose: β -N-acetylglucosamine β 1,3-galactosyltransferase-I region 1 is located at amino acid residues 78-83, region 2 is located at amino acid residues 93-102, region 3 is located at amino acid residues 116-119, region 4 is located at amino acid residues 147-158, region 5 is located at amino acid residues 172-183, region 6 is located at amino acid residues 203-206, region 7 is located at amino acid residues
35 236-246, and region 8 is located at amino acid residues 264-275. A variant of a sequence found

within mouse UDP-galactose:β-N-acetylglucosamine β1,3-galactosyltransferase-I region 8 is also found in bacterial galactosyltransferases, suggesting that this sequence defines a galactosyltransferase sequence motif (Hennet, T. supra). Recent work suggests that brainiac protein is a β1,3-galactosyltransferase. (Yuan, Y. et al. (1997) Cell 88:9-11; and Hennet, T. supra).

- 5 UDP-Gal:GlcNAc-1,4-galactosyltransferase (-1,4-GalT) (Sato, T. et al., (1997) EMBO J. 16:1850-1857) catalyzes the formation of Type II carbohydrate chains with Gal (β1-4)GlcNAc linkages. As is the case with the β1,3-galactosyltransferase, a soluble form of the enzyme is formed by cleavage of the membrane-bound form. Amino acids conserved among β1,4-galactosyltransferases include two cysteines linked through a disulfide-bonded and a putative UDP-galactose-binding site in the catalytic domain (Yadav, S. and Brew, K. (1990) J. Biol. Chem. 265:14163-14169; Yadav, S.P. and Brew, K. (1991) J. Biol. Chem. 266:698-703; and Shaper, N.L. et al. (1997) J. Biol. Chem. 272:31389-31399). β1,4-galactosyltransferases have several specialized roles in addition to synthesizing carbohydrate chains on glycoproteins or glycolipids. In mammals a β1,4-galactosyltransferase, as part of a heterodimer with α-lactalbumin, functions in lactating
- 10 mammary gland lactose production. A β1,4-galactosyltransferase on the surface of sperm functions as a receptor that specifically recognizes the egg. Cell surface β1,4-galactosyltransferases also function in cell adhesion, cell/basal lamina interaction, and normal and metastatic cell migration. (Shur, B. (1993) Curr. Opin. Cell Biol. 5:854-863; and Shaper, J. (1995) Adv. Exp. Med. Biol. 376:95-104).

20 Glutathione S-transferase

- The basic reaction catalyzed by glutathione S-transferases (GST) is the conjugation of an electrophile with reduced glutathione (GSH). GSTs are homodimeric or heterodimeric proteins localized mainly in the cytosol, but some level of activity is present in microsomes as well. The major isozymes share common structural and catalytic properties; in humans they have been
- 25 classified into four major classes, Alpha, Mu, Pi, and Theta. The two largest classes, Alpha and Mu, are identified by their respective protein isoelectric points; pI ~ 7.5-9.0 (Alpha), and pI ~ 6.6 (Mu). Each GST possesses a common binding site for GSH and a variable hydrophobic binding site. The hydrophobic binding site in each isozyme is specific for particular electrophilic substrates. Specific amino acid residues within GSTs have been identified as important for these binding sites and for
- 30 catalytic activity. Residues Q67, T68, D101, E104, and R131 are important for the binding of GSH (Lee, H-C et al. (1995) J. Biol. Chem. 270: 99-109). Residues R13, R20, and R69 are important for the catalytic activity of GST (Stenberg G et al. (1991) Biochem. J. 274: 549-55).

- In most cases, GSTs perform the beneficial function of deactivation and detoxification of potentially mutagenic and carcinogenic chemicals. However, in some cases their action is
- 35 detrimental and results in activation of chemicals with consequent mutagenic and carcinogenic

effects. Some forms of rat and human GSTs are reliable preneoplastic markers that aid in the detection of carcinogenesis. Expression of human GSTs in bacterial strains, such as Salmonella typhimurium used in the well-known Ames test for mutagenicity, has helped to establish the role of these enzymes in mutagenesis. Dihalomethanes, which produce liver tumors in mice, are believed to be activated by GST. This view is supported by the finding that dihalomethanes are more mutagenic in bacterial cells expressing human GST than in untransfected cells (Thier, R. et al. (1993) Proc. Natl. Acad. Sci. USA 90: 8567-80). The mutagenicity of ethylene dibromide and ethylene dichloride is increased in bacterial cells expressing the human Alpha GST, A1-1, while the mutagenicity of aflatoxin B1 is substantially reduced by enhancing the expression of GST (Simula, T.P. et al. (1993) Carcinogenesis 14: 1371-6). Thus, control of GST activity may be useful in the control of mutagenesis and carcinogenesis.

GST has been implicated in the acquired resistance of many cancers to drug treatment, the phenomenon known as multi-drug resistance (MDR). MDR occurs when a cancer patient is treated with a cytotoxic drug such as cyclophosphamide and subsequently becomes resistant to this drug and to a variety of other cytotoxic agents as well. Increased GST levels are associated with some of these drug resistant cancers, and it is believed that this increase occurs in response to the drug agent which is then deactivated by the GST catalyzed GSH conjugation reaction. The increased GST levels then protect the cancer cells from other cytotoxic agents which bind to GST. Increased levels of A1-1 in tumors has been linked to drug resistance induced by cyclophosphamide treatment (Dirven H.A. et al. (1994) Cancer Res. 54: 6215-20). Thus control of GST activity in cancerous tissues may be useful in treating MDR in cancer patients.

Gamma-glutamyl transpeptidase

Gamma-glutamyl transpeptidases are ubiquitously expressed enzymes that initiate extracellular glutathione (GSH) breakdown by cleaving gamma-glutamyl amide bonds. The breakdown of GSH provides cells with a regional cysteine pool for biosynthetic pathways. Gamma-glutamyl transpeptidases also contribute to cellular antioxidant defenses and expression is induced by oxidative stress. The cell surface-localized glycoproteins are expressed at high levels in cancer cells. Studies have suggested that the high level of gamma-glutamyl transpeptidases activity present on the surface of cancer cells could be exploited to activate precursor drugs, resulting in high local concentrations of anti-cancer therapeutic agents (Hanigan, M.H. (1998) Chem. Biol. Interact. 111-112:333-42; Taniguchi, N. and Ikeda, Y. (1998) Adv. Enzymol. Relat. Areas Mol. Biol. 72:239-78; Chikhi, N. et al. (1999) Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 122:367-80).

Acyltransferase

N-acyltransferase enzymes catalyze the transfer of an amino acid conjugate to an activated carboxylic group. Endogenous compounds and xenobiotics are activated by acyl-CoA synthetases in

the cytosol, microsomes, and mitochondria. The acyl-CoA intermediates are then conjugated with an amino acid (typically glycine, glutamine, or taurine, but also ornithine, arginine, histidine, serine, aspartic acid, and several dipeptides) by N-acyltransferases in the cytosol or mitochondria to form a metabolite with an amide bond. This reaction is complementary to O-glucuronidation, but amino acid conjugation does not produce the reactive and toxic metabolites which often result from glucuronidation.

One well-characterized enzyme of this class is the bile acid-CoA:amino acid N-acyltransferase (BAT) responsible for generating the bile acid conjugates which serve as detergents in the gastrointestinal tract (Falany, C. N. et al. (1994) J. Biol. Chem. 269:19375-9; Johnson, M. R. et al. (1991) J. Biol. Chem. 266:10227-33). BAT is also useful as a predictive indicator for prognosis of hepatocellular carcinoma patients after partial hepatectomy (Furutani, M. et al. (1996) Hepatology 24:1441-5).

Acetyltransferases

Acetyltransferases have been extensively studied for their role in histone acetylation. Histone acetylation results in the relaxing of the chromatin structure in eukaryotic cells, allowing transcription factors to gain access to promoter elements of the DNA templates in the affected region of the genome (or the genome in general). In contrast, histone deacetylation results in a reduction in transcription by closing the chromatin structure and limiting access of transcription factors. To this end, a common means of stimulating cell transcription is the use of chemical agents that inhibit the deacetylation of histones (e.g., sodium butyrate), resulting in a global (albeit artifactual) increase in gene expression. The modulation of gene expression by acetylation also results from the acetylation of other proteins, including but not limited to, p53, GATA-1, MyoD, ACTR, TFIIE, TFIIF and the high mobility group proteins (HMG). In the case of p53, acetylation results in increased DNA binding, leading to the stimulation of transcription of genes regulated by p53. The prototypic histone acetylase (HAT) is Gcn5 from Saccharomyces cerevisiae. Gcn5 is a member of a family of acetylases that includes Tetrahymena p55, human Gcn5, and human p300/CBP. Histone acetylation is reviewed in (Cheung, W.L. et al. (2000) Current Opinion in Cell Biology 12:326-333 and Berger, S.L (1999) Current Opinion in Cell Biology 11:336-341). Some acetyltransferase enzymes possess the alpha/beta hydrolase fold (Center of Applied Molecular Engineering Inst. of Chemistry and Biochemistry - University of Salzburg, <http://predict.sanger.ac.uk/irbm-course97/Docs/ms/>) common to several other major classes of enzymes, including but not limited to, acetylcholinesterases and carboxylesterases (Structural Classification of Proteins, <http://scop.mrc-lmb.cam.ac.uk/scop/index.html>).

N-acetyltransferase

Aromatic amines and hydrazine-containing compounds are subject to N-acetylation by the N-acetyltransferase enzymes of liver and other tissues. Some xenobiotics can be O-acetylated to some

extent by the same enzymes. N-acetyltransferases are cytosolic enzymes which utilize the cofactor acetyl-coenzyme A (acetyl-CoA) to transfer the acetyl group in a two step process. In the first step, the acetyl group is transferred from acetyl-CoA to an active site cysteine residue; in the second step, the acetyl group is transferred to the substrate amino group and the enzyme is regenerated.

5 In contrast to most other DME classes, there are a limited number of known N-acetyltransferases. In humans, there are two highly similar enzymes, NAT1 and NAT2; mice appear to have a third form of the enzyme, NAT3. The human forms of N-acetyltransferase have independent regulation (NAT1 is widely-expressed, whereas NAT2 is in liver and gut only) and overlapping substrate preferences. Both enzymes appear to accept most substrates to some extent, but
10 NAT1 does prefer some substrates (para-aminobenzoic acid, para-aminosalicylic acid, sulfamethoxazole, and sulfanilamide), while NAT2 prefers others (isoniazid, hydralazine, procainamide, dapsone, aminogluthethimide, and sulfamethazine).

Clinical observations of patients taking the antituberculosis drug isoniazid in the 1950s led to the description of fast and slow acetylators of the compound. These phenotypes were shown
15 subsequently to be due to mutations in the NAT2 gene which affected enzyme activity or stability. The slow isoniazid acetylator phenotype is very prevalent in Middle Eastern populations (approx. 70%), and is less prevalent in Caucasian (approx. 50%) and Asian (<25%) populations. More recently, functional polymorphism in NAT1 has been detected, with approximately 8% of the population tested showing a slow acetylator phenotype (Butcher, N. J. et al. (1998) Pharmacogenetics
20 8:67-72). Since NAT1 can activate some known aromatic amine carcinogens, polymorphism in the widely-expressed NAT1 enzyme may be important in determining cancer risk (OMIM *108345 N-acetyltransferase 1).

Aminotransferases

Aminotransferases comprise a family of pyridoxal 5'-phosphate (PLP) -dependent enzymes that
25 catalyze transformations of amino acids. Aspartate aminotransferase (AspAT) is the most extensively studied PLP-containing enzyme. It catalyzes the reversible transamination of dicarboxylic L-amino acids, aspartate and glutamate, and the corresponding 2-oxo acids, oxalacetate and 2-oxoglutarate. Other members of the family included pyruvate aminotransferase, branched-chain amino acid aminotransferase, tyrosine aminotransferase, aromatic aminotransferase, alanine:glyoxylate
30 aminotransferase (AGT), and kynurenine aminotransferase (Vacca, R.A. et al. (1997) J. Biol. Chem. 272:21932-21937).

Primary hyperoxaluria type-1 is an autosomal recessive disorder resulting in a deficiency in the liver-specific peroxisomal enzyme, alanine:glyoxylate aminotransferase-1. The phenotype of the disorder is a deficiency in glyoxylate metabolism. In the absence of AGT, glyoxylate is oxidized to
35 oxalate rather than being transaminated to glycine. The result is the deposition of insoluble calcium

oxalate in the kidneys and urinary tract, ultimately causing renal failure (Lumb, M.J. et al. (1999) J. Biol. Chem. 274:20587-20596).

Kynurenine aminotransferase catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid. The enzyme may also catalyzes the reversible
5 transamination reaction between L-2-aminoadipate and 2-oxoglutarate to produce 2-oxoadipate and L-glutamate. Kynurenic acid is a putative modulator of glutamatergic neurotransmission, thus a deficiency in kynurenine aminotransferase may be associated with pleiotropic effects (Buchli, R. et al. (1995) J. Biol. Chem. 270:29330-29335).

Catechol-O-methyltransferase:

10 Catechol-O-methyltransferase (COMT) catalyzes the transfer of the methyl group of S-adenosyl-L-methionine (AdoMet; SAM) donor to one of the hydroxyl groups of the catechol substrate (e.g., L-dopa, dopamine, or DBA). Methylation of the 3'-hydroxyl group is favored over methylation of the 4'-hydroxyl group and the membrane bound isoform of COMT is more regiospecific than the soluble form. Translation of the soluble form of the enzyme results from utilization of an internal
15 start codon in a full-length mRNA (1.5 kb) or from the translation of a shorter mRNA (1.3 kb), transcribed from an internal promoter. The proposed S_N2 -like methylation reaction requires Mg^{++} and is inhibited by Ca^{++} . The binding of the donor and substrate to COMT occurs sequentially. AdoMet first binds COMT in a Mg^{++} -independent manner, followed by the binding of Mg^{++} and the binding of the catechol substrate.

20 The amount of COMT in tissues is relatively high compared to the amount of activity normally required, thus inhibition is problematic. Nonetheless, inhibitors have been developed for in vitro use (e.g., gallates, tropolone, U-0521, and 3',4'-dihydroxy-2-methyl-propionphenetropolone) and for clinical use (e.g., nitrocatechol-based compounds and tolcapone). Administration of these inhibitors results in the increased half-life of L-dopa and the consequent formation of dopamine. Inhibition of COMT is
25 also likely to increase the half-life of various other catechol-structure compounds, including but not limited to epinephrine/norepinephrine, isoprenaline, rimeterol, dobutamine, fenoldopam, apomorphine, and α -methyldopa. A deficiency in norepinephrine has been linked to clinical depression, hence the use of COMT inhibitors could be useful in the treatment of depression. COMT inhibitors are generally well tolerated with minimal side effects and are ultimately
30 metabolized in the liver with only minor accumulation of metabolites in the body (Männistö, P.T. and Kaakkola, S. (1999) Pharmacological Reviews 51:593-628).

Copper-zinc superoxide dismutases

Copper-zinc superoxide dismutases are compact homodimeric metalloenzymes involved in cellular defenses against oxidative damage. The enzymes contain one atom of zinc and one atom of
35 copper per subunit and catalyze the dismutation of superoxide anions into O_2 and H_2O_2 . The rate of

dismutation is diffusion-limited and consequently enhanced by the presence of favorable electrostatic interactions between the substrate and enzyme active site. Examples of this class of enzyme have been identified in the cytoplasm of all the eukaryotic cells as well as in the periplasm of several bacterial species. Copper-zinc superoxide dismutases are robust enzymes that are highly resistant to proteolytic digestion and denaturing by urea and SDS. In addition to the compact structure of the enzymes, the presence of the metal ions and intrasubunit disulfide bonds is believed to be responsible for enzyme stability. The enzymes undergo reversible denaturation at temperatures as high as 70 °C (Battistoni, A. et al. (1998) J. Biol. Chem. 273:5655-5661).

Overexpression of superoxide dismutase has been implicated in enhancing freezing tolerance of transgenic Alfalfa as well as providing resistance to environmental toxins such as the diphenyl ether herbicide, acifluorfen (McKersie, B.D. et al. (1993) Plant Physiol. 103:1155-1163). In addition, yeast cells become more resistant to freeze-thaw damage following exposure to hydrogen peroxide which causes the yeast cells to adapt to further peroxide stress by upregulating expression of superoxide dismutases. In this study, mutations to yeast superoxide dismutase genes had a more detrimental effect on freeze-thaw resistance than mutations which affected the regulation of glutathione metabolism, long suspected of being important in determining an organisms survival through the process of cryopreservation (Jong-In Park, J-I. et al. (1998) J. Biol. Chem. 273:22921-22928).

Expression of superoxide dismutase is also associated with Mycobacterium tuberculosis, the organism that causes tuberculosis. Superoxide dismutase is one of the ten major proteins secreted by M. tuberculosis and its expression is upregulated approximately 5-fold in response to oxidative stress. M. tuberculosis expresses almost two orders of magnitude more superoxide dismutase than the nonpathogenic mycobacterium M. smegmatis, and secretes a much higher proportion of the expressed enzyme. The result is the secretion of ~350-fold more enzyme by M. tuberculosis than M. smegmatis, providing substantial resistance to oxidative stress (Harth, G. and Horwitz, M.A. (1999) J. Biol. Chem. 274:4281-4292).

The reduced expression of copper-zinc superoxide dismutases, as well as other enzymes with anti-oxidant capabilities, has been implicated in the early stages of cancer. The expression of copper-zinc superoxide dismutases has been shown to be lower in prostatic intraepithelial neoplasia and prostate carcinomas, compared to normal prostate tissue (Bostwick, D.G. (2000) Cancer 89:123-134).

Phosphodiesterases

Phosphodiesterases make up a class of enzymes which catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound. Phosphodiesterases are therefore crucial to a variety of cellular processes. Phosphodiesterases include DNA and RNA endonucleases and exonucleases, which are essential for cell growth and replication, and topoisomerases, which break and rejoin

nucleic acid strands during topological rearrangement of DNA. A Tyr-DNA phosphodiesterase functions in DNA repair by hydrolyzing dead-end covalent intermediates formed between topoisomerase I and DNA (Pouliot, J.J. et al. (1999) *Science* 286:552-555; Yang, S.-W. (1996) *Proc. Natl. Acad. Sci. USA* 93:11534-11539).

- 5 Acid sphingomyelinase is a phosphodiesterase which hydrolyzes the membrane phospholipid sphingomyelin to produce ceramide and phosphorylcholine. Phosphorylcholine is used in the synthesis of phosphatidylcholine, which is involved in numerous intracellular signaling pathways, while ceramide is an essential precursor for the generation of gangliosides, membrane lipids found in high concentration in neural tissue. Defective acid sphingomyelinase leads to a build-up of
- 10 sphingomyelin molecules in lysosomes, resulting in Niemann-Pick disease (Schuchman, E.H. and S.R. Miranda (1997) *Genet. Test.* 1:13-19).

- Glycerophosphoryl diester phosphodiesterase (also known as glycerophosphodiester phosphodiesterase) is a phosphodiesterase which hydrolyzes deacetylated phospholipid glycerophosphodiester to produce sn-glycerol-3-phosphate and an alcohol. Glycerophosphocholine,
- 15 glycerophosphoethanolamine, glycerophosphoglycerol, and glycerophosphoinositol are examples of substrates for glycerophosphoryl diester phosphodiesterases. A glycerophosphoryl diester phosphodiesterase from *E. coli* has broad specificity for glycerophosphodiester substrates (Larson, T.J. et al. (1983) *J. Biol. Chem.* 248:5428-5432).

- Cyclic nucleotide phosphodiesterases (PDEs) are crucial enzymes in the regulation of the
- 20 cyclic nucleotides cAMP and cGMP. cAMP and cGMP function as intracellular second messengers to transduce a variety of extracellular signals including hormones, light, and neurotransmitters. PDEs degrade cyclic nucleotides to their corresponding monophosphates, thereby regulating the intracellular concentrations of cyclic nucleotides and their effects on signal transduction. Due to their roles as regulators of signal transduction, PDEs have been extensively studied as chemotherapeutic
- 25 targets (Perry, M.J. and G.A. Higgs (1998) *Curr. Opin. Chem. Biol.* 2:472-481; Torphy, J.T. (1998) *Am. J. Resp. Crit. Care Med.* 157:351-370).

- Families of mammalian PDEs have been classified based on their substrate specificity and affinity, sensitivity to cofactors, and sensitivity to inhibitory agents (Beavo, J.A. (1995) *Physiol. Rev.* 75:725-748; Conti, M. et al. (1995) *Endocrine Rev.* 16:370-389). Several of these families contain
- 30 distinct genes, many of which are expressed in different tissues as splice variants. Within PDE families, there are multiple isozymes and multiple splice variants of these isozymes (Conti, M. and S.-L.C. Jin (1999) *Prog. Nucleic Acid Res. Mol. Biol.* 63:1-38). The existence of multiple PDE families, isozymes, and splice variants is an indication of the variety and complexity of the regulatory pathways involving cyclic nucleotides (Houslay, M.D. and G. Milligan (1997) *Trends Biochem. Sci.*
- 35 22:217-224).

Type 1 PDEs (PDE1s) are Ca^{2+} /calmodulin-dependent and appear to be encoded by at least three different genes, each having at least two different splice variants (Kakkar, R. et al. (1999) Cell Mol. Life Sci. 55:1164-1186). PDE1s have been found in the lung, heart, and brain. Some PDE1 isozymes are regulated in vitro by phosphorylation/dephosphorylation. Phosphorylation of these

5 PDE1 isozymes decreases the affinity of the enzyme for calmodulin, decreases PDE activity, and increases steady state levels of cAMP (Kakkar, supra). PDE1s may provide useful therapeutic targets for disorders of the central nervous system, and the cardiovascular and immune systems due to the involvement of PDE1s in both cyclic nucleotide and calcium signaling (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481).

10 PDE2s are cGMP-stimulated PDEs that have been found in the cerebellum, neocortex, heart, kidney, lung, pulmonary artery, and skeletal muscle (Sadhu, K. et al. (1999) J. Histochem. Cytochem. 47:895-906). PDE2s are thought to mediate the effects of cAMP on catecholamine secretion, participate in the regulation of aldosterone (Beavo, supra), and play a role in olfactory signal transduction (Juilfs, D.M. et al. (1997) Proc. Natl. Acad. Sci. USA 94:3388-3395).

15 PDE3s have high affinity for both cGMP and cAMP, and so these cyclic nucleotides act as competitive substrates for PDE3s. PDE3s play roles in stimulating myocardial contractility, inhibiting platelet aggregation, relaxing vascular and airway smooth muscle, inhibiting proliferation of T-lymphocytes and cultured vascular smooth muscle cells, and regulating catecholamine-induced release of free fatty acids from adipose tissue. The PDE3 family of phosphodiesterases are sensitive

20 to specific inhibitors such as cilostamide, enoximone, and lixazinone. Isozymes of PDE3 can be regulated by cAMP-dependent protein kinase, or by insulin-dependent kinases (Degerman, E. et al. (1997) J. Biol. Chem. 272:6823-6826).

PDE4s are specific for cAMP; are localized to airway smooth muscle, the vascular endothelium, and all inflammatory cells; and can be activated by cAMP-dependent phosphorylation.

25 Since elevation of cAMP levels can lead to suppression of inflammatory cell activation and to relaxation of bronchial smooth muscle, PDE4s have been studied extensively as possible targets for novel anti-inflammatory agents, with special emphasis placed on the discovery of asthma treatments. PDE4 inhibitors are currently undergoing clinical trials as treatments for asthma, chronic obstructive pulmonary disease, and atopic eczema. All four known isozymes of PDE4 are susceptible to the

30 inhibitor rolipram, a compound which has been shown to improve behavioral memory in mice (Barad, M. et al. (1998) Proc. Natl. Acad. Sci. USA 95:15020-15025). PDE4 inhibitors have also been studied as possible therapeutic agents against acute lung injury, endotoxemia, rheumatoid arthritis, multiple sclerosis, and various neurological and gastrointestinal indications (Doherty, A.M. (1999) Curr. Opin. Chem. Biol. 3:466-473).

35 PDE5 is highly selective for cGMP as a substrate (Turko, I.V. et al. (1998) Biochemistry

37:4200-4205), and has two allosteric cGMP-specific binding sites (McAllister-Lucas, L.M. et al. (1995) J. Biol. Chem. 270:30671-30679). Binding of cGMP to these allosteric binding sites seems to be important for phosphorylation of PDE5 by cGMP-dependent protein kinase rather than for direct regulation of catalytic activity. High levels of PDE5 are found in vascular smooth muscle, platelets, lung, and kidney. The inhibitor zaprinast is effective against PDE5 and PDE1s. Modification of zaprinast to provide specificity against PDE5 has resulted in sildenafil (VIAGRA; Pfizer, Inc., New York NY), a treatment for male erectile dysfunction (Terrett, N. et al. (1996) Bioorg. Med. Chem. Lett. 6:1819-1824). Inhibitors of PDE5 are currently being studied as agents for cardiovascular therapy (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481).

10 PDE6s, the photoreceptor cyclic nucleotide phosphodiesterases, are crucial components of the phototransduction cascade. In association with the G-protein transducin, PDE6s hydrolyze cGMP to regulate cGMP-gated cation channels in photoreceptor membranes. In addition to the cGMP-binding active site, PDE6s also have two high-affinity cGMP-binding sites which are thought to play a regulatory role in PDE6 function (Artemyev, N.O. et al. (1998) Methods 14:93-104). Defects in
15 PDE6s have been associated with retinal disease. Retinal degeneration in the rd mouse (Yan, W. et al. (1998) Invest. Ophthalmol. Vis. Sci. 39:2529-2536), autosomal recessive retinitis pigmentosa in humans (Danciger, M. et al. (1995) Genomics 30:1-7), and rod/cone dysplasia 1 in Irish Setter dogs (Suber, M.L. et al. (1993) Proc. Natl. Acad. Sci. USA 90:3968-3972) have been attributed to mutations in the PDE6B gene.

20 The PDE7 family of PDEs consists of only one known member having multiple splice variants (Bloom, T.J. and J.A. Beavo (1996) Proc. Natl. Acad. Sci. USA 93:14188-14192). PDE7s are cAMP specific, but little else is known about their physiological function. Although mRNAs encoding PDE7s are found in skeletal muscle, heart, brain, lung, kidney, and pancreas, expression of PDE7 proteins is restricted to specific tissue types (Han, P. et al. (1997) J. Biol. Chem. 272:16152-16157;
25 Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481). PDE7s are very closely related to the PDE4 family; however, PDE7s are not inhibited by rolipram, a specific inhibitor of PDE4s (Beavo, *supra*).

PDE8s are cAMP specific, and are closely related to the PDE4 family. PDE8s are expressed in thyroid gland, testis, eye, liver, skeletal muscle, heart, kidney, ovary, and brain. The cAMP-
30 hydrolyzing activity of PDE8s is not inhibited by the PDE inhibitors rolipram, vinpocetine, milrinone, IBMX (3-isobutyl-1-methylxanthine), or zaprinast, but PDE8s are inhibited by dipyrindamole (Fisher, D.A. et al. (1998) Biochem. Biophys. Res. Commun. 246:570-577; Hayashi, M. et al. (1998) Biochem. Biophys. Res. Commun. 250:751-756; Soderling, S.H. et al. (1998) Proc. Natl. Acad. Sci. USA 95:8991-8996).

35 PDE9s are cGMP specific and most closely resemble the PDE8 family of PDEs. PDE9s are

expressed in kidney, liver, lung, brain, spleen, and small intestine. PDE9s are not inhibited by sildenafil (VIAGRA; Pfizer, Inc., New York NY), rolipram, vinpocetine, dipyridamole, or IBMX (3-isobutyl-1-methylxanthine), but they are sensitive to the PDE5 inhibitor zaprinast (Fisher, D.A. et al. (1998) *J. Biol. Chem.* 273:15559-15564; Soderling, S.H. et al. (1998) *J. Biol. Chem.* 273:15553-5 15558).

PDE10s are dual-substrate PDEs, hydrolyzing both cAMP and cGMP. PDE10s are expressed in brain, thyroid, and testis. (Soderling, S.H. et al. (1999) *Proc. Natl. Acad. Sci. USA* 96:7071-7076; Fujishige, K. et al. (1999) *J. Biol. Chem.* 274:18438-18445; Loughney, K. et al (1999) *Gene* 234:109-117).

10 PDEs are composed of a catalytic domain of about 270-300 amino acids, an N-terminal regulatory domain responsible for binding cofactors, and, in some cases, a hydrophilic C-terminal domain of unknown function (Conti, M. and S.-L.C. Jin (1999) *Prog. Nucleic Acid Res. Mol. Biol.* 63:1-38). A conserved, putative zinc-binding motif, HDXXHXGXXN, has been identified in the catalytic domain of all PDEs. N-terminal regulatory domains include non-catalytic cGMP-binding
15 domains in PDE2s, PDE5s, and PDE6s; calmodulin-binding domains in PDE1s; and domains containing phosphorylation sites in PDE3s and PDE4s. In PDE5, the N-terminal cGMP-binding domain spans about 380 amino acid residues and comprises tandem repeats of the conserved sequence motif N(R/K)XnFX₃DE (McAllister-Lucas, L.M. et al. (1993) *J. Biol. Chem.* 268:22863-22873). The NKXnD motif has been shown by mutagenesis to be important for cGMP binding (Turko, I.V. et al.
20 (1996) *J. Biol. Chem.* 271:22240-22244). PDE families display approximately 30% amino acid identity within the catalytic domain; however, isozymes within the same family typically display about 85-95% identity in this region (e.g. PDE4A vs PDE4B). Furthermore, within a family there is extensive similarity (>60%) outside the catalytic domain; while across families, there is little or no sequence similarity outside this domain.

25 Many of the constituent functions of immune and inflammatory responses are inhibited by agents that increase intracellular levels of cAMP (Verghese, M.W. et al. (1995) *Mol. Pharmacol.* 47:1164-1171). A variety of diseases have been attributed to increased PDE activity and associated with decreased levels of cyclic nucleotides. For example, a form of diabetes insipidus in mice has been associated with increased PDE4 activity, an increase in low-K_m cAMP PDE activity has been
30 reported in leukocytes of atopic patients, and PDE3 has been associated with cardiac disease.

Many inhibitors of PDEs have been identified and have undergone clinical evaluation (Perry, M.J. and G.A. Higgs (1998) *Curr. Opin. Chem. Biol.* 2:472-481; Torphy, T.J. (1998) *Am. J. Respir. Crit. Care Med.* 157:351-370). PDE3 inhibitors are being developed as antithrombotic agents, antihypertensive agents, and as cardiotonic agents useful in the treatment of congestive heart failure.
35 Rolipram, a PDE4 inhibitor, has been used in the treatment of depression, and other inhibitors of

PDE4 are undergoing evaluation as anti-inflammatory agents. Rolipram has also been shown to inhibit lipopolysaccharide (LPS) induced TNF- α which has been shown to enhance HIV-1 replication in vitro. Therefore, rolipram may inhibit HIV-1 replication (Angel, J.B. et al. (1995) AIDS 9:1137-1144). Additionally, rolipram, based on its ability to suppress the production of cytokines
5 such as TNF- α and β and interferon γ , has been shown to be effective in the treatment of encephalomyelitis. Rolipram may also be effective in treating tardive dyskinesia and was effective in treating multiple sclerosis in an experimental animal model (Sommer, N. et al. (1995) Nat. Med. 1:244-248; Sasaki, H. et al. (1995) Eur. J. Pharmacol. 282:71-76).

Theophylline is a nonspecific PDE inhibitor used in the treatment of bronchial asthma and
10 other respiratory diseases. Theophylline is believed to act on airway smooth muscle function and in an anti-inflammatory or immunomodulatory capacity in the treatment of respiratory diseases (Banner, K.H. and C.P. Page (1995) Eur. Respir. J. 8:996-1000). Pentoxifylline is another nonspecific PDE inhibitor used in the treatment of intermittent claudication and diabetes-induced peripheral vascular disease. Pentoxifylline is also known to block TNF- α production and may inhibit HIV-1 replication
15 (Angel et al., supra).

PDEs have been reported to affect cellular proliferation of a variety of cell types (Conti et al. (1995) Endocrine Rev. 16:370-389) and have been implicated in various cancers. Growth of prostate carcinoma cell lines DU145 and LNCaP was inhibited by delivery of cAMP derivatives and PDE inhibitors (Bang, Y.J. et al. (1994) Proc. Natl. Acad. Sci. USA 91:5330-5334). These cells also
20 showed a permanent conversion in phenotype from epithelial to neuronal morphology. It has also been suggested that PDE inhibitors have the potential to regulate mesangial cell proliferation (Matousovic, K. et al. (1995) J. Clin. Invest. 96:401-410) and lymphocyte proliferation (Joulain, C. et al. (1995) J. Lipid Mediat. Cell Signal. 11:63-79). A cancer treatment has been described that involves intracellular delivery of PDEs to particular cellular compartments of tumors, resulting in cell
25 death (Deonarain, M.P. and A.A. Epenetos (1994) Br. J. Cancer 70:786-794).

Phosphotriesterases

Phosphotriesterases (PTE, paraoxonases) are enzymes that hydrolyze toxic organophosphorus compounds and have been isolated from a variety of tissues. The enzymes appear to be lacking in birds and insects and abundant in mammals, explaining the reduced tolerance of birds and insects to
30 organophosphorus compound (Vilanova, E. and Sogorb, M.A. (1999) Crit. Rev. Toxicol. 29:21-57). Phosphotriesterases play a central role in the detoxification of insecticides by mammals. Phosphotriesterase activity varies among individuals and is lower in infants than adults. Knockout mice are markedly more sensitive to the organophosphate-based toxins diazoxon and chlorpyrifos oxon (Furlong, C.E., et al. (2000) Neurotoxicology 21:91-100). PTEs have attracted interest as
35 enzymes capable of the detoxification of organophosphate-containing chemical waste and warfare

reagents (e.g., parathion), in addition to pesticides and insecticides. Some studies have also implicated phosphotriesterase in atherosclerosis and diseases involving lipoprotein metabolism.

Thioesterases

Two soluble thioesterases involved in fatty acid biosynthesis have been isolated from
5 mammalian tissues, one which is active only toward long-chain fatty-acyl thioesters and one which is active toward thioesters with a wide range of fatty-acyl chain-lengths. These thioesterases catalyze the chain-terminating step in the *de novo* biosynthesis of fatty acids. Chain termination involves the hydrolysis of the thioester bond which links the fatty acyl chain to the 4'-phosphopantetheine prosthetic group of the acyl carrier protein (ACP) subunit of the fatty acid synthase (Smith, S. (1981a) Methods Enzymol. 71:181-188; Smith, S. (1981b) Methods Enzymol. 71:188-200).

E. coli contains two soluble thioesterases, thioesterase I which is active only toward long-chain acyl thioesters, and thioesterase II (TEII) which has a broad chain-length specificity (Naggert, J. et al. (1991) J. Biol. Chem. 266:11044-11050). *E. coli* TEII does not exhibit sequence similarity with either of the two types of mammalian thioesterases which function as chain-terminating enzymes in
15 *de novo* fatty acid biosynthesis. Unlike the mammalian thioesterases, *E. coli* TEII lacks the characteristic serine active site gly-X-ser-X-gly sequence motif and is not inactivated by the serine modifying agent diisopropyl fluorophosphate. However, modification of histidine 58 by iodoacetamide and diethylpyrocarbonate abolished TEII activity. Overexpression of TEII did not alter fatty acid content in *E. coli*, which suggests that it does not function as a chain-terminating
20 enzyme in fatty acid biosynthesis (Naggert et al., *supra*). For that reason, Naggert et al. (*supra*) proposed that the physiological substrates for *E. coli* TEII may be coenzyme A (CoA)-fatty acid esters instead of ACP-phosphopantetheine-fatty acid esters.

Carboxylesterases

Mammalian carboxylesterases constitute a multigene family expressed in a variety of tissues
25 and cell types. Isozymes have significant sequence homology and are classified primarily on the basis of amino acid sequence. Acetylcholinesterase, butyrylcholinesterase, and carboxylesterase are grouped into the serine super family of esterases (B-esterases). Other carboxylesterases included thyroglobulin, thrombin, Factor IX, gliotactin, and plasminogen. Carboxylesterases catalyze the hydrolysis of ester- and amide- groups from molecules and are involved in detoxification of drugs,
30 environmental toxins, and carcinogens. Substrates for carboxylesterases include short- and long-chain acyl-glycerols, acylcarnitine, carbonates, dipivefrin hydrochloride, cocaine, salicylates, capsaicin, palmitoyl-coenzyme A, imidapril, haloperidol, pyrrolizidine alkaloids, steroids, p-nitrophenyl acetate, malathion, butanilicaine, and isocarboxazide. The enzymes often demonstrate low substrate specificity. Carboxylesterases are also important for the conversion of prodrugs to their
35 respective free acids, which may be the active form of the drug (e.g., lovastatin, used to lower blood

cholesterol) (reviewed in Satoh, T. and Hosokawa, M. (1998) *Annu. Rev. Pharmacol. Toxicol.* 38:257-288).

Neuroligins are a class of molecules that (i) have N-terminal signal sequences, (ii) resemble cell-surface receptors, (iii) contain carboxylesterase domains, (iv) are highly expressed in the brain, and (v) bind to neurexins in a calcium-dependent manner. Despite the homology to carboxylesterases, neuroligins lack the active site serine residue, implying a role in substrate binding rather than catalysis (Ichtchenko, K. et al. (1996) *J. Biol. Chem.* 271:2676-2682).

Squalene epoxidase

Squalene epoxidase (squalene monooxygenase, SE) is a microsomal membrane-bound, FAD-dependent oxidoreductase that catalyzes the first oxygenation step in the sterol biosynthetic pathway of eukaryotic cells. Cholesterol is an essential structural component of cytoplasmic membranes acquired via the LDL receptor-mediated pathway or the biosynthetic pathway. In the latter case, all 27 carbon atoms in the cholesterol molecule are derived from acetyl-CoA (Stryer, L., *supra*). SE converts squalene to 2,3(*S*)-oxidosqualene, which is then converted to lanosterol and then cholesterol. The steps involved in cholesterol biosynthesis are summarized below (Stryer, L (1988) Biochemistry. W.H Freeman and Co., Inc. New York. pp. 554-560 and Sakakibara, J. et al. (1995) 270:17-20):

acetate (from Acetyl-CoA) → 3-hydroxy-3-methyl-glutaryl CoA → mevalonate →
5-phosphomevalonate → 5-pyrophosphomevalonate → isopentenyl pyrophosphate →
dimethylallyl pyrophosphate → geranyl pyrophosphate → farnesyl pyrophosphate →
squalene → squalene epoxide → lanosterol → cholesterol

While cholesterol is essential for the viability of eukaryotic cells, inordinately high serum cholesterol levels results in the formation of atherosclerotic plaques in the arteries of higher organisms. This deposition of highly insoluble lipid material onto the walls of essential blood vessels (e.g., coronary arteries) results in decreased blood flow and potential necrosis of the tissues deprived of adequate blood flow. HMG-CoA reductase is responsible for the conversion of 3-hydroxy-3-methyl-glutaryl CoA (HMG-CoA) to mevalonate, which represents the first committed step in cholesterol biosynthesis. HMG-CoA is the target of a number of pharmaceutical compounds designed to lower plasma cholesterol levels. However, inhibition of MHG-CoA also results in the reduced synthesis of non-sterol intermediates (e.g., mevalonate) required for other biochemical pathways. SE catalyzes a rate-limiting reaction that occurs later in the sterol synthesis pathway and cholesterol in the only end product of the pathway following the step catalyzed by SE. As a result, SE is the ideal target for the design of anti-hyperlipidemic drugs that do not cause a reduction in other necessary intermediates (Nakamura, Y. et al. (1996) 271:8053-8056).

Epoxide hydrolases

Epoxide hydrolases catalyze the addition of water to epoxide-containing compounds, thereby hydrolyzing epoxides to their corresponding 1,2-diols. They are related to bacterial haloalkane dehalogenases and show sequence similarity to other members of the α/β hydrolase fold family of enzymes (e.g., bromoperoxidase A2 from *Streptomyces aureofaciens*, hydroxymuconic semialdehyde hydrolases from *Pseudomonas putida*, and haloalkane dehalogenase from *Xanthobacter autotrophicus*). Epoxide hydrolases are ubiquitous in nature and have been found in mammals, invertebrates, plants, fungi, and bacteria. This family of enzymes is important for the detoxification of xenobiotic epoxide compounds which are often highly electrophilic and destructive when introduced into an organism. Examples of epoxide hydrolase reactions include the hydrolysis of

5 cis-9,10-epoxyoctadec-9(Z)-enoic acid (leukotoxin) to form its corresponding diol, threo-9,10-dihydroxyoctadec-12(Z)-enoic acid (leukotoxin diol), and the hydrolysis of

10 cis-12,13-epoxyoctadec-9(Z)-enoic acid (isoleukotoxin) to form its corresponding diol threo-12,13-dihydroxyoctadec-9(Z)-enoic acid (isoleukotoxin diol). Leukotoxins alter membrane permeability and ion transport and cause inflammatory responses. In addition, epoxide carcinogens

15 are known to be produced by cytochrome P450 as intermediates in the detoxification of drugs and environmental toxins.

The enzymes possess a catalytic triad composed of Asp (the nucleophile), Asp (the histidine-supporting acid), and His (the water-activating histidine). The reaction mechanism of epoxide hydrolase proceeds via a covalently bound ester intermediate initiated by the nucleophilic

20 attack of one of the Asp residues on the primary carbon atom of the epoxide ring of the target molecule, leading to a covalently bound ester intermediate (Michael Arand, M. et al. (1996) J. Biol. Chem. 271:4223-4229; Rink, R. et al. (1997) J. Biol. Chem. 272:14650-14657; Argiriadi, M.A. et al. (2000) J. Biol. Chem. 275:15265-15270).

Enzymes involved in tyrosine catalysis

25 The degradation of the amino acid tyrosine to either succinate and pyruvate or fumarate and acetoacetate, requires a large number of enzymes and generates a large number of intermediate compounds. In addition, many xenobiotic compounds may be metabolized using one or more reactions that are part of the tyrosine catabolic pathway. While the pathway has been studied primarily in bacteria, tyrosine degradation is known to occur in a variety of organisms and is likely to

30 involve many of the same biological reactions.

The enzymes involved in the degradation of tyrosine to succinate and pyruvate (e.g., in *Arthrobacter* species) include 4-hydroxyphenylpyruvate oxidase, 4-hydroxyphenylacetate 3-hydroxylase, 3,4-dihydroxyphenylacetate 2,3-dioxygenase, 5-carboxymethyl-2-hydroxymuconic semialdehyde dehydrogenase, *trans,cis*-5-carboxymethyl-2-hydroxymuconate isomerase,

35 homoprotocatechuate isomerase/decarboxylase, *cis*-2-oxohept-3-ene-1,7-dioate hydratase,

2,4-dihydroxyhept-*trans*-2-ene-1,7-dioate aldolase, and succinic semialdehyde dehydrogenase.

The enzymes involved in the degradation of tyrosine to fumarate and acetoacetate (e.g., in *Pseudomonas* species) include 4-hydroxyphenylpyruvate dioxygenase, homogentisate 1,2-dioxygenase, maleylacetoacetate isomerase, and fumarylacetoacetase. 4-hydroxyphenylacetate 5 1-hydroxylase may also be involved if intermediates from the succinate/pyruvate pathway are accepted.

Additional enzymes associated with tyrosine metabolism in different organisms include 4-chlorophenylacetate-3,4-dioxygenase, aromatic aminotransferase, 5-oxopent-3-ene-1,2,5-tricarboxylate decarboxylase, 2-oxo-hept-3-ene-1,7-dioate hydratase, and 10 5-carboxymethyl-2-hydroxymuconate isomerase (Ellis, L.B.M. *et al.* (1999) *Nucleic Acids Res.* 27:373-376; Wackett, L.P. and Ellis, L.B.M. (1996) *J. Microbiol. Meth.* 25:91-93; and Schmidt, M. (1996) *Amer. Soc. Microbiol. News* 62:102).

In humans, acquired or inherited genetic defects in enzymes of the tyrosine degradation pathway may result in hereditary tyrosinemia. One form of this disease, hereditary tyrosinemia 1 15 (HT1) is caused by a deficiency in the enzyme fumarylacetoacetate hydrolase, the last enzyme in the pathway in organisms that metabolize tyrosine to fumarate and acetoacetate. HT1 is characterized by progressive liver damage beginning at infancy, and increased risk for liver cancer (Endo, F. *et al.* (1997) *J. Biol. Chem.* 272:24426-24432).

20 The discovery of new drug metabolizing enzymes and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of drug 25 metabolizing enzymes.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, drug metabolizing enzymes, referred to collectively as "DME" and individually as "DME-1," "DME-2," "DME-3," "DME-4," "DME-5," 30 "DME-6," "DME-7," "DME-8," "DME-9," "DME-10," "DME-11," "DME-12," "DME-13," "DME-14," "DME-15," "DME-16," "DME-17," "DME-18," "DME-19," "DME-20," "DME-21," "DME-22," "DME-23," and "DME-24." In one aspect, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a naturally occurring amino acid sequence 35 having at least 90% sequence identity to an amino acid sequence selected from the group consisting

of SEQ ID NO:1-24, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-24.

5 The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of an amino acid sequence selected from the
10 group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-24. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:25-48.

 Additionally, the invention provides a recombinant polynucleotide comprising a promoter
15 sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of an amino acid sequence selected from the group consisting of
20 SEQ ID NO:1-24, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

 The invention also provides a method for producing a polypeptide comprising an amino acid
25 sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of an amino acid sequence selected from the
30 group consisting of SEQ ID NO:1-24. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

 Additionally, the invention provides an isolated antibody which specifically binds to a
35 polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino

acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24.

The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or

condition associated with overexpression of functional DME, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:25-48, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID

NO:25-48, ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific

5 hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, iii) a

10 polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological

15 sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide

20 sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for each polypeptide of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

Table 3 shows structural features of each polypeptide sequence, including predicted motifs

25 and domains, along with the methods, algorithms, and searchable databases used for analysis of each polypeptide.

Table 4 lists the cDNA and genomic DNA fragments which were used to assemble each polynucleotide sequence, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for each polynucleotide of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction

30 of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"DME" refers to the amino acid sequences of substantially purified DME obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of DME. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of DME either by directly interacting with DME or by acting on components of the biological pathway in which DME participates.

An "allelic variant" is an alternative form of the gene encoding DME. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding DME include those sequences with deletions,

insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as DME or a polypeptide with at least one functional characteristic of DME. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding DME, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding DME. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent DME. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of DME is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of DME. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of DME either by directly interacting with DME or by acting on components of the biological pathway in which DME participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind DME polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired.

Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic DME, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding DME or fragments of DME may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium

dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
15	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
20	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
25	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
30	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
35	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide.

Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

A "fragment" is a unique portion of DME or the polynucleotide encoding DME which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:25-48 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:25-48, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:25-48 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:25-48 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:25-48 and the region of SEQ ID NO:25-48 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-24 is encoded by a fragment of SEQ ID NO:25-48. A fragment of SEQ ID NO:1-24 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-24. For example, a fragment of SEQ ID NO:1-24 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-24. The precise length of a fragment of SEQ ID NO:1-24 and the region of SEQ ID NO:1-24 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A

“full length” polynucleotide sequence encodes a “full length” polypeptide sequence.

“Homology” refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the “BLAST 2 Sequences” tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example,
5 as defined by a particular SEQ ID number, or may be measured over a shorter length, for example,
over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at
least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous
nucleotides. Such lengths are exemplary only, and it is understood that any fragment length
supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to
10 describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode
similar amino acid sequences due to the degeneracy of the genetic code. It is understood that
changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic
acid sequences that all encode substantially the same protein.

15 The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer
to the percentage of residue matches between at least two polypeptide sequences aligned using a
standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some
alignment methods take into account conservative amino acid substitutions. Such conservative
substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at
20 the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default
parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e
sequence alignment program (described and referenced above). For pairwise alignments of
polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap
25 penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default
residue weight table. As with polynucleotide alignments, the percent identity is reported by
CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise
comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version
30 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for
example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

35 *Expect: 10*

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

“Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press,

Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of DME which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of DME which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of DME. For example, modulation

may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of DME.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an DME may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of DME.

"Probe" refers to nucleic acid sequences encoding DME, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR
5 Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such
10 purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of
15 Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the
20 selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved
25 regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic
30 acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques
35 such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have

been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

5 Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

 A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions
10 (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

 "Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and
15 other moieties known in the art.

 An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

20 The term "sample" is used in its broadest sense. A sample suspected of containing DME, nucleic acids encoding DME, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

 The terms "specific binding" and "specifically binding" refer to that interaction between a
25 protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A
30 and the antibody will reduce the amount of labeled A that binds to the antibody.

 The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free; preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

35 A "substitution" refers to the replacement of one or more amino acid residues or nucleotides

by different amino acid residues or nucleotides, respectively.

“Substrate” refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A “transcript image” refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

“Transformation” describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term “transformed cells” includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A “transgenic organism,” as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or *in vitro* fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), *supra*.

A “variant” of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the “BLAST 2 Sequences” tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least

98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The
5 corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass
10 "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of
15 the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

20 THE INVENTION

The invention is based on the discovery of new human drug metabolizing enzymes (DME), the polynucleotides encoding DME, and the use of these compositions for the diagnosis, treatment, or prevention of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders.

25 Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide
30 sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the
35 polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte

polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog.

5 Table 3 shows various structural features of each of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as
10 determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

 Together, Tables 2 and 3 summarize the properties of each polypeptide of the invention, and
15 these properties establish that the claimed polypeptides are drug metabolizing enzymes. The algorithms and parameters for the analysis of SEQ ID NO:1-24 are described in Table 7.

 As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence
20 identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:25-48 or that distinguish between SEQ ID NO:25-48 and
25 related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and genomic sequences in column 5 relative to their
30 respective full length sequences.

 The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 6537030H1 is the identification number of an Incyte cDNA sequence, and (OVARIN02) is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from
35 pooled cDNA libraries (e.g., 70614021V1). Alternatively, the identification numbers in column 5

may refer to GenBank cDNAs or ESTs (e.g., g758933) which contributed to the assembly of the full length polynucleotide sequences. Alternatively, the identification numbers in column 5 may refer to coding regions predicted by Genscan analysis of genomic DNA. For example, g5091644.v113.gs_1.1.nt.edit is the identification number of a Genscan-predicted coding sequence, with g5091644 being the GenBank identification number of the sequence to which Genscan was applied. The Genscan-predicted coding sequences may have been edited prior to assembly. (See Example IV.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. (See Example V.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon-stretching" algorithm. (See Example V.) In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

The invention also encompasses DME variants. A preferred DME variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the DME amino acid sequence, and which contains at least one functional or structural characteristic of DME.

The invention also encompasses polynucleotides which encode DME. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:25-48, which encodes DME. The polynucleotide sequences of SEQ ID NO:25-48, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding DME. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding DME. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:25-48 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting

of SEQ ID NO:25-48. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of DME.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding DME, some bearing minimal
5 similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring DME, and all such variations are to be considered as
10 being specifically disclosed.

Although nucleotide sequences which encode DME and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring DME under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding DME or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally
15 occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding DME and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater
20 half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode DME and DME derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to
25 introduce mutations into a sequence encoding DME or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:25-48 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.*
30 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied
35 Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or

combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal
5 cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers,
10 R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding DME may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic
15 DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA
20 fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res.
25 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in
30 length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T)
35 library does not yield a full-length cDNA. Genomic libraries may be useful for extension of

sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode DME may be cloned in recombinant DNA molecules that direct expression of DME, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express DME.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter DME-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of DME, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are

optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

5 In another embodiment, sequences encoding DME may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) *Nucleic Acids Symp. Ser.* 7:215-223; and Horn, T. et al. (1980) *Nucleic Acids Symp. Ser.* 7:225-232.) Alternatively, DME itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques.
10 (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp.55-60; and Roberge, J.Y. et al. (1995) *Science* 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of DME, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide
15 or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

20 In order to express a biologically active DME, the nucleotide sequences encoding DME or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in
25 polynucleotide sequences encoding DME. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding DME. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding DME and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional
30 or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See,
35 e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding DME and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989)

- 5 Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

- A variety of expression vector/host systems may be utilized to contain and express sequences encoding DME. These include, but are not limited to, microorganisms such as bacteria
 10 transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke,
 15 G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors
 20 derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M.
 25 and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

- In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding DME. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding DME can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1
 30 plasmid (Life Technologies). Ligation of sequences encoding DME into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol.
 35 Chem. 264:5503-5509.) When large quantities of DME are needed, e.g. for the production of

antibodies, vectors which direct high level expression of DME may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of DME. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) *Methods Enzymol.* 153:516-544; and Scorer, C.A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of DME. Transcription of sequences encoding DME may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding DME may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses DME in host cells. (See, e.g., Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of DME in cell lines is preferred. For example, sequences encoding DME can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the

introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding DME is inserted within a marker gene sequence, transformed cells containing sequences encoding DME can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding DME under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding DME and that express DME may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of DME using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques

include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on DME is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art.

- 5 (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

- A wide variety of labels and conjugation techniques are known by those skilled in the art and
10 may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding DME include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding DME, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are
15 commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent,
20 chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

- Host cells transformed with nucleotide sequences encoding DME may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the
25 sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode DME may be designed to contain signal sequences which direct secretion of DME through a prokaryotic or eukaryotic cell membrane.

- In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of
30 the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the
35 American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct

modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding DME may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric DME protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of DME activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the DME encoding sequence and the heterologous protein sequence, so that DME may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled DME may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

DME of the present invention or fragments thereof may be used to screen for compounds that specifically bind to DME. At least one and up to a plurality of test compounds may be screened for specific binding to DME. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of DME, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which DME binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express DME, either as a secreted

protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing DME or cell membrane fractions which contain DME are then contacted with a test compound and binding, stimulation, or inhibition of activity of either DME or the compound is analyzed.

- 5 An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with DME, either in solution or affixed to a solid support, and detecting the binding of DME to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a
- 10 labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

DME of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of DME. Such compounds may include agonists, antagonists, or partial or

15 inverse agonists. In one embodiment, an assay is performed under conditions permissive for DME activity, wherein DME is combined with at least one test compound, and the activity of DME in the presence of a test compound is compared with the activity of DME in the absence of the test compound. A change in the activity of DME in the presence of the test compound is indicative of a compound that modulates the activity of DME. Alternatively, a test compound is combined with an

20 in vitro or cell-free system comprising DME under conditions suitable for DME activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of DME may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding DME or their mammalian homologs may

25 be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the

30 gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic

35 Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell

blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

5 Polynucleotides encoding DME may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

10 Polynucleotides encoding DME can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding DME is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and
15 treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress DME, e.g., by secreting DME in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists
20 between regions of DME and drug metabolizing enzymes. In addition, the expression of DME is closely associated with brain, breast, prostate, ovary, testicle, bone, blood, kidney, lung, thyroid, and gastrointestinal tissues; Crohn's disease; breast, sigmoid mesentery, and ureter tumors; and cancers of the lung, prostate, bone, and blood. Therefore, DME appears to play a role in autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and
25 gastrointestinal disorders, including liver disorders. In the treatment of disorders associated with increased DME expression or activity, it is desirable to decrease the expression or activity of DME. In the treatment of disorders associated with decreased DME expression or activity, it is desirable to increase the expression or activity of DME.

Therefore, in one embodiment, DME or a fragment or derivative thereof may be
30 administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME. Examples of such disorders include, but are not limited to, an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune
35 thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED),

bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis,

5 myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and

10 trauma; a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix,

15 gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation),

20 Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; an endocrine disorder, such as disorders of the hypothalamus and

25 pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with hypopituitarism including hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and

30 dwarfism; disorders associated with hyperpituitarism including acromegaly, gigantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma; disorders associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism; disorders associated with hyperthyroidism including

35 thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter,

thyroid carcinoma, and Plummer's disease; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalcemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 α -reductase, and gynecomastia; an eye disorder, such as conjunctivitis, keratoconjunctivitis sicca, keratitis, episcleritis, iritis, posterior uveitis, glaucoma, amaurosis fugax, ischemic optic neuropathy, optic neuritis, Leber's hereditary optic neuropathy, toxic optic neuropathy, vitreous detachment, retinal detachment, cataract, macular degeneration, central serous chorioretinopathy, retinitis pigmentosa, melanoma of the choroid, retrobulbar tumor, and chiasmal tumor; a metabolic disorder, such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, Menkes syndrome, occipital horn syndrome, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, pseudovitamin D-deficiency rickets; hypocalcemia, hypophosphatemia, and postpubescent cerebellar ataxia, tyrosinemia, and a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, hereditary hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic

encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, α_1 -antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, 5 intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas.

In another embodiment, a vector capable of expressing DME or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME including, but not limited to, those described above.

10 In a further embodiment, a composition comprising a substantially purified DME in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of DME may be 15 administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME including, but not limited to, those listed above.

In a further embodiment, an antagonist of DME may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of DME. Examples of such disorders include, but are not limited to, those autoimmune/inflammatory, cell proliferative, 20 developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders, described above. In one aspect, an antibody which specifically binds DME may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express DME.

In an additional embodiment, a vector expressing the complement of the polynucleotide 25 encoding DME may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of DME including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made 30 by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of DME may be produced using methods which are generally known in the 35 art. In particular, purified DME may be used to produce antibodies or to screen libraries of

pharmaceutical agents to identify those which specifically bind DME. Antibodies to DME may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit
5 dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with DME or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's,
10 mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to
15 DME have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of DME amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

20 Monoclonal antibodies to DME may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA
25 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda,
30 S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce DME-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

35 Antibodies may also be produced by inducing in vivo production in the lymphocyte

population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for DME may also be generated.

- 5 For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)
- 10 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between DME and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies
- 15 reactive to two non-interfering DME epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

- Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for DME. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of DME-antibody complex
- 20 divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple DME epitopes, represents the average affinity, or avidity, of the antibodies for DME. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular DME epitope, represents a true measure of affinity. High-affinity antibody preparations
- 25 with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the DME-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of DME, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC;
- 30 Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

- The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml,
- 35 preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation

of DME-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding DME, or any
5 fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding DME. Such technology is well known in the art, and antisense oligonucleotides or larger
10 fragments can be designed from various locations along the coding or control regions of sequences encoding DME. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence
15 complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.)
20 Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding DME may be used for
25 somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475),
30 cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 389:239-242)),
(ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from
35 unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular

parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in DME expression or regulation causes disease, the expression of DME from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in DME are treated by constructing mammalian expression vectors encoding DME and introducing these vectors by mechanical means into DME-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev. Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr. Opin. Biotechnol.* 9:445-450).

Expression vectors that may be effective for the expression of DME include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). DME may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547-5551; Gossen, M. et al. (1995) *Science* 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) *Curr. Opin. Biotechnol.* 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding DME from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to DME expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding DME under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding DME to cells which have one or more genetic abnormalities with respect to the expression of DME. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding DME to target cells which have one or more genetic abnormalities with respect to the expression of DME. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing DME to cells of the central nervous system, for which HSV has a

tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) *Exp. Eye Res.* 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) *J. Virol.* 73:519-532 and Xu, H. et al. (1994) *Dev. Biol.* 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding DME to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for DME into the alphavirus genome in place of the capsid-coding region results in the production of a large number of DME-coding RNAs and the synthesis of high levels of DME in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) *Virology* 228:74-83). The wide host range of alphaviruses will allow the introduction of DME into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions

-10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using
5 triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of
10 RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding DME.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by
15 scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary
20 oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo
25 transcription of DNA sequences encoding DME. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible
30 modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of
35 adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous

endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding DME. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased DME expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding DME may be therapeutically useful, and in the treatment of disorders associated with decreased DME expression or activity, a compound which specifically promotes expression of the polynucleotide encoding DME may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding DME is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding DME are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding DME. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a *Schizosaccharomyces pombe* gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides,

ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of DME, antibodies to DME, and mimetics, agonists, antagonists, or inhibitors of DME.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of

macromolecules comprising DME or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, DME or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to
5 transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration
10 range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example DME or fragments thereof, antibodies of DME, and agonists, antagonists or inhibitors of DME, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by
15 standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are
20 used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the
25 subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week,
30 or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their
35 inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells,

conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind DME may be used for the diagnosis of disorders characterized by expression of DME, or in assays to monitor patients being
5 treated with DME or agonists, antagonists, or inhibitors of DME. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for DME include methods which utilize the antibody and a label to detect DME in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A
10 wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring DME, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of DME expression. Normal or standard values for DME expression are established by combining body fluids or cell extracts
15 taken from normal mammalian subjects, for example, human subjects, with antibodies to DME under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of DME expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding DME may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of DME may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of
20 DME, and to monitor regulation of DME levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding DME or closely related molecules may be used to identify nucleic acid sequences which encode DME. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g.,
30 a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding DME, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the DME encoding sequences. The hybridization probes of the subject
35 invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:25-48 or from

genomic sequences including promoters, enhancers, and introns of the DME gene.

Means for producing specific hybridization probes for DNAs encoding DME include the cloning of polynucleotide sequences encoding DME or DME derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and
5 may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding DME may be used for the diagnosis of disorders
10 associated with expression of DME. Examples of such disorders include, but are not limited to, an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED),
15 bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis,
20 polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis,
25 bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas,
30 parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia,
35 hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and

neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; an endocrine disorder, such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with hypopituitarism including hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism; disorders associated with hyperpituitarism including acromegaly, gigantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma; disorders associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism; disorders associated with hyperthyroidism including thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalcemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 α -reductase, and gynecomastia; an eye disorder, such as conjunctivitis, keratoconjunctivitis sicca, keratitis, episcleritis, iritis, posterior uveitis, glaucoma, amaurosis fugax, ischemic optic neuropathy, optic neuritis, Leber's hereditary optic neuropathy, toxic optic neuropathy, vitreous detachment, retinal detachment, cataract, macular degeneration, central serous chorioretinopathy, retinitis pigmentosa, melanoma of the choroid, retrobulbar tumor, and chiasmal tumor; a metabolic disorder, such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism,

hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, Menkes syndrome, occipital horn syndrome, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, pseudovitamin D-deficiency rickets; hypocalcemia, hypophosphatemia, and

5 postpubescent cerebellar ataxia, tyrosinemia, and a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary

10 tract disease, hepatitis, hyperbilirubinemia, hereditary hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic

15 encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha₁-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas,

20 and carcinomas. The polynucleotide sequences encoding DME may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered DME expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding DME may be useful in assays that

25 detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding DME may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to

30 a control sample then the presence of altered levels of nucleotide sequences encoding DME in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of

35 DME, a normal or standard profile for expression is established. This may be accomplished by

combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding DME, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially-purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding DME may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding DME, or a fragment of a polynucleotide complementary to the polynucleotide encoding DME, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding DME may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding DME are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the

oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus

5 sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

10 Methods which may also be used to quantify the expression of DME include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide
15 of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels
20 of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be
25 used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, DME, fragments of DME, or antibodies specific for DME may be
30 used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed
35 by quantifying the number of expressed genes and their relative abundance under given conditions

and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared

with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global
5 pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the
10 separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical
15 density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic
20 cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for DME to quantify the
25 levels of DME expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoz, L.G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol-
30 or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson,
35 N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be

useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

5 In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic
10 response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

 In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are
15 incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

20 Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of
25 microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

 In another embodiment of the invention, nucleic acid sequences encoding DME may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be
30 preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1
35 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat.

Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP).

5 (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding DME
10 on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse,
15 may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for
20 further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, DME, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug
25 screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between DME and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT
30 application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with DME, or fragments thereof, and washed. Bound DME is then detected by methods well known in the art. Purified DME can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a
35 solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding DME specifically compete with a test compound for binding DME. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with DME.

5 In additional embodiments, the nucleotide sequences which encode DME may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding
10 description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. Nos. 60/176,139, 60/177,443, and 60/178,574, are hereby expressly incorporated
15 by reference.

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database
20 (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium
25 acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively,
30 RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the
35 recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra,

units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column

5 chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPO1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells
10 including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using
15 at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

20 Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence
25 scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal
30 cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides
35 were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the

ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the

5 techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public

10 databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) *Curr. Opin. Struct. Biol.* 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and

15 HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs

20 based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO,

25 PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence

30 alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used,

35 the second column provides brief descriptions thereof, the third column presents appropriate

references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

5 The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:25-48. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

IV. Identification and Editing of Coding Sequences from Genomic DNA

10 Putative drug metabolizing enzymes were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpr1 and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) *J. Mol. Biol.* 268:78-94, and Burge, C. and S. Karlin (1998) *Curr. Opin. Struct. Biol.* 8:346-354). The program concatenates predicted exons to
15 form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode drug metabolizing enzymes, the encoded polypeptides were analyzed by querying against PFAM models for drug metabolizing enzymes. Potential drug
20 metabolizing enzymes were also identified by homology to Incyte cDNA sequences that had been annotated as drug metabolizing enzymes. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpr1 public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST
25 analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in
30 Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene
35 identification program described in Example IV. Partial cDNAs assembled as described in Example

III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or
5 extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by
10 cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences
15 were translated and compared by BLAST analysis to the genpept and gbpr public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

20 Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in
25 Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences
30 were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of DME Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:25-48 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other
35 implementations of the Smith-Waterman algorithm. Sequences from these databases that matched

SEQ ID NO:25-48 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences
 5 had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

Map locations are represented by ranges, or intervals, or human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between
 10 chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site
 15 (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs
 20 from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel (1995) *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of
 25 the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum \{length(Seq. 1), length(Seq. 2)\}}}$$

30

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is
 35 calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair

(HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding DME are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding DME. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of DME Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing

primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:25-48 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Skena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Skena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope

slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a
5 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

10 Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

15 Hybridization

Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just
20 slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

25 Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide
30 containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477,
35 Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores.

Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores
5 simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples
10 from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital
15 (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping
20 emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

25 **XI. Complementary Polynucleotides**

Sequences complementary to the DME-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring DME. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are
30 designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of DME. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the DME-encoding transcript.

35 **XII. Expression of DME**

Expression and purification of DME is achieved using bacterial or virus-based expression systems. For expression of DME in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express DME upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of DME in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding DME by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, DME is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from DME at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified DME obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.

XIII. Functional Assays

DME function is assessed by expressing the sequences encoding DME at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected

into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of DME on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding DME and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding DME and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of DME Specific Antibodies

DME substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the DME amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-

Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-DME activity by, for example, binding the peptide or DME to a substrate,
5 blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring DME Using Specific Antibodies

Naturally occurring or recombinant DME is substantially purified by immunoaffinity chromatography using antibodies specific for DME. An immunoaffinity column is constructed by
10 covalently coupling anti-DME antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing DME are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of DME (e.g., high ionic strength
15 buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/DME binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and DME is collected.

XVI. Identification of Molecules Which Interact with DME

DME, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent.
20 (See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled DME, washed, and any wells with labeled DME complex are assayed. Data obtained using different concentrations of DME are used to calculate values for the number, affinity, and association of DME with the candidate molecules.

25 Alternatively, molecules interacting with DME are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

DME may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all
30 interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

XVII. Demonstration of DME Activity

Cytochrome P450 activity of DME is measured using the 4-hydroxylation of aniline. Aniline is converted to 4-aminophenol by the enzyme, and has an absorption maximum at 630 nm (Gibson
35 and Skett, supra). This assay is a convenient measure, but underestimates the total hydroxylation,

which also occurs at the 2- and 3- positions. Assays are performed at 37 °C and contain an aliquot of the enzyme and a suitable amount of aniline (approximately 2 mM) in reaction buffer. For this reaction, the buffer must contain NADPH or an NADPH-generating cofactor system. One formulation for this reaction buffer includes 85 mM Tris pH 7.4, 15 mM MgCl₂, 50 mM
5 nicotinamide, 40 mg trisodium isocitrate, and 2 units isocitrate dehydrogenase, with 8 mg NADP⁺ added to a 10 mL reaction buffer stock just prior to assay. Reactions are carried out in an optical cuvette, and the absorbance at 630 nm is measured. The rate of increase in absorbance is proportional to the enzyme activity in the assay. A standard curve can be constructed using known concentrations of 4-aminophenol.

- 10 1 α ,25-dihydroxyvitamin D 24-hydroxylase activity of DME is determined by monitoring the conversion of ³H-labeled 1 α ,25-dihydroxyvitamin D (1 α ,25(OH)₂D) to 24,25-dihydroxyvitamin D (24,25(OH)₂D) in transgenic rats expressing DME. 1 μ g of 1 α ,25(OH)₂D dissolved in ethanol (or ethanol alone as a control) is administered intravenously to approximately 6-week-old male transgenic rats expressing DME or otherwise identical control rats expressing either a defective
15 variant of DME or not expressing DME. The rats are killed by decapitation after 8 hrs, and the kidneys are rapidly removed, rinsed, and homogenized in 9 volumes of ice-cold buffer (15 mM Tris-acetate (pH 7.4), 0.19 M sucrose, 2 mM magnesium acetate, and 5 mM sodium succinate). A portion (e.g., 3 ml) of each homogenate is then incubated with 0.25 nM 1 α ,25(OH)₂[1-³H]D, with a specific activity of approximately 3.5 GBq/mmol, for 15 min at 37 °C under oxygen with constant shaking.
- 20 Total lipids are extracted as described (Bligh, E.G. and Dyer, W.J. (1959) Can. J. Biochem. Physiol. 37: 911-917) and the chloroform phase is analyzed by HPLC using a FINEPAK SIL column (JASCO, Tokyo, Japan) with a *n*-hexane/chloroform/methanol (10:2.5:1.5) solvent system at a flow rate of 1 ml/min. In the alternative, the chloroform phase is analyzed by reverse phase HPLC using a J SPHERE ODS-AM column (YMC Co. Ltd., Kyoto, Japan) with an acetonitrile buffer system (40
25 to 100%, in water, in 30 min) at a flow rate of 1 ml/min. The eluates are collected in fractions of 30 seconds (or less) and the amount of ³H present in each fraction is measured using a scintillation counter. By comparing the chromatograms of control samples (i.e., samples comprising 1 α ,25-dihydroxyvitamin D or 24,25-dihydroxyvitamin D (24,25(OH)₂D), with the chromatograms of the reaction products, the relative mobilities of the substrate (1 α ,25(OH)₂[1-³H]D) and product
30 (24,25(OH)₂[1-³H]D) are determined and correlated with the fractions collected. The amount of 24,25(OH)₂[1-³H]D produced in control rats is subtracted from that of transgenic rats expressing DME. The difference in the production of 24,25(OH)₂[1-³H]D in the transgenic and control animals is proportional to the amount of 25-hydroxylase activity of DME present in the sample. Confirmation of the identity of the substrate and product(s) is confirmed by means of mass spectroscopy
35 (Miyamoto, Y. et al. (1997) J. Biol. Chem. 272:14115-14119).

Flavin-containing monooxygenase activity of DME is measured by chromatographic analysis of metabolic products. For example, Ring, B. J. et al. (1999; Drug Metab. Dis. 27:1099-1103) incubated FMO in 0.1 M sodium phosphate buffer (pH 7.4 or 8.3) and 1 mM NADPH at 37°C, stopped the reaction with an organic solvent, and determined product formation by HPLC.

5 Alternatively, activity is measured by monitoring oxygen uptake using a Clark-type electrode. For example, Ziegler, D. M. and Poulsen, L. L. (1978; Methods Enzymol. 52:142-151) incubated the enzyme at 37°C in an NADPH-generating cofactor system (similar to the one described above) containing the substrate methimazole. The rate of oxygen uptake is proportional to enzyme activity.

UDP glucuronyltransferase activity of DME is measured using a colorimetric determination
10 of free amine groups (Gibson and Skett, *supra*). An amine-containing substrate, such as 2-aminophenol, is incubated at 37°C with an aliquot of the enzyme in a reaction buffer containing the necessary cofactors (40 mM Tris pH 8.0, 7.5 mM MgCl₂, 0.025% Triton X-100, 1 mM ascorbic acid, 0.75 mM UDP-glucuronic acid). After sufficient time, the reaction is stopped by addition of ice-cold 20% trichloroacetic acid in 0.1 M phosphate buffer pH 2.7, incubated on ice, and centrifuged to
15 clarify the supernatant. Any unreacted 2-aminophenol is destroyed in this step. Sufficient freshly-prepared sodium nitrite is then added; this step allows formation of the diazonium salt of the glucuronidated product. Excess nitrite is removed by addition of sufficient ammonium sulfamate, and the diazonium salt is reacted with an aromatic amine (for example, N-naphthylethylenediamine) to produce a colored azo compound which can be assayed spectrophotometrically (at 540 nm for the
20 example). A standard curve can be constructed using known concentrations of aniline, which will form a chromophore with similar properties to 2-aminophenol glucuronide.

Glutathione S-transferase activity of DME is measured using a model substrate, such as 2,4-dinitro-1-chlorobenzene, which reacts with glutathione to form a product, 2,4-dinitrophenyl-glutathione, that has an absorbance maximum at 340 nm. It is important to note that GSTs have
25 differing substrate specificities, and the model substrate should be selected based on the substrate preferences of the GST of interest. Assays are performed at ambient temperature and contain an aliquot of the enzyme in a suitable reaction buffer (for example, 1 mM glutathione, 1 mM dinitrochlorobenzene, 90 mM potassium phosphate buffer pH 6.5). Reactions are carried out in an optical cuvette, and the absorbance at 340 nm is measured. The rate of increase in absorbance is
30 proportional to the enzyme activity in the assay.

N-acyltransferase activity of DME is measured using radiolabeled amino acid substrates and measuring radiolabel incorporation into conjugated products. Enzyme is incubated in a reaction buffer containing an unlabeled acyl-CoA compound and radiolabeled amino acid, and the radiolabeled acyl-conjugates are separated from the unreacted amino acid by extraction into n-
35 butanol or other appropriate organic solvent. For example, Johnson, M. R. et al. (1990; J. Biol.

Chem. 266:10227-10233) measured bile acid-CoA:amino acid N-acyltransferase activity by incubating the enzyme with cholesteryl-CoA and ^3H -glycine or ^3H -taurine, separating the tritiated cholate conjugate by extraction into n-butanol, and measuring the radioactivity in the extracted product by scintillation. Alternatively, N-acyltransferase activity is measured using the spectrophotometric
5 determination of reduced CoA (CoASH) described below.

N-acetyltransferase activity of DME is measured using the transfer of radiolabel from [^{14}C]acetyl-CoA to a substrate molecule (for example, see Deguchi, T. (1975) J. Neurochem. 24:1083-5). Alternatively, a spectrophotometric assay based on DTNB (5,5'-dithio-bis(2-nitrobenzoic acid; Ellman's reagent) reaction with CoASH may be used. Free thiol-containing
10 CoASH is formed during N-acetyltransferase catalyzed transfer of an acetyl group to a substrate. CoASH is detected using the absorbance of DTNB conjugate at 412 nm (De Angelis, J. et al. (1997) J. Biol. Chem. 273:3045-3050). Enzyme activity is proportional to the rate of radioactivity incorporation into substrate, or the rate of absorbance increase in the spectrophotometric assay.

Catechol-O-methyltransferase activity of DME is measured in a reaction mixture consisting
15 of 50 mM Tris-HCl (pH 7.4), 1.2 mM MgCl_2 , 200 μM SAM (*S*-adenosyl-L-methionine) iodide (containing 0.5 μCi of methyl- $[\text{H}^3]\text{SAM}$), 1 mM dithiothreitol, and varying concentrations of catechol substrate (e.g., L-dopa, dopamine, or DBA) in a final volume of 1.0 ml. The reaction is initiated by the addition of 250-500 μg of purified DME or crude DME-containing sample and performed at 37 °C for 30 min. The reaction is arrested by rapidly cooling on ice and immediately
20 extracting with 7 ml of ice-cold n-heptane. Following centrifugation at 1000 x g for 10 min, 3-ml aliquots of the organic extracts are analyzed for radioactivity content by liquid scintillation counting. The level of catechol-associated radioactivity in the organic phase is proportional to the catechol-O-methyltransferase activity of DME (Zhu, B.T. Liehr, J.G. (1996) 271:1357-1363).

DHFR activity of DME is determined spectrophotometrically at 15 °C by following the
25 disappearance of NADPH at 340 nm ($\epsilon_{340} = 11,800 \text{ M}^{-1}\cdot\text{cm}^{-1}$). The standard assay mixture contains 100 μM NADPH, 14 mM 2-mercaptoethanol, MTEN buffer (50 mM 2-morpholinoethanesulfonic acid, 25 mM tris(hydroxymethyl)aminomethane, 25 mM ethanolamine, and 100 mM NaCl, pH 7.0), and DME in a final volume of 2.0 ml. The reaction is started by the addition of 50 μM dihydrofolate (as substrate). The oxidation of NADPH to NADP^+ corresponds to the reduction of dihydrofolate in
30 the reaction and is proportional to the amount of DHFR activity in the sample (Nakamura, T. and Iwakura, M. (1999) J. Biol. Chem. 274:19041-19047).

Aldo/keto reductase activity of DME is measured using the decrease in absorbance at 340 nm as NADPH is consumed. A standard reaction mixture is 135 mM sodium phosphate buffer (pH 6.2-7.2 depending on enzyme), 0.2 mM NADPH, 0.3 M lithium sulfate, 0.5-2.5 μg enzyme and an
35 appropriate level of substrate. The reaction is incubated at 30 °C and the reaction is monitored

continuously with a spectrophotometer. Enzyme activity is calculated as mol NADPH consumed / μg of enzyme.

Alcohol dehydrogenase activity of DME is measured using the increase in absorbance at 340 nm as NAD^+ is reduced to NADH. A standard reaction mixture is 50 mM sodium phosphate, pH 7.5, and 0.25 mM EDTA. The reaction is incubated at 25 °C and monitored using a spectrophotometer. Enzyme activity is calculated as mol NADH produced / μg of enzyme.

Carboxylesterase activity of DME activity is determined using 4-methylumbelliferyl acetate as a substrate. The enzymatic reaction is initiated by adding approximately 10 μl of DME-containing sample to 1 ml of reaction buffer (90 mM KH_2PO_4 , 40 mM KCl, pH 7.3) with 0.5 mM 4-methylumbelliferyl acetate at 37 °C. The production of 4-methylumbelliferone is monitored with a spectrophotometer ($\epsilon_{350} = 12.2 \text{ mM}^{-1} \text{ cm}^{-1}$) for 1.5 min. Specific activity is expressed as micromoles of product formed per minute per milligram of protein and corresponds to the activity of DME in the sample (Evgenia, V. et al. (1997) J. Biol. Chem. 272:14769-14775).

In the alternative, the cocaine benzoyl ester hydrolase activity of DME is measured by incubating approximately 0.1 ml of enzyme and 3.3 mM cocaine in reaction buffer (50 mM NaH_2PO_4 , pH 7.4) with 1 mM benzamidine, 1 mM EDTA, and 1 mM dithiothreitol at 37 °C. The reaction is incubated for 1 h in a total volume of 0.4 ml then terminated with an equal volume of 5% trichloroacetic acid. 0.1 ml of the internal standard 3,4-dimethylbenzoic acid (10 $\mu\text{g}/\text{ml}$) is added. Precipitated protein is separated by centrifugation at $12,000 \times g$ for 10 min. The supernatant is transferred to a clean tube and extracted twice with 0.4 ml of methylene chloride. The two extracts are combined and dried under a stream of nitrogen. The residue is resuspended in 14% acetonitrile, 250 mM KH_2PO_4 , pH 4.0, with 8 μl of diethylamine per 100 ml and injected onto a C18 reverse-phase HPLC column for separation. The column eluate is monitored at 235 nm. DME activity is quantified by comparing peak area ratios of the analyte to the internal standard. A standard curve is generated with benzoic acid standards prepared in a trichloroacetic acid-treated protein matrix (Evgenia, V. et al. (1997) J. Biol. Chem. 272:14769-14775).

In another alternative, DME carboxyl esterase activity against the water-soluble substrate para-nitrophenyl butyric acid is determined by spectrophotometric methods well known to those skilled in the art. In this procedure, the DME-containing samples are diluted with 0.5 M Tris-HCl (pH 7.4 or 8.0) or sodium acetate (pH 5.0) in the presence of 6 mM taurocholate. The assay is initiated by adding a freshly prepared para-nitrophenyl butyric acid solution (100 $\mu\text{g}/\text{ml}$ in sodium acetate, pH 5.0). Carboxyl esterase activity is then monitored and compared with control autohydrolysis of the substrate using a spectrophotometer set at 405 nm (Wan, L. et al. (2000) J. Biol. Chem. 275:10041-10046).

Sulfotransferase activity of DME is measured using the incorporation of ^{35}S from [^{35}S]PAPS

into a model substrate such as phenol (Folds, A. and Meek, J. L. (1973) *Biochim. Biophys. Acta* 327:365-374). An aliquot of enzyme is incubated at 37 °C with 1 mL of 10 mM phosphate buffer, pH 6.4, 50 µM phenol, and 0.4-4.0 µM [³⁵S]PAPS. After sufficient time for 5-20% of the radiolabel to be transferred to the substrate, 0.2 mL of 0.1 M barium acetate is added to precipitate protein and phosphate buffer. Then 0.2 mL of 0.1 M Ba(OH)₂ is added, followed by 0.2 mL ZnSO₄. The supernatant is cleared by centrifugation, which removes proteins as well as unreacted [³⁵S]PAPS. Radioactivity in the supernatant is measured by scintillation. The enzyme activity is determined from the number of moles of radioactivity in the reaction product.

Heparan sulfate 6-sulfotransferase activity of DME is measured in vitro by incubating a sample containing DME along with 2.5 µmol imidazole HCl (pH 6.8), 3.75 µg of protamine chloride, 25 nmol (as hexosamine) of completely desulfated and N-resulfated heparin, and 50 pmol (about 5 x 10⁵ cpm) of [³⁵S] adenosine 3'-phosphate 5'-phosphosulfate (PAPS) in a final reaction volume of 50 µl at 37 °C for 20 min. The reaction is stopped by immersing the reaction tubes in a boiling water bath for 1 min. 0.1 µmol (as glucuronic acid) of chondroitin sulfate A is added to the reaction mixture as a carrier. ³⁵S-Labeled polysaccharides are precipitated with 3 volumes of cold ethanol containing 1.3% potassium acetate and separated completely from unincorporated [³⁵S]PAPS and its degradation products by gel chromatography using desalting columns. One unit of enzyme activity is defined as the amount required to transfer 1 pmol of sulfate/min., determined by the amount of [³⁵S]PAPS incorporated into the precipitated polysaccharides (Habuchi, H. et al. (1995) *J. Biol. Chem.* 270:4172-4179).

In the alternative, heparan sulfate 6-sulfotransferase activity of DME is measured by extraction and renaturation of enzyme from gels following separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Following separation, the gel is washed with buffer (0.05 M Tris-HCl, pH 8.0), cut into 3-5 mm segments and subjected to agitation at 4 °C with 100 µl of the same buffer containing 0.15 M NaCl for 48 h. The eluted enzyme is collected by centrifugation and assayed for the sulfotransferase activity as described above (Habuchi, H. et al. (1995) *J. Biol. Chem.* 270:4172-4179).

In another alternative, DME sulfotransferase activity is determined by measuring the transfer of [³⁵S]sulfate from [³⁵S]PAPS to an immobilized peptide that represents the N-terminal 15 residues of the mature P-selectin glycoprotein ligand-1 polypeptide to which a C-terminal cysteine residue is added. The peptide spans three potential tyrosine sulfation sites. The peptide is linked via the cysteine residue to iodoacetamide-activated resin at a density of 1.5-3.0 µmol peptide/ml of resin. The enzyme assay is performed by combining 10 µl of peptide-derivitized beads with 2-20 µl of DME-containing sample in 40 mM Pipes (pH 6.8), 0.3 M NaCl, 20 mM MnCl₂, 50 mM NaF, 1% Triton X-100, and 1 mM 5'-AMP in a final volume of 130 µl. The assay is initiated by addition of

0.5 μ Ci of [35 S]PAPS (1.7 μ M; 1 Ci = 37 GBq). After 30 min at 37°C, the reaction beads are washed with 6 M guanidine at 65°C and the radioactivity incorporated into the beads is determined by liquid scintillation counting. Transfer of [35 S]sulfate to the bead-associated peptide is measured to determine the DME activity in the sample. One unit of activity is defined as 1 pmol of product
5 formed per min (Ouyang, Y-B. et al. (1998) Biochemistry 95:2896-2901).

In another alternative, DME sulfotransferase assays are performed using [35 S]PAPS as the sulfate donor in a final volume of 30 μ l, containing 50 mM Hepes-NaOH (pH 7.0), 250 mM sucrose, 1 mM dithiothreitol, 14 μ M [35 S]PAPS (15 Ci/mmol), and dopamine (25 μ M), *p*-nitrophenol (5 μ M), or other candidate substrates. Assay reactions are started by the addition of a purified DME enzyme
10 preparation or a sample containing DME activity, allowed to proceed for 15 min at 37 °C, and terminated by heating at 100 °C for 3 min. The precipitates formed are cleared by centrifugation. The supernatants are then subjected to the analysis of 35 S-sulfated product by either thin-layer chromatography or a two-dimensional thin layer separation procedure. Appropriate standards are run in parallel with the supernatants to allow the identification of the 35 S-sulfated products and
15 determine the enzyme specificity of the DME-containing samples based on relative rates of migration of reaction products (Sakakibara, Y. et al. (1998) J. Biol. Chem. 273:6242-6247).

Squalene epoxidase activity of DME is assayed in a mixture comprising purified DME (or a crude mixture comprising DME), 20 mM Tris-HCl (pH 7.5), 0.01 mM FAD, 0.2 unit of NADPH-cytochrome C (P-450) reductase, 0.01 mM [14 C]squalene (dispersed with the aid of 20 μ l of
20 Tween 80), and 0.2% Triton X-100. 1 mM NADPH is added to initiate the reaction followed by incubation at 37 °C for 30 min. The nonsaponifiable lipids are analyzed by silica gel TLC developed with ethyl acetate/benzene (0.5:99.5, v/v). The reaction products are compared to those from a reaction mixture without DME. The presence of 2,3(*S*)-oxidosqualene is confirmed using appropriate lipid standards (Sakakibara, J. et al. (1995) 270:17-20).

Epoxide hydrolase activity of DME is determined by following substrate depletion using gas chromatographic (GC) analysis of ethereal extracts or by following substrate depletion and diol production by GC analysis of reaction mixtures quenched in acetone. A sample containing DME or an epoxide hydrolase control sample is incubated in 10 mM Tris-HCl (pH 8.0), 1 mM ethylenediaminetetraacetate (EDTA), and 5 mM epoxide substrate (e.g., ethylene oxide, styrene
30 oxide, propylene oxide, isoprene monoxide, epichlorohydrin, epibromohydrin, epifluorohydrin, glycidol, 1,2-epoxybutane, 1,2-epoxyhexane, or 1,2-epoxyoctane). A portion of the sample is withdrawn from the reaction mixture at various time points, and added to 1 ml of ice-cold acetone containing an internal standard for GC analysis (e.g., 1-nonanol). Protein and salts are removed by centrifugation (15 min, 4000 \times g) and the extract is analyzed by GC using a 0.2 mm \times 25-m
35 CP-Wax57-CB column (CHROMPACK, Middelburg, The Netherlands) and a flame-ionization

detector. The identification of GC products is performed using appropriate standards and controls well known to those skilled in the art. 1 Unit of DME activity is defined as the amount of enzyme that catalyzes the production of 1 μ mol of diol/min (Rink, R. et al. (1997) J. Biol. Chem. 272:14650-14657).

- 5 Aminotransferase activity of DME is assayed by incubating samples containing DME for 1 hour at 37 °C in the presence of 1 mM L-kynurenine and 1 mM 2-oxoglutarate in a final volume of 200 μ l of 150 mM Tris acetate buffer (pH 8.0) containing 70 μ M PLP. The formation of kynurenic acid is quantified by HPLC with spectrophotometric detection at 330 nm using the appropriate standards and controls well known to those skilled in the art. In the alternative,
- 10 L-3-hydroxykynurenine is used as substrate and the production of xanthurenic acid is determined by HPLC analysis of the products with UV detection at 340 nm. The production of kynurenic acid and xanthurenic acid, respectively, is indicative of aminotransferase activity (Buchli, R. et al. (1995) J. Biol. Chem. 270:29330-29335).

- In another alternative, aminotransferase activity of DME is measured by determining the
- 15 activity of purified DME or crude samples containing DME toward various amino and oxo acid substrates under single turnover conditions by monitoring the changes in the UV/VIS absorption spectrum of the enzyme-bound cofactor, pyridoxal 5'-phosphate (PLP). The reactions are performed at 25 °C in 50 mM 4-methylmorpholine (pH 7.5) containing 9 μ M purified DME or DME containing samples and substrate to be tested (amino and oxo acid substrates). The half-reaction from amino
- 20 acid to oxo acid is followed by measuring the decrease in absorbance at 360 nm and the increase in absorbance at 330 nm due to the conversion of enzyme-bound PLP to pyridoxamine 5' phosphate (PMP). The specificity and relative activity of DME is determined by the activity of the enzyme preparation against specific substrates (Vacca, R.A. et al. (1997) J. Biol. Chem. 272:21932-21937).

- Superoxide dismutase activity of DME is assayed from cell pellets, culture supernatants, or
- 25 purified protein preparations. Samples or lysates are resolved by electrophoresis on 15% non-denaturing polyacrylamide gels. The gels are incubated for 30 min in 2.5 mM nitro blue tetrazolium, followed by incubation for 20 min in 30 mM potassium phosphate, 30 mM TEMED, and 30 μ M riboflavin (pH 7.8). Superoxide dismutase activity is visualized as white bands against a blue background, following illumination of the gels on a lightbox. Quantitation of superoxide
- 30 dismutase activity is performed by densitometric scanning of the activity gels using the appropriate superoxide dismutase positive and negative controls (e.g., various amounts of commercially available *E. coli* superoxide dismutase (Harth, G. and Horwitz, M.A. (1999) J. Biol. Chem. 274:4281-4292).

XVIII. Identification of DME Inhibitors

- 35 Compounds to be tested are arrayed in the wells of a multi-well plate in varying

concentrations along with an appropriate buffer and substrate, as described in the assays in Example XVII. DME activity is measured for each well and the ability of each compound to inhibit DME activity can be determined, as well as the dose-response profiles. This assay could also be used to identify molecules which enhance DME activity.

5

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific
10 embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Nucleotide SEQ ID NO:	Incyte Nucleotide ID
1799250	1	1799250CD1	25	1799250CB1
2242475	2	2242475CD1	26	2242475CB1
2706492	3	2706492CD1	27	2706492CB1
2766688	4	2766688CD1	28	2766688CB1
2788823	5	2788823CD1	29	2788823CB1
3348822	6	3348822CD1	30	3348822CB1
4290251	7	4290251CD1	31	4290251CB1
4904188	8	4904188CD1	32	4904188CB1
638419	9	638419CD1	33	638419CB1
1844394	10	1844394CD1	34	1844394CB1
2613056	11	2613056CD1	35	2613056CB1
5053617	12	5053617CD1	36	5053617CB1
5483256	13	5483256CD1	37	5483256CB1
5741354	14	5741354CD1	38	5741354CB1
5872615	15	5872615CD1	39	5872615CB1
2657543	16	2657543CD1	40	2657543CB1
3041639	17	3041639CD1	41	3041639CB1
3595451	18	3595451CD1	42	3595451CB1
4169101	19	4169101CD1	43	4169101CB1
2925182	20	2925182CD1	44	2925182CB1
3271838	21	3271838CD1	45	3271838CB1
3292871	22	3292871CD1	46	3292871CB1
4109179	23	4109179CD1	47	4109179CB1
4780365	24	4780365CD1	48	4780365CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability Score	GenBank Homolog
1	1799250CD1	g9622124	7.00e-39	androgen-regulated short-chain dehydrogenase/reductase 1 [Homo sapiens]
2	2242475CD1	g181350	2.3e-250	debrisoquine 4-hydroxylase [Homo sapiens]
3	2706492CD1	g9622124	2.00e-29	androgen-regulated short-chain dehydrogenase/reductase 1 [Homo sapiens]
4	2766688CD1	g7533022	0	oxysterol 7alpha-hydroxylase [Mus musculus]
5	2788823CD1	g9622124	4.00e-63	androgen-regulated short-chain dehydrogenase/reductase 1 [Homo sapiens]
6	3348822CD1	g164981	7.9e-138	cytochrome P-450p-2 [Oryctolagus cuniculus]
7	4290251CD1	g3135970	2.7e-150	dJ352A20.2 (aldehyde dehydrogenase family)
8	4904188CD1	g10039619	2.00e-92	PAN2 [Homo sapiens]
9	638419CD1	g3004922	3.8e-99	phenol sulfotransferase [Mus musculus]
10	1844394CD1	g2621120	7.6e-14	O-linked GlcNAc transferase [Methanobacterium thermoautotrophicum]
11	2613056CD1	g6063487	7.1e-100	cytochrome P450 XL-301 [Xenopus laevis]
12	5053617CD1	g2662573	0.00075	similar to UDP-glucuronosyltransferase [Caenorhabditis elegans]
13	5483256CD1	g3879119	5.5e-61	similar to Glutathione S-transferases.; cDNA EST...
14	5741354CD1	g1185452	1.5e-104	cytochrome P450 monooxygenase CYP2J2 [Homo sapiens]
15	5872615CD1	g5410280	7.0e-38	HSPCO34 protein [Homo sapiens]
		g2921821	0.81	Cytochrome P450 IIE1 [Rattus norvegicus]

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability Score	GenBank Homolog
16	2657543CD1	g510905	4.5e-27	glutathione transferase T1 [Homo sapiens]
17	3041639CD1	g1280387	5.3e-95	alpha 2,6-sialyltransferase [Rattus norvegicus]
18	3595451CD1	g3355516	1.6e-118	dJ248E1.1 (DOPAMINE-BETA-MONOOXYGENASE PRECURSOR (DOPAMINE BETA-HYDROXYLASE) (DBH)) [Homo sapiens]
19	4169101CD1	g1055177	6.0e-97	weakly similar to E. nidulans bimA gene product
		g2621120	1.1e-28	O-linked GlcNAc transferase [Methanobacterium thermoautotrophicum]
20	2925182CD1	g6329074	5.0e-289	UDP-GlcNAc:a-1,3-D-mannoside b-1,4-N-acetylglucosaminyltransferase IV [Homo sapiens]
21	3271838CD1	g4827177	2.6e-285	thioredoxin reductase II alpha [Homo sapiens]
22	3292871CD1	g8515441	0	cytochrome P450 retinoid metabolizing protein P450RAI-2 [Homo sapiens]
23	4109179CD1	g155947	2.4e-06	cytochrome P450 [Blaberus discoidalis]
24	4780365CD1	g4590450	2.9e-183	Al-specific alpha 1->3 N-acetylglactosaminyltransferase [Homo sapiens]

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino acid residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences and Motifs	Analytical Methods and Databases
1	1799250CD1	330	T59 T91 S108 T165 S175 S269	N76	Signal Peptide:M1-G31 Short-chain alcohol dehydrogenase:R44-D246, D195-L222, I121-G131, V188-L225, H232-G241 Short-chain alcohol dehydrogenase family: DM00034 S42651 28-318:A46-M322	BLAST-DOMO BLIMPS-BLOCKS BLIMPS-PRINTS HMMER Motifs SPScan
2	2242475CD1	497	T93 T138 S168 T249 S289 T378 S379 T407	N166 N398	Signal peptide: M1-R25 Transmembrane domain:M1-L18 P450:P34-A494 Cytochrome P450 cysteine BL00086:F422-F453 E-class P450 group I sig: PR00463A-I:R62-L81, A86-T107, A181-D199, N294-S311, L314-G340, D346-Q364, F387-K411, D422-A432, A432-L455 Cytochrome_P450: P34-A494, F404-S454, F436-L444 Cytochrome P450 heme-iron ligand sig: H416-S465 Cytochrome P450 family: DM00022 I49427 46-483:L43-F481 PD000021:L251-G386	BLAST-DOMO BLAST-PRODOR BLIMPS HMMER Motifs ProfileScan
3	2706492CD1	286	S10 S187 S216 S264 S265 T272		Signal cleavage:M1-A68 Short-chain alcohol dehydrogenase family: M1-E142, BL00061A:P23-G33, BL00061C:G128-G137, PR00080A:P23-I34, PR00080C:Y106-E125 Short-chain alcohol dehydrogenase family: DM00034 S42651 28-318:M1-L219	BLAST-DOMO BLIMPS-BLOCKS BLIMPS-PRINTS Motifs SPScan

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino acid residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences and Motifs	Analytical Methods and Databases
4	2766688CD1	469	T77 S88 T182 S218 S238 T258 S259 S291 S318 T335 T345 S409 S438	N176 N214	Signal peptide:M1-Q22 Transmembrane domain:S5-Q22 Cytochrome P450:P29-R396 E-class cytochrome P450 sig: PR00465A-F,H:P29-G46, E51-T74, P264-L290, L325-P341, Y357-W371, H373-E391, C414-L432 Cytochrome P450: DM02967 Q09736 16-486:L21-W390 DM00022 S50211 59-488:W272-E458	BLAST-DOMO BLIMPS-PRINTS HMMER Motifs
5	2788823CD1	331	T54 S100 S103 T134 T135 T191 S215 S284 S313 S323	N171	Signal cleavage:M1-A17 Short-chain dehydrogenase:K39-E236 Short-chain dehydrogenase: BL00051A-C:E116-G126, G180-R217, G222-G231 Alcohol dehydrogenase: PR00080A-C:E116-V127, S167-L175, Y200-Q219 Short-chain alcohol dehydrogenase family: DM00034 S42651 28-318:T40-V317	BLAST-DOMO BLIMPS-BLOCKS BLIMPS-PRINTS Motifs SPScan
6	3348822CD1	509	S4 S104 T106 S159 S172 T173 T176 S177 S207 T208 T278 S292 S300 S302 T374 T393	N206	Signal peptide:M1-L32 Signal cleavage:M1-A29 Transmembrane domain:L16-L34 Cytochrome P450:F46-L503 Cytochrome P450 cys heme-iron ligand: F426-H474 Cytochrome P450 cysteine: BL00086: Y444-F475 Cytochrome P450: DM00022 P10611 120-497:P119-M499	BLAST-DOMO BLIMPS-BLOCKS HMMER Motifs SPScan ProfileScan

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino acid residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences and Motifs	Analytical Methods and Databases
7	4290251CD1	433	S23 Y24 S31 T32 S42 S62 S63 S65 S83 T129 T140 T162 S220 T275 S350 T430		Aldehyde dehydrogenase family: aldehyd:K17-H433 aldehyde_dehydr_glu.prf:G211-S279 Aldehyde dehydrogenase: L242-P259 Aldoketoreductase 3: L101-F116 Aldehyde dehydrogenase: BL00687A-F: W61-D78, A143-S184, P200-A236, G255-G301, G316-L365, P402-G412 Aldehyde dehydrogenase family: PD000218:D29-L307 DM00100 P19059 1-462:L10-Y317	BLAST-DOMO BLAST-PRODOM BLIMPS-BLOCKS Motifs HMMER Motifs ProfileScan
8	4904188CD1	186	S41 S42 T128 S141 S142 S149	N62 N89.	Signal cleavage:M1-S31 Glucose rubitol dehydrogenase: PR00081C-F: L29-Y45, Y67-E86, T88-G105, W122-S142 Short-chain alcohol dehydrogenase family: DM00034 Q03326 1-259:D5-E158 DM00034 S39394 69-356:T3-S42	BLAST-DOMO BLIMPS-PRINTS Motifs SPScan
9	638419CD1	304	S173 S180 T194 T236 S237	N248 N258	Sulfotransferase: PD001218:F18-K292 PAPS Cofactor Binding Site: DM00981 P52840 1-291:I20-I304	BLAST-DOMO BLAST-PRODOM HMMER Motifs
10	1844394CD1	629	S11 S83 T92 T148 T150 T179 S185 T186 S209 S299 Y310 S312 S339 S366 T403 T424 T466 T488 S510 S542 S566 S576 T609 T284	N386 N563	TPR Domain TPR:Q316-P344, W350-P378 HYPOTHETICAL 90.0 KD PROTEIN T20B12.1 IN CHROMOSOME III PD141851:K2-L246 Intermediate filaments signature I435-D443 Cytochrome c and c1 heme BL00821E:L71-N84	HMMER-PFAM BLAST-PRODOM MOTIFS BLIMPS-BLOCKS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino acid residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences and Motifs	Analytical Methods and Databases
11	2613056CD1	320	S21 T72 S82 T92 S105 S115 T206 S249	N32 N196	Cytochrome P450 p450:M1-A316 Cytochrome_P450 F260-G269 Cytochrome P450 cysteine heme-iron ligand signature cytochrome_p450.prf:F239-R287 CYTOCHROME P450 MONOOXYGENASE OXIDOREDUCTASE HEME ELECTRON TRANSPORT MEMBRANE MICROSOME ENDOPLASMIC PD000021:L50-S198 CYTOCHROME P450 DM00022 P10611 120-497:M1-I312 Cytochrome P450 cysteine heme-iron ligand signature BL00086:F257-F288 E-class P450 group II signature PR00464B:M1-Q18 PR00464C:D118-A146, PR00464D:K147-G164, PR00464E:Q176-N196, PR00464F:G216-Y231, PR00464G:F232-E247, PR00464H:P254-C267, PR00464I:C267-L290	HMMER-PFAM MOTIFS ProfileScan BLAST-PRODOM BLAST-DOMO BLIMPS-BLOCKS BLIMPS-PRINTS
12	5053617CD1	56			signal_cleavage:M1-A50	SPSCAN
13	5483256CD1	377	S55 T75 S97 S144 T253 S290	N163	Glutathione S-transferases GST:L102-V152, A278-I370 Glutaredoxin proteins: BL00195A:L104-V116 Glutaredoxin signature: PR00160A:L102-L120 PROTEIN SUP R11A8.5: PD134628:S98-E372	HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino acid residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences and Motifs	Analytical Methods and Databases
14	5741354CD1	501	S70 S143 T171 T201 S303 S351 T383 Y431	N189	CYTOCHROME P450 DM00022 P52786 83-492:G83-P491 Cytochrome_P450: F441-L449 signal_peptide:M1-L31 signal_cleavage:M1-Q29 transmem_domain:A12-L30 Cytochrome_P450: p450:P40-A498 Cytochrome_P450 cysteine heme-iron ligand signature: BL00086:L438-F469 E-class P450 group I signature PR00463A:S70-L89, PR00463B:V94-F115, PR00463C:A186-D204, PR00463D:N299-T316, PR00463E:L319-G345, PR00463F:E362-F380, PR00463G:N403-D427, PR00463H:L438-C448, PR00463I:C448-L471 Cytochrome_P450 cysteine heme-iron ligand signature: cytochrome_p450.prf:F420-H470 CYTOCHROME P450 MONOOXYGENASE OXIDOREDUCTASE HEME ELECTRON TRANSPORT MEMBRANE MICROSOME ENDOPLASMIC PD000021:Q244-G391	BLAST-DOMO MOTIFS HMMER SPSCAN HMMER HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS
15	5872615CD1	144	T19 S20 T71 T78 S121	N141		ProfileScan BLAST-PRODOM
16	2657543CD1	218	T90 S72 S152		signal peptide:M1-G23 GST (glutathione S-transferases):N9-V161 Dichloromethane dehalogenase: DM02033 Q01579 70-200:V68-M162	SPScan HMMER-PFAM BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation sites	Signature Sequences and Motifs	Analytical Methods and Databases
17	3041639CD1	210	S9 T53 T189 T204 S194	N148	signal_cleavage:M1-E30 ALPHANACETYL GALACTOSAMINIDE ALPHA2,6SIALYLTRANSFERASE: PD129519:M1-Q74 GLYCOSYLTRANSFERASE: PD129520:W155-D207 LUMENAL DOMAIN, SIALYLTRANSFERASE: DM01020 S41114 71-400:C80-P157	SPScan BLAST-PRODOM BLAST-PRODOM BLAST-PRODOM
18	3595451CD1	613	S21 T29 S42 T118 S135 T140 S162 S168 S249 S253 T295 T312 S459 T460 S482 S511 S519 T530 S551 S609	N114 N247 N476 N517	COPPER TYPE II, ASCORBATE-DEPENDENT MONOOXYGENASES: DM04634 P08478 1-399:T268-Y472 PEPTIDYLGLYCINE MONOOXYGENASE I: DM07918 P15101 1-609:L6-P573 signal_peptide:M1-A18 signal_cleavage:M1-A18 Copper type II, ascorbate-dependent monooxygenase: Cu2_monooxygen:M1-G337 Copper type II, ascorbate-dependent monooxygenases signature: cu2_monooxygenase_1.prf:V212-L317 DOPAMINE BETAMONOOXYGENASE: PD014255:V338-P573 MONOOXYGENASE: PD004410:D193-W344 Dopamine-beta-monooxygenase: PR00767C:I120-D138, PR00767D:Y203-E223, PR00767E:V225-S243, PR00767G:V272-L291, PR00767H:A336-P353	BLAST-DOMO BLAST-DOMO BLAST-DOMO HMMER SPScan HMMER-PFAM ProfileScan BLAST-PRODOM BLAST-PRODOM BLIMPS-PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation sites	Signature Sequences and Motifs	Analytical Methods and Databases
19	4169101CD1	741	T6 S80 S83 Y84 T91 T136 S195 T299 S306 S349 T436 T454 S562 S572 Y588 S665	N78 N497 N609	Aldoketo_Reductase_3: L346-L361 transmem_domain: I112-F130 transmem_domain: K440-R460 TPR Domain (tetra-trico-peptide repeat): TPR (6 domains): H485-P513, M519-P547, Y587-P615, W621-P649, M655-P683, H689-P717 F32D1.3 PROTEIN SIMILAR E NIDULANS BIMA GENE PRODUCT: PD041324: Y285-L447	Motifs HMMER HMMER HMMER-PFAM
20	2925182CD1	535	S56 T90 T98 S99 T143 S158 T180 S209 T224 T272 S281 S369 T376 Y380 S399 T459 Y486 T534	N5 N77 N458	signal_peptide: M1-S22 signal_cleavage: M1-Y24 transmem_domain: S282-M299 UDPGLCNAC: A1, 3D MANNOSIDE B1, 4NACETYLGLUCOSAMINYLTRANSFERASE IV EC 2.4.1.145: PD185013: M1-N535	HMMER SPScan HMMER BLAST-PRODOM
21	3271838CD1	522	S66 S160 T196 T207 T295 T301 T334 T338 T401 S411 T499 S510 S513		Pyridine_Redox_1: G83-P93 Pyridine nucleotide-disulphide oxidoreductase: pyr_redox: L42-V519 Pyridine nucleotide-disulphide oxidoreductases class-I active site: pyridine_redox_1.prf: C54-Y113 Pyridine nucleotide-disulphide oxidoreductases class-I: BL00076A: Y40-D69, BL00076B: G83-K95 BL00076C: D310-T349	Motifs HMMER-PFAM ProfileScan BLIMPS-BLOCKS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation sites	Signature Sequences and Motifs	Analytical Methods and Databases
21					Pyridine nucleotide disulfide oxidoreductase: PR00411A:D41-R63, PR00411B:L82-M97, PR00411C:I184-R193, PR00411D:K220-T245, PR00411E:D310-S324, PR00411F:I354-V361, PR00411G:D391-E412, PR00411H:V460-Q475, PR00411I:K482-E502	BLIMPS-PRINTS
(cont)					FAD-dependent pyridine n...: PR00368A:D41-R63, PR00368B:I184-R193, PR00368C:K220-T245, PR00368D:D310-S324, PR00368E:I354-V361	BLIMPS-PRINTS
					FAD REDUCTASE REDOXACTIVE CENTER: PD000139:V294-K482	BLAST-PRODOM
					PYRIDINE NUCLEOTIDE-DISULPHIDE OXIDOREDUCTASES CLASS-I: DM00071 S57658 39-320:D39-D321	BLAST-DOMO
22	329287 CD1	495	S32 T41 S57 S58 T80 S103 S116 T151 S157 T172 S184 S256 T265 T300 T325 S378 T444 S445 S470	N3	Cytochrome_P450: F417-G426 signal_cleavage:M1-G19 Cytochrome P450: W48-L89, E160-L432 Cytochrome P450 cysteine heme-iron ligand signature: D396-L441 Cytochrome P450 cysteine heme-iron ligand proteins: BL00086:Y414-S445	Motifs SPScan HMMER-PFAM ProfileScan BLIMPS-BLOCKS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation sites	Signature Sequences and Motifs	Analytical Methods and Databases
22 (cont)					Mitochondrial P450 signature: PR00408E:K297-R310, PR00408F:S332-P350, PR00408H:L415-C424, PR00408I:C424-K435 P450 superfamily signature: PR00385A:A279-L296, PR00385B:K297-R310, PR00385C:C339-P350, PR00385D:L415-C424, PR00385E:C424-K435 CYTOCHROME P450: DM00022 P08684 58-487:Q221-P465 Cytochrome P450: M1-R45 (Score=9.6, E-value=0.027) Cytochrome P450: DM00022 P29981 79-497:M1-I39 (p=1.2e-6)	BLIMPS-PRINTS BLAST-DOMO HMMER-PFAM BLAST-DOMO HMMER SPScan HMMER BLAST-PRODOM BLAST-PRODOM BLAST-DOMO BLAST-DOMO
23	4109179CD1	51			signal_peptide:M1-S19 signal_cleavage:M1-G14 transmem_domain:M1-P20 GALACTOSYLTRANSFERASE: PD010022:L47-N334 TRANSFERASE HISTOBLOOD GROUP ABO SYSTEM: PD041469:M1-L47 SIGNAL-ANCHOR TRANSMEM (includes galactosyltransferases): DM07533 P16442 16-353:M1-P335 GALACTOSYLTRANSFERASE: DM08008 I49698 1-371:R62-N334	HMMER SPScan HMMER BLAST-PRODOM BLAST-PRODOM BLAST-DOMO BLAST-DOMO
24	4780365CD1	335	S19 T147 S152 S166 S183 Y187 S220 Y246 S254	N94		

Table 4

Nucleotide SEQ ID NO:	Incyte Nucleotide ID	Sequence length	Selected fragment(s)	Sequence fragments	5' position	3' position
25	1799250CB1	1269	1-630	6537030H1 (OVARIN02)	580	1169
				1620357T6 (BRAITUT13)	706	1269
				1607327H1 (LUNGNOT15)	1	205
				1620357F6 (BRAITUT13)	16	502
				1799250F6 (COLNNOT27)	218	663
				6846328H1 (KIDNMTN03)	689	1223
26	2242475CB1	1593	323-848, 1-116	3699419H1 (SININOT05)	1	293
				70614021V1	446	1165
				7061458V1	1022	1622
				70611772V1	5	645
				1921856R6 (BRSTTUT01)	1291	1779
27	2706492CB1	1779	1-1058	6969174U1	465	1204
				2706492F6 (PONSAT01)	1	554
				6568102H1 (MCLDTXN05)	914	1433
				5893501H1 (BRAYDIN03)	1112	1340
				4273116H1 (PROSTMT01)	899	1183
28	2766688CB1	1931	1-1041	9758933	1221	1831
				6702946H1 (DRGCNOT02)	115	751
				2950040H1 (KIDNFET01)	1	294
				2514733F7 (LIVRTUT04)	367	902
				6336624H1 (BRANDIN01)	1382	1931
				2766688F6 (BRSTNOT12)	498	1010
29	2788823CB1	1282	1-399, 1252- 1282, 427-529	6875661H1 (EPTMUNN04)	85	643
				6333929H1 (BRANDIN01)	665	1141
				1944989H1 (PITUNOT01)	1045	1282
				6916176H1 (PLACFER06)	336	919
				2788823H1 (HEAONOT02)	32	315
				1573860H1 (LNODNOT03)	1	26

Table 4 (cont.)

Nucleotide SEQ ID NO:	Incyte Nucleotide ID	Sequence length	Selected fragment(s)	Sequence fragments	5' position	3' position
30	3348822CB1	2416	2339-2416, 1- 1024, 1515- 1636	70882367V1 6620514H1 (MUSLTR02) 6574030H1 (COLHTUS02) 2525166H1 (BRAITUT21) 60138453V1 70879864V1 7176308H1 (BRSTTMC01) 1985721H1 (LUNGAST01) 6420342H1 (BRSTUNT01)	945 851 1328 1 2052 1477 357 2162 126	1462 1390 1918 243 2338 2103 953 2416 679
31	4290251CB1	1574	1-29, 1359- 1574, 859-997, 402-454	2515438F6 (LIVRTUT04) 4290037R6 (BRABDIR01) 5521434H1 (LIVRDIR01) 4701356H1 (SMCRTXT01) 4290251F6 (BRABDIR01) 5543059T8 (TESTNOC01) 70327902D1 70326347D1 4029455T6 (BRAINOT23)	38 1081 1 956 554 283 1 785 603	627 1574 266 1223 1080 1212 551 1227 1224
32	4904188CB1	1227	1-403	638419H1 (BRSTNOT03) 70568268V1 2817590T6 (BRSTNOT14) 70568923V1	1011 1 726 439	1240 600 1221 1034
33	638419CB1	1240	1-496, 1028- 1240			

Table 4 (cont.)

Nucleotide SEQ ID NO:	Incyte Nucleotide ID	Sequence length	Selected fragment(s)	Sequence fragments	5' position	3' position
34	1844394	2275	1-431, 1030- 1366	2501918H1 (ADRETUT05)	1	240
				2501918F6 (ADRETUT05)	1	543
				2669184F6 (ESOGTUT02)	802	1464
				3114958H1 (BRSTNOT17)	283	610
				3135773F6 (SMCCNOT01)	1898	2275
				2343269F6 (TESTTUT02)	617	1235
				4529167H1 (LYMBTXT01)	1311	1601
				5571305H1 (TYMNOT08)	367	622
35	2613056	1586	400-532	2669184T6 (ESOGTUT02)	1608	2247
				2057708T6 (BEPINOT01)	1316	2246
				2742715F6 (BRSTTUT14)	490	1025
				2743015X306D1 (BRSTTUT14)	1	487
				4187166F6 (BRSTNOT31)	449	936
				2742715T6 (BRSTTUT14)	930	1586
				g1330846	275	859
				206675F1 (SPLNNOT02)	422	837
36	5053617	859	1-291	001071H1 (U937NOT01)	480	853
				206675R1 (SPLNNOT02)	313	831
				3880457F6 (SPLNNOT11)	1	343
				6144620H1 (BRANDIT03)	431	1075
				7179844H1 (BRAXDIC01)	1	574
				6773457J1 (OVARDIR01)	1730	2302
				930526R1 (CERVNOT01)	769	1326
				2059641T6 (OVARNOT03)	1350	2009
37	5483256	2302	1-1336, 2022- 2302	6576653H1 (COLHTUS02)	1284	1982
				2229885F6 (PROSNOT16)	800	1280
				2717950F6 (THYRNOT09)	1	618
				g1551782	1077	1653
				494427F1 (HNT2NOT01)	1104	1653
				SBLA03737F1	496	1049
38	5741354	1653	1-985			

Table 4 (cont.)

Nucleotide SEQ ID NO:	Incyte Nucleotide ID	Sequence length	Selected fragment (s)	Sequence fragments	5' position	3' position
39	5872615	683	1-25	6873589H1 (EPIMUNN04)	47	683
40	2657543	657	161-181, 343- 657	2938376H1 (THYMFET02)	1	260
41	3041639	1122	637-808, 1- 138, 911-1122	g5420326.v113.gs_3.nt	1	657
42	3595451	2982	1-2274	2657543H1 (LUNGTTUT09)	341	568
				70827651V1	435	1025
				3041639T6 (BRSTNOT16)	466	1096
				70827016V1	1	470
				70465056V1	1759	2410
				70465685V1	1136	1753
				3595451F6 (FIBPNOT01)	123	686
				70465630V1	2330	2982
				70466466V1	1024	1692
				7255550H1 (FIBRTXC01)	459	1116
				3596949H1 (FIBPNOT01)	1	300
				70467798V1	1705	2399
				70484641V1	1373	2025
				6849059H1 (KIDNTMN03)	2060	2633
				70483292V1	814	1408
				6757006J1 (SINTFER02)	1	711
				1546352H1 (PROSTUT04)	3316	3517
				6494614H1 (BONRNOT01)	2692	3344
				6937377H1 (FTUBTUR01)	1623	2128
				70483348V1	663	1173
				1691757T6 (PROSTUT10)	2737	3379
				2499325F6 (ADRETUT05)	2217	2716
43	4169101	3517	3409-3517, 1- 1773			

Table 4 (cont.)

Nucleotide SEQ ID NO:	Incyte Nucleotide ID	Sequence length	Selected fragment(s)	Sequence fragments	5' position	3' position
44	2925182	2339	368-920, 1-20	3423537H1 (BRSTNOR01) 7094242H1 (SINTME01) 6595856H1 (COLENOT03) 4447810H1 (SINDNOT01) 60141115D1 70684441V1 60141117D1 4190070T6 (BRAPDIT01)	510 1378 743 407 1 1734 624 1347	750 1947 1371 666 462 2339 1078 1931
45	3271838	1955	1-943	2519257H1 (BRAITUT21) 2101033R6 (BRAITUT02) 60213368U1 7178847H1 (BRAXDIC01) 1998271R6 (BRSTTUT03) 2417893F6 (HNT3AZT01)	1 499 1027 102 1425 896	253 1008 1443 693 1955 1378
46	3292871	2065	791-1046, 1- 159, 1481- 2065, 258-292	95091644.v113.gs_1.1.nt.edit 3537160H1 (SEMNOT04) 3292871F6 (BONREF01) 6754650J1 (SINTFER02) 6314941H1 (NERDTN03) 6819509H1 (OVARDIR01) 7267351H1 (NOSEDIC01) 5872309H1 (COLTDIT04) 7093802H1 (SINTME01) 6847686H1 (KIDNTMN03)	147 1 1055 260 1435 609 1 585 548 370	410 203 1462 902 2065 1217 523 866 800 672
47	4109179	866	1-87, 697-866	6801412J1 (COLENOT03) 6755595J1 (SINTFER02)	347 1	834 424
48	4780365	1593	791-1048, 1- 717	6829516H1 (SINTNOR01) 6801420H1 (COLENOT03)	1173 718	1593 1196

Table 5

Nucleotide SEQ ID NO:	Incyte Project ID	Representative Library
25	1799250	TESTNOT17
26	2242475	BRSTNON02
27	2706492	COLNNOT19
28	2766688	PROSTMT01
29	2788823	OVARDIN02
30	3348822	BRAITUT21
31	4290251	BRABDIR01
32	4904188	SININOT04
33	638419	BRSTNOT14
34	1844394	BEPINOT01
35	2613056	BRSTTUT14
36	5053617	URETTUT01
37	5483256	BRAINOT09
38	5741354	THYRNOT09
39	5872615	CONUTUT01
40	2657543	LUNGUTUT09
41	3041639	BONSTUT01
42	3595451	KIDNNOT05
43	4169101	FIBPFEN06
44	2925182	SINITME01
45	3271838	THPIAZT01
46	3292871	BONRFET01
47	4109179	PROSBPT07
48	4780365	SINTNOR01

Table 6

Library	Vector	Library Description
BRABDIR01	pINCY	Library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male, who died from a cerebrovascular accident. Patient history included Huntington's disease, emphysema, and tobacco abuse.
BRAITUT21	pINCY	Library was constructed using RNA isolated from brain tumor tissue removed from the midline frontal lobe of a 61-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated subfrontal meningotheelial meningioma with no atypia. One ethmoid and mucosal tissue sample indicated meningioma. Family history included cerebrovascular disease, senile dementia, hyperlipidemia, benign hypertension, atherosclerotic coronary artery disease, congestive heart failure, and breast cancer.
BRSTNON02	pINCY	This normalized breast tissue library was constructed from 6.2 million independent clones from a pool of two libraries from two different donors. Starting RNA was made from breast tissue removed from a 46-year-old Caucasian female during a bilateral reduction mamoplasty (donor A), and from breast tissue removed from a 60-year-old Caucasian female during a bilateral reduction mamoplasty (donor B). Pathology indicated normal breast parenchyma, bilaterally (A) and bilateral mammary hypertrophy (B). Patient history included hypertrophy of breast, obesity, lumbago, and glaucoma (A) and joint pain in the shoulder, thyroid cyst, colon cancer, normal delivery and cervical cancer (B). Family history included cataract, osteoarthritis, uterine cancer, benign hypertension, hyperlipidemia, and alcoholic cirrhosis of the liver, cerebrovascular disease, and type II diabetes (A) and cerebrovascular accident, atherosclerotic coronary artery disease, colon cancer, type II diabetes, hyperlipidemia, depressive disorder, and Alzheimer's Disease. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48 hours/round) reannealing hybridization was used.

Table 6 (cont.)

Library	Vector	Library Description
BRSTNOT14	pINCY	Library was constructed using RNA isolated from breast tissue removed from a 62-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated an invasive grade 3 (of 4), nuclear grade 3 (of 3) adenocarcinoma, ductal type. Ductal carcinoma in situ, comedo type, comprised 60% of the tumor mass. Metastatic adenocarcinoma was identified in one (of 14) axillary lymph nodes with no perinodal extension. The tumor cells were strongly positive for estrogen receptors and weakly positive for progesterone receptors. Patient history included a benign colon neoplasm, hyperlipidemia, cardiac dysrhythmia, and obesity. Family history included atherosclerotic coronary artery disease, myocardial infarction, colon cancer, ovarian cancer, lung cancer, and cerebrovascular disease.
COLNNOT19	pINCY	Library was constructed using RNA isolated from the cecal tissue of an 18-year-old Caucasian female. The cecal tissue, along with the appendix and ileum tissue, were removed during bowel anastomosis. Pathology indicated Crohn's disease of the ileum, involving 15 cm of the small bowel.
OVARDIN02	pINCY	This normalized ovarian tissue library was constructed from 5.76 million independent clones from an ovary library. Starting RNA was made from diseased ovarian tissue removed from a 39-year-old Caucasian female during total abdominal hysterectomy, bilateral salpingo-oophorectomy, dilation and curettage, partial colectomy, incidental appendectomy, and temporary colostomy. Pathology indicated the right and left adnexa, mesentery and muscularis propria of the sigmoid colon were extensively involved by endometriosis. Endometriosis also involved the anterior and posterior serosal surfaces of the uterus and the cul-de-sac. The endometrium was proliferative. Pathology for the associated tumor tissue indicated multiple (3 intramural, 1 subserosal) leiomyomata. The patient presented with abdominal pain and infertility. Patient history included scoliosis. Family history included hyperlipidemia, benign hypertension, atherosclerotic coronary artery disease, depressive disorder, brain cancer, and type II diabetes. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS(1994) 91:9228 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48-hours/round) reannealing hybridization was used.

Table 6 (cont.)

Library	Vector	Library Description
PROSTMT01	pINCY	Library was constructed using RNA isolated from diseased prostate tissue removed from a 67-year-old Caucasian male during radical prostatectomy with regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated grade 3, Gleason grade 3+3 adenocarcinoma. The patient presented elevated prostate specific antigen (PSA) and induration. Patient history included hyperlipidemia cerebrovascular disease, and a depressive disorder. Family history included atherosclerotic coronary artery disease and hyperlipidemia.
SININOT04	pINCY	The SININOT04 library was constructed using RNA isolated from diseased ileum tissue obtained from a 26-year-old Caucasian male during a partial colectomy, permanent colostomy, and an incidental appendectomy. Pathology indicated moderately to severely active Crohn's disease. Family history included enteritis of the small intestine.
TESTNOT17	pINCY	Library was constructed using 1.5 micrograms of polyA RNA isolated from testis tissue removed from a 26-year-old Caucasian male who died from head trauma due to a motor vehicle accident. Serologies were negative. Patient history included a hernia at birth, tobacco use (1 1/2 ppd), marijuana use, and daily alcohol use (beer and hard liquor). cDNA synthesis was initiated using a NotI-anchored oligo(dT) primer. Double-stranded cDNA was blunted, ligated to EcoRI adaptors, digested with NotI, size-selected, and cloned into the NotI and EcoRI sites of the pINCY vector (Incyte). The library was then linearized and recircularized to select for insert-containing clones as follows: plasmid DNA was prepped from approximately 1 million clones from the testis tissue library following soft agar transformation. The DNA was linearized with NotI and insert-containing clones were size-selected by agarose gel electrophoresis and recircularized by ligation.
BEPINOT01	PSPORT1	Library was constructed using RNA isolated from a bronchial epithelium primary cell line derived from a 54-year-old Caucasian male.
BRAINOT09	pINCY	Library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus, who died at 23 weeks' gestation.

Table 6 (cont.)

Library	Vector	Library Description
BRSTTUT14	pINCY	Library was constructed using RNA isolated from breast tumor tissue removed from a 62-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated an invasive grade 3 (of 4), nuclear grade 3 (of 3) adenocarcinoma, ductal type. Ductal carcinoma in situ, comedo type, comprised 60% of the tumor mass. Metastatic adenocarcinoma was identified in one (of 14) axillary lymph nodes with no perinodal extension. Tumor cells were strongly positive for estrogen receptors and weakly positive for progesterone receptors. Patient history included benign colon neoplasm, hyperlipidemia, cardiac dysrhythmia, and obesity. Family history included atherosclerotic coronary artery disease, myocardial infarction, colon cancer, ovarian cancer, lung cancer, and cerebrovascular disease.
CONUTUT01	pINCY	Library was constructed using RNA isolated from sigmoid mesentery tumor tissue obtained from a 61-year-old female during a total abdominal hysterectomy and bilateral salpingo-oophorectomy with regional lymph node excision. Pathology indicated a metastatic grade 4 malignant mixed müllerian tumor present in the sigmoid mesentery at two sites.
THYRN0T09	pINCY	Library was constructed using RNA isolated from diseased thyroid tissue removed from an 18-year-old Caucasian female during an unilateral thyroid lobectomy and regional lymph node excision. Pathology indicated adenomatous goiter. This was associated with a follicular adenoma of the thyroid. Family history included thyroid cancer in the father.
URETTUT01	pINCY	Library was constructed using RNA isolated from right ureter tumor tissue of a 69-year-old Caucasian male during ureterectomy and lymph node excision. Pathology indicated invasive grade 3 transitional cell carcinoma. Patient history included benign colon neoplasm, tobacco use, asthma, emphysema, acute duodenal ulcer, and hyperplasia of the prostate. Family history included atherosclerotic coronary artery disease, congestive heart failure, and malignant lung neoplasm.
BONRFET01	pINCY	Library was constructed using RNA isolated from rib bone tissue removed from a Caucasian male fetus, who died from Patau's syndrome (trisomy 13) at 20-weeks' gestation.

Table 6 (cont.)

Library	Vector	Library Description
BONSTUT01	pINCY	Library was constructed using RNA isolated from sacral bone tumor tissue removed from an 18-year-old Caucasian female during an exploratory laparotomy with soft tissue excision. Pathology indicated giant cell tumor of the sacrum. Patient history included a soft tissue malignant neoplasm. Family history included prostate cancer.
FIBPFEN06	pINCY	The normalized prostate stromal fibroblast tissue libraries were constructed from 1.56 million independent clones from a fibroblast library. Starting RNA was made from fibroblasts of prostate stroma removed from a male fetus, who died after 26 weeks' gestation. The libraries were normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48-hours/round) reannealing hybridization was used. The library was then linearized and recircularized to select for insert containing clones as follows: plasmid DNA was prepped from approximately 1 million clones from the normalized prostate stromal fibroblast tissue libraries following soft agar transformation. The DNA was linearized with NotI and insert containing clones were size-selected by agarose gel electrophoresis and then recircularized by ligation.
KIDNNOT05	PSPORT1	Library was constructed using RNA isolated from the kidney tissue of a 2-day-old Hispanic female, who died from cerebral anoxia. Family history included congenital heart disease.
LUNGTUT09	pINCY	Library was constructed using RNA isolated from lung tumor tissue removed from a 68-year-old Caucasian male during segmental lung resection. Pathology indicated invasive grade 3 squamous cell carcinoma and a metastatic tumor. Patient history included type II diabetes, thyroid disorder, depressive disorder, hyperlipidemia, esophageal ulcer, and tobacco use.
PROSBPT07	pINCY	Library was constructed using RNA isolated from diseased prostate tissue removed from a 53-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated adenocarcinoma (Gleason grade 3+2). The patient presented with elevated prostate specific antigen and induration. Patient history included hyperlipidemia. Family history included atherosclerotic coronary artery disease, coronary artery bypass graft, perforated gallbladder, hyperlipidemia, and kidney stones.

Table 6 (cont.)

Library	Vector	Library Description
SINTWE01	pINCY	This 5' biased random primed library was constructed using RNA isolated from ileum tissue removed from a 70-year-old Caucasian female during right hemicolectomy, open liver biopsy, flexible sigmoidoscopy, colonoscopy, and permanent colostomy. Pathology for the matched tumor tissue indicated invasive grade 2 adenocarcinoma forming an ulcerated mass, situated 2 cm distal to the ileocecal valve. The tumor invaded through the muscularis propria just into the serosal adipose tissue. One (of 16) regional lymph node was positive for a microfocus of metastatic adenocarcinoma. Focal fat necrosis was identified from pelvic region tissue. Patient history included a malignant breast neoplasm, type II diabetes, hyperlipidemia, viral hepatitis, an unspecified thyroid disorder, osteoarthritis, a malignant skin neoplasm, deficiency anemia, and normal delivery. Family history included breast cancer, atherosclerotic coronary artery disease, benign hypertension, cerebrovascular disease, ovarian cancer, and hyperlipidemia.
SINTNOR01	PCDNA2.1	This random primed library was constructed using RNA isolated from small intestine tissue removed from a 31-year-old Caucasian female during Roux-en-Y gastric bypass. Patient history included clinical obesity.
THPLAZT01	pINCY	Library was constructed using polyA RNA isolated from THP-1 promonocyte cells treated for three days with 0.8 micromolar 5-aza-2'-deoxycytidine. THP-1 (ATCC TIB 202) is a human promonocyte line derived from peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171).

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, and tfastx.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less Signal peptide hits: Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribkov, M. et al. (1988) CABIOS 4:61-66; Gribkov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - 5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-24,
 - b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24,
 - c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and
 - 10 d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-24.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-24.
- 15 3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
- 20 5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:25-48.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
- 25 7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
- 30 9. A method for producing a polypeptide of claim 1, the method comprising:
 - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
 - 35 b) recovering the polypeptide so expressed.

10. An isolated antibody which specifically binds to a polypeptide of claim 1.

11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

- 5 a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48,
 b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48,
 c) a polynucleotide sequence complementary to a),
 d) a polynucleotide sequence complementary to b), and
10 e) an RNA equivalent of a)-d).

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

15 13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization
20 complex is formed between said probe and said target polynucleotide or fragments thereof, and
 b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

25 14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

 15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
30 b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

 16. A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

35

17. A composition of claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-24.

18. A method for treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

21. A method for treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment a composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

24. A method for treating a disease or condition associated with overexpression of functional DME, comprising administering to a patient in need of such treatment a composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and

b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,

b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and

c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,

b) detecting altered expression of the target polynucleotide, and

c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

28. A method for assessing toxicity of a test compound, said method comprising:

a) treating a biological sample containing nucleic acids with the test compound;

b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;

c) quantifying the amount of hybridization complex; and

d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

SEQUENCE LISTING

<110> INCYTE GENOMICS, INC.

YANG, Junming
 BAUGHN, Mariah R.
 BURFORD, Neil
 AU-YOUNG, Janice
 LU, Dyung Aina M.
 REDDY, Roopa
 RING, Huijun Z.
 HILLMAN, Jennifer L.
 YUE, Henry
 AZIMZAI, Yalda
 YAO, Monique G.
 GANDHI, Aameena R.
 NGUYEN, Danniel B.
 BAUGHN, Mariah R.
 TANG, Y. Tom
 LAL, Preeti
 YUE, Henry
 BANDMAN, Olga

<120> DRUG METABOLIZING ENZYMES

<130> PI-0007 PCT

<140> To Be Assigned

<141> Herewith

<160> 48

<170> PERL Program

<210> 1

<211> 330

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1799250CD1

<400> 1

Met	Ser	Pro	Leu	Ser	Ala	Ala	Arg	Ala	Ala	Leu	Arg	Val	Tyr	Ala
1				5					10					15
Val	Gly	Ala	Ala	Val	Ile	Leu	Ala	Gln	Leu	Leu	Arg	Arg	Cys	Arg
				20					25					30
Gly	Gly	Phe	Leu	Glu	Pro	Val	Leu	Pro	Pro	Arg	Pro	Asp	Arg	Val
				35					40					45
Ala	Ile	Val	Thr	Gly	Gly	Thr	Asp	Gly	Ile	Gly	Tyr	Ser	Thr	Ala
				50					55					60
Lys	His	Leu	Ala	Arg	Leu	Gly	Met	His	Val	Ile	Ile	Ala	Gly	Asn
				65					70					75
Asn	Asp	Ser	Lys	Ala	Lys	Gln	Val	Val	Ser	Lys	Ile	Lys	Glu	Glu
				80					85					90
Thr	Leu	Asn	Asp	Lys	Val	Glu	Phe	Leu	Tyr	Cys	Asp	Leu	Ala	Ser
				95					100					105
Met	Thr	Ser	Ile	Arg	Gln	Phe	Val	Gln	Lys	Phe	Lys	Met	Lys	Lys
				110					115					120
Ile	Pro	Leu	His	Val	Leu	Ile	Asn	Asn	Ala	Gly	Val	Met	Met	Val
				125					130					135
Pro	Gln	Arg	Lys	Thr	Arg	Asp	Gly	Phe	Glu	Glu	His	Phe	Gly	Leu
				140					145					150
Asn	Tyr	Leu	Gly	His	Phe	Leu	Leu	Thr	Asn	Leu	Leu	Leu	Asp	Thr

Leu Lys Glu Ser	155	Gly Ser Pro Gly His	160	Ser Ala Arg Val Val	165
	170		175		180
Val Ser Ser Ala	185	Thr His Tyr Val Ala	190	Glu Leu Asn Met Asp	195
	200		205		210
Leu Gln Ser Ser	215	Ala Cys Tyr Ser Pro	220	His Ala Ala Tyr Ala	225
	230		235		240
Leu Ala Ala Glu	245	Gly Ser His Val Thr	250	Ala Asn Val Val Asp	255
	260		265		270
Gly Val Val Asn	275	Thr Asp Val Tyr Lys	280	His Val Phe Trp Ala	285
	290		295		300
Arg Leu Ala Lys	305	Lys Leu Leu Gly Trp	310	Leu Leu Phe Lys Thr	315
	320		325		330
Asp Glu Gly Ala		Trp Thr Ser Ile Tyr		Ala Ala Val Thr Pro	
Leu Glu Gly Val		Gly Gly Arg Tyr Leu		Tyr Asn Lys Lys Glu	
Lys Ser Leu His		Val Thr Tyr Asn Gln		Lys Leu Gln Gln Gln	
Trp Ser Lys Ser		Cys Glu Met Thr Gly		Val Leu Asp Val Thr	

<210> 2
 <211> 497
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2242475CD1

<400> 2

Met Gly Leu Glu Ala	1	Leu Val Pro Leu Ala	10	Val Ile Val Ala Ile	15
	5		10		15
Phe Leu Leu Leu Val	20	Asp Leu Met His Arg	25	Arg Arg Gln Arg Trp	30
	25		30		35
Ala Arg Tyr Pro Pro	35	Gly Pro Leu Pro Leu	40	Pro Gly Leu Gly Asn	45
	40		45		50
Leu Leu His Val Asp	50	Phe Gln Asn Thr Pro	55	Tyr Cys Phe Asp Gln	60
	55		60		65
Leu Arg Arg Arg Phe	65	Gly Asp Val Phe Ser	70	Leu Gln Leu Ala Trp	75
	70		75		80
Thr Pro Val Val Val	80	Leu Asn Gly Leu Ala	85	Ala Val Arg Glu Ala	90
	85		90		95
Leu Val Thr His Gly	95	Glu Asp Thr Ala Asp	100	Arg Pro Pro Val Pro	105
	100		105		110
Ile Thr Gln Ile Leu	110	Gly Phe Gly Pro Arg	115	Ser Gln Gly Val Phe	120
	115		120		125
Leu Ala Arg Tyr Gly	125	Pro Ala Trp Arg Glu	130	Gln Arg Arg Phe Ser	135
	130		135		140
Val Ser Thr Leu Arg	140	Asn Leu Gly Leu Gly	145	Lys Lys Ser Leu Glu	150
	145		150		155
Gln Trp Val Thr Glu	155	Glu Ala Ala Cys Leu	160	Cys Ala Ala Phe Ala	165
	160		165		170
Asn His Ser Gly Arg	170	Pro Phe Arg Pro Asn	175	Gly Leu Leu Asp Lys	180
	175		180		185
Ala Val Ser Asn Val	185	Ile Ala Ser Leu Thr	190	Cys Gly Arg Arg Phe	195
	190		195		200
Glu Tyr Asp Asp Pro	200	Arg Phe Leu Arg Leu	205	Leu Asp Leu Ala Gln	210
	205		210		215
Glu Gly Leu Lys Glu		Glu Ser Gly Phe Leu		Arg Glu Val Leu Asn	

	215		220		225
Ala Val Pro Val	Leu Pro His Ile Pro	Ala Leu Ala Gly Lys Val			
	230		235		240
Leu Arg Phe Gln	Lys Ala Phe Leu Thr	Gln Leu Asp Glu Leu Leu			
	245		250		255
Thr Glu His Arg	Met Thr Trp Asp Pro	Ala Gln Pro Pro Arg Asp			
	260		265		270
Leu Thr Glu Ala	Phe Leu Ala Lys Lys	Glu Lys Ala Lys Gly Ser			
	275		280		285
Pro Glu Ser Ser	Phe Asn Asp Glu Asn	Leu Arg Ile Val Val Gly			
	290		295		300
Asn Leu Phe Leu	Ala Gly Met Val Thr	Thr Ser Thr Thr Leu Ala			
	305		310		315
Trp Ala Leu Leu	Leu Met Ile Leu His	Pro Asp Val Gln Cys Arg			
	320		325		330
Val Gln Gln Glu	Ile Asp Glu Val Ile	Gly Gln Val Arg His Pro			
	335		340		345
Glu Met Ala Asp	Gln Ala His Met Pro	Phe Thr Asn Ala Val Ile			
	350		355		360
His Glu Val Gln	Arg Phe Ala Asp Ile	Val Pro Met Asn Leu Pro			
	365		370		375
His Lys Thr Ser	Arg Asp Ile Glu Val	Gln Gly Phe Leu Ile Pro			
	380		385		390
Lys Gly Thr Thr	Leu Ile Pro Asn Leu	Ser Ser Val Leu Lys Asp			
	395		400		405
Glu Thr Val Trp	Glu Lys Pro Leu Arg	Phe His Pro Glu His Phe			
	410		415		420
Leu Asp Ala Gln	Gly Asn Phe Val Lys	His Glu Ala Phe Met Pro			
	425		430		435
Phe Ser Ala Gly	Arg Arg Ala Cys Leu	Gly Glu Pro Leu Ala Arg			
	440		445		450
Met Glu Leu Phe	Leu Phe Phe Thr Cys	Leu Leu Gln Arg Phe Ser			
	455		460		465
Phe Ser Val Pro	Thr Gly Gln Pro Arg	Pro Ser Asp Tyr Gly Val			
	470		475		480
Phe Ala Phe Leu	Leu Ser Pro Ser Pro	Tyr Gln Leu Cys Ala Phe			
	485		490		495
Lys Arg					

<210> 3
 <211> 286
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2706492CD1

<400> 3
 Met Ala Leu Asp Leu Ala Ser Leu Ala Ser Val Arg Ala Phe Ala
 1 5 10 15
 Thr Ala Phe Leu Ser Ser Glu Pro Arg Leu Asp Ile Leu Ile His
 20 25 30
 Asn Ala Gly Ile Ser Ser Cys Gly Arg Thr Arg Glu Ala Phe Asn
 35 40 45
 Leu Leu Leu Arg Val Asn His Ile Gly Pro Phe Leu Leu Thr His
 50 55 60
 Leu Leu Leu Pro Cys Leu Lys Ala Cys Ala Pro Ser Arg Val Val
 65 70 75
 Val Val Ala Ser Ala Ala His Cys Arg Gly Arg Leu Asp Phe Lys
 80 85 90
 Arg Leu Asp Arg Pro Val Val Gly Trp Arg Gln Glu Leu Arg Ala
 95 100 105

Tyr	Ala	Asp	Thr	Lys	Leu	Ala	Asn	Val	Leu	Phe	Ala	Arg	Glu	Leu
				110					115					120
Ala	Asn	Gln	Leu	Glu	Ala	Thr	Gly	Val	Thr	Cys	Tyr	Ala	Ala	His
				125					130					135
Pro	Gly	Pro	Val	Asn	Ser	Glu	Leu	Phe	Leu	Arg	His	Val	Pro	Gly
				140					145					150
Trp	Leu	Arg	Pro	Leu	Leu	Arg	Pro	Leu	Ala	Trp	Leu	Val	Leu	Arg
				155					160					165
Ala	Pro	Arg	Gly	Gly	Ala	Gln	Thr	Pro	Leu	Tyr	Cys	Ala	Leu	Gln
				170					175					180
Glu	Gly	Ile	Glu	Pro	Leu	Ser	Gly	Arg	Tyr	Phe	Ala	Asn	Cys	His
				185					190					195
Val	Glu	Glu	Val	Pro	Pro	Ala	Ala	Arg	Asp	Asp	Arg	Ala	Ala	His
				200					205					210
Arg	Leu	Trp	Glu	Ala	Ser	Lys	Arg	Leu	Ala	Gly	Leu	Gly	Pro	Gly
				215					220					225
Glu	Asp	Ala	Glu	Pro	Asp	Glu	Asp	Pro	Gln	Ser	Glu	Asp	Ser	Glu
				230					235					240
Ala	Pro	Ser	Ser	Leu	Ser	Thr	Pro	His	Pro	Glu	Glu	Pro	Thr	Val
				245					250					255
Ser	Gln	Pro	Tyr	Pro	Ser	Pro	Gln	Ser	Ser	Pro	Asp	Leu	Ser	Lys
				260					265					270
Met	Thr	His	Arg	Ile	Gln	Ala	Lys	Val	Glu	Pro	Glu	Ile	Gln	Leu
				275					280					285

Ser

<210> 4

<211> 469

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2766688CD1

<400> 4

Met	Glu	Leu	Ile	Ser	Pro	Thr	Val	Ile	Ile	Ile	Leu	Gly	Cys	Leu
1				5					10					15
Ala	Leu	Phe	Leu	Leu	Leu	Gln	Arg	Lys	Asn	Leu	Arg	Arg	Pro	Pro
				20					25					30
Cys	Ile	Lys	Gly	Trp	Ile	Pro	Trp	Ile	Gly	Val	Gly	Phe	Glu	Phe
				35					40					45
Gly	Lys	Ala	Pro	Leu	Glu	Phe	Ile	Glu	Lys	Ala	Arg	Ile	Lys	Tyr
				50					55					60
Gly	Pro	Ile	Phe	Thr	Val	Phe	Ala	Met	Gly	Asn	Arg	Met	Thr	Phe
				65					70					75
Val	Thr	Glu	Glu	Glu	Gly	Ile	Asn	Val	Phe	Leu	Lys	Ser	Lys	Lys
				80					85					90
Val	Asp	Phe	Glu	Leu	Ala	Val	Gln	Asn	Ile	Val	Tyr	His	Thr	Ala
				95					100					105
Ser	Ile	Pro	Lys	Asn	Val	Phe	Leu	Ala	Leu	His	Glu	Lys	Leu	Tyr
				110					115					120
Ile	Met	Leu	Lys	Gly	Lys	Met	Gly	Thr	Val	Asn	Leu	His	Gln	Phe
				125					130					135
Thr	Gly	Gln	Leu	Thr	Glu	Glu	Leu	His	Glu	Gln	Leu	Glu	Asn	Leu
				140					145					150
Gly	Thr	His	Gly	Thr	Met	Asp	Leu	Asn	Asn	Leu	Val	Arg	His	Leu
				155					160					165
Leu	Tyr	Pro	Val	Thr	Val	Asn	Met	Leu	Phe	Asn	Lys	Ser	Leu	Phe
				170					175					180
Ser	Thr	Asn	Lys	Lys	Lys	Ile	Lys	Glu	Phe	His	Gln	Tyr	Phe	Gln
				185					190					195
Val	Tyr	Asp	Glu	Asp	Phe	Glu	Tyr	Gly	Ser	Gln	Leu	Pro	Glu	Cys

	200		205		210
Leu Leu Arg Asn Trp Ser Lys Ser Lys	Lys Trp Phe Leu Glu Leu				
	215		220		225
Phe Glu Lys Asn Ile Pro Asp Ile Lys	Ala Cys Lys Ser Ala Lys				
	230		235		240
Asp Asn Ser Met Thr Leu Leu Gln Ala	Thr Leu Asp Ile Val Glu				
	245		250		255
Thr Glu Thr Ser Lys Glu Asn Ser Pro	Asn Tyr Gly Leu Leu Leu				
	260		265		270
Leu Trp Ala Ser Leu Ser Asn Ala Val	Pro Val Ala Phe Trp Thr				
	275		280		285
Leu Ala Tyr Val Leu Ser His Pro Asp	Ile His Lys Ala Ile Met				
	290		295		300
Glu Gly Ile Ser Ser Val Phe Gly Lys	Ala Gly Lys Asp Lys Ile				
	305		310		315
Lys Val Ser Glu Asp Asp Leu Glu Asn	Leu Leu Leu Ile Lys Trp				
	320		325		330
Cys Val Leu Glu Thr Ile Arg Leu Lys	Ala Pro Gly Val Ile Thr				
	335		340		345
Arg Lys Val Val Lys Pro Val Glu Ile	Leu Asn Tyr Ile Ile Pro				
	350		355		360
Ser Gly Asp Leu Leu Met Leu Ser Pro	Phe Trp Leu His Arg Asn				
	365		370		375
Pro Lys Tyr Phe Pro Glu Pro Glu Leu	Phe Lys Pro Glu Arg Trp				
	380		385		390
Glu Lys Gly Lys Phe Arg Glu Ala Leu	Phe Leu Gly Leu Leu His				
	395		400		405
Gly Ile Gly Ser Gly Lys Phe Gln Cys	Pro Ala Arg Trp Phe Ala				
	410		415		420
Leu Leu Glu Val Gln Met Cys Ile Ile	Leu Ile Leu Tyr Lys Tyr				
	425		430		435
Asp Cys Ser Leu Leu Asp Pro Leu Pro	Lys Gln Ser Tyr Leu His				
	440		445		450
Leu Val Gly Val Pro Gln Pro Glu Gly	Gln Cys Arg Ile Glu Tyr				
	455		460		465
Lys Gln Arg Ile					

<210> 5
 <211> 331
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2788823CD1

<400> 5
 Met Ser Arg Tyr Leu Leu Pro Leu Ser Ala Leu Gly Thr Val Ala
 1 5 10 15
 Gly Ala Ala Val Leu Leu Lys Asp Tyr Val Thr Gly Gly Ala Cys
 20 25 30
 Pro Ser Lys Ala Thr Ile Pro Gly Lys Thr Val Ile Val Thr Gly
 35 40 45
 Ala Asn Thr Gly Ile Gly Lys Gln Thr Ala Leu Glu Leu Ala Arg
 50 55 60
 Arg Gly Gly Asn Ile Ile Leu Ala Cys Arg Asp Met Glu Lys Cys
 65 70 75
 Glu Ala Ala Ala Lys Asp Ile Arg Gly Glu Thr Leu Asn His His
 80 85 90
 Val Asn Ala Arg His Leu Asp Leu Ala Ser Leu Lys Ser Ile Arg
 95 100 105
 Glu Phe Ala Ala Lys Ile Ile Glu Glu Glu Glu Arg Val Asp Ile
 110 115 120

Met	Glu	Phe	Ser	Trp	Leu	Glu	Thr	Arg	Trp	Ala	Arg	Pro	Phe	Tyr
1				5					10					15
Leu	Ala	Phe	Val	Phe	Cys	Leu	Ala	Leu	Gly	Leu	Leu	Gln	Ala	Ile
				20					25					30
Lys	Leu	Tyr	Leu	Arg	Arg	Gln	Arg	Leu	Leu	Arg	Asp	Leu	Arg	Pro
				35					40					45
Phe	Pro	Ala	Pro	Pro	Thr	His	Trp	Phe	Leu	Gly	His	Gln	Lys	Phe
				50					55					60
Ile	Gln	Asp	Asp	Asn	Met	Glu	Lys	Leu	Glu	Glu	Ile	Ile	Glu	Lys
				65					70					75
Tyr	Pro	Arg	Ala	Phe	Pro	Phe	Trp	Ile	Gly	Pro	Phe	Gln	Ala	Phe
				80					85					90
Phe	Cys	Ile	Tyr	Asp	Pro	Asp	Tyr	Ala	Lys	Thr	Leu	Leu	Ser	Arg
				95					100					105
Thr	Asp	Pro	Lys	Ser	Gln	Tyr	Leu	Gln	Lys	Phe	Ser	Pro	Pro	Leu
				110					115					120
Leu	Gly	Lys	Gly	Leu	Ala	Ala	Leu	Asp	Gly	Pro	Lys	Trp	Phe	Gln
				125					130					135
His	Arg	Arg	Leu	Leu	Thr	Pro	Gly	Phe	His	Phe	Asn	Ile	Leu	Lys
				140					145					150
Ala	Tyr	Ile	Glu	Val	Met	Ala	His	Ser	Val	Lys	Met	Met	Leu	Asp
				155					160					165
Lys	Trp	Glu	Lys	Ile	Cys	Ser	Thr	Gln	Asp	Thr	Ser	Val	Glu	Val

	170		175		180
Tyr Glu His Ile Asn Ser Met Ser Leu Asp Ile Ile Met Lys Cys					
	185		190		195
Ala Phe Ser Lys Glu Thr Asn Cys Gln Thr Asn Ser Thr His Asp					
	200		205		210
Pro Tyr Ala Lys Ala Ile Phe Glu Leu Ser Lys Ile Ile Phe His					
	215		220		225
Arg Leu Tyr Ser Leu Leu Tyr His Ser Asp Ile Ile Phe Lys Leu					
	230		235		240
Ser Pro Gln Gly Tyr Arg Phe Gln Lys Leu Ser Arg Val Leu Asn					
	245		250		255
Gln Tyr Thr Asp Thr Ile Ile Gln Glu Arg Lys Lys Ser Leu Gln					
	260		265		270
Ala Gly Val Lys Gln Asp Asn Thr Pro Lys Arg Lys Tyr Gln Asp					
	275		280		285
Phe Leu Asp Ile Val Leu Ser Ala Lys Asp Glu Ser Gly Ser Ser					
	290		295		300
Phe Ser Asp Ile Asp Val His Ser Glu Val Ser Thr Phe Leu Leu					
	305		310		315
Ala Gly His Asp Thr Leu Ala Ala Ser Ile Ser Trp Ile Leu Tyr					
	320		325		330
Cys Leu Ala Leu Asn Pro Glu His Gln Glu Arg Cys Arg Glu Glu					
	335		340		345
Val Arg Gly Ile Leu Gly Asp Gly Ser Ser Ile Thr Trp Asp Gln					
	350		355		360
Leu Gly Glu Met Ser Tyr Thr Thr Met Cys Ile Lys Glu Thr Cys					
	365		370		375
Arg Leu Ile Pro Ala Val Pro Ser Ile Ser Arg Asp Leu Ser Lys					
	380		385		390
Pro Leu Thr Phe Pro Asp Gly Cys Thr Leu Pro Ala Gly Ile Thr					
	395		400		405
Val Val Leu Ser Ile Trp Gly Leu His His Asn Pro Ala Val Trp					
	410		415		420
Lys Asn Pro Lys Val Phe Asp Pro Leu Arg Phe Ser Gln Glu Asn					
	425		430		435
Ser Asp Gln Arg His Pro Tyr Ala Tyr Leu Pro Phe Ser Ala Gly					
	440		445		450
Ser Arg Asn Cys Ile Gly Gln Glu Phe Ala Met Ile Glu Leu Lys					
	455		460		465
Val Thr Ile Ala Leu Ile Leu Leu His Phe Arg Val Thr Pro Asp					
	470		475		480
Pro Thr Arg Pro Leu Thr Phe Pro Asn His Phe Ile Leu Lys Pro					
	485		490		495
Lys Asn Gly Met Tyr Leu His Leu Lys Lys Leu Ser Glu Cys					
	500		505		

<210> 7

<211> 433

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4290251CD1

<400> 7

Met Ala Gly Thr Asn Ala Leu Leu Met Leu Glu Asn Phe Ile Asp		
1	5	10
Gly Lys Phe Leu Pro Cys Ser Ser Tyr Ile Asp Ser Tyr Asp Pro		
	20	25
Ser Thr Gly Glu Val Tyr Cys Arg Val Pro Asn Ser Gly Lys Asp		
	35	40
Glu Ile Glu Ala Ala Val Lys Ala Ala Arg Glu Ala Phe Pro Ser		
	50	55
		60

```

Trp Ser Ser Arg Ser Pro Gln Glu Arg Ser Arg Val Leu Asn Gln
65 70 75
Val Ala Asp Leu Leu Glu Gln Ser Leu Glu Glu Phe Ala Gln Ala
80 85 90
Glu Ser Lys Asp Gln Gly Lys Thr Leu Ala Leu Ala Arg Thr Met
95 100 105
Asp Ile Pro Arg Ser Val Gln Asn Phe Arg Phe Phe Ala Ser Ser
110 115 120
Ser Leu His His Thr Ser Glu Cys Thr Gln Met Glu His Leu Gly
125 130 135
Cys Met His Tyr Thr Val Arg Ala Pro Val Gly Val Ala Gly Leu
140 145 150
Ile Ser Pro Trp Asn Leu Pro Leu Tyr Leu Leu Thr Trp Lys Ile
155 160 165
Ala Pro Ala Met Ala Ala Gly Asn Thr Val Ile Ala Lys Pro Ser
170 175 180
Glu Leu Thr Ser Val Thr Ala Trp Met Leu Cys Lys Leu Leu Asp
185 190 195
Lys Ala Gly Val Pro Pro Gly Val Val Asn Ile Val Phe Gly Thr
200 205 210
Gly Pro Arg Val Gly Glu Ala Leu Val Ser His Pro Glu Val Pro
215 220 225
Leu Ile Ser Phe Thr Gly Ser Gln Pro Thr Ala Glu Arg Ile Thr
230 235 240
Gln Leu Ser Ala Pro His Cys Lys Lys Leu Ser Leu Glu Leu Gly
245 250 255
Gly Lys Asn Pro Ala Ile Ile Phe Glu Asp Ala Asn Leu Asp Glu
260 265 270
Cys Ile Pro Ala Thr Val Arg Ser Ser Phe Ala Asn Gln Val Arg
275 280 285
Ser Tyr Val Lys Arg Ala Leu Ala Glu Ser Ala Gln Ile Trp Cys
290 295 300
Gly Glu Gly Val Asp Lys Leu Ser Leu Pro Ala Arg Asn Gln Ala
305 310 315
Gly Tyr Phe Met Leu Pro Thr Val Ile Thr Asp Ile Lys Asp Glu
320 325 330
Ser Cys Cys Met Thr Glu Glu Ile Phe Gly Pro Val Thr Cys Val
335 340 345
Val Pro Phe Asp Ser Glu Glu Glu Val Ile Glu Arg Ala Asn Asn
350 355 360
Val Lys Tyr Gly Leu Ala Ala Thr Val Trp Ser Ser Asn Val Gly
365 370 375
Arg Val His Arg Val Ala Lys Lys Leu Gln Ser Gly Leu Val Trp
380 385 390
Thr Asn Cys Trp Leu Ile Arg Glu Leu Asn Leu Pro Phe Gly Gly
395 400 405
Met Lys Ser Ser Gly Ile Gly Arg Glu Gly Ala Lys Asp Ser Tyr
410 415 420
Asp Phe Phe Thr Glu Ile Lys Thr Ile Thr Val Lys His
425 430

```

<210> 8

<211> 186

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4904188CD1

<400> 8

```

Met Lys Thr Glu Asp Gly Phe Glu Met Gln Phe Gly Val Asn His
1 5 10 15
Leu Gly His Phe Leu Leu Thr Asn Leu Leu Leu Gly Leu Leu Lys

```

	20		25		30
Ser Ser Ala Pro Ser Arg Ile Val Val Val Ser Ser Lys Leu Tyr					
	35		40		45
Lys Tyr Gly Asp Ile Asn Phe Asp Asp Leu Asn Ser Glu Gln Ser					
	50		55		60
Tyr Asn Lys Ser Phe Cys Tyr Ser Arg Ser Lys Leu Ala Asn Ile					
	65		70		75
Leu Phe Thr Arg Glu Leu Ala Arg Arg Leu Glu Gly Thr Asn Val					
	80		85		90
Thr Val Asn Val Leu His Pro Gly Ile Val Arg Thr Asn Leu Gly					
	95		100		105
Arg His Ile His Ile Pro Leu Leu Val Lys Pro Leu Phe Asn Leu					
	110		115		120
Val Ser Trp Ala Phe Phe Lys Thr Pro Val Glu Gly Ala Gln Thr					
	125		130		135
Ser Ile Tyr Leu Ala Ser Ser Pro Glu Val Glu Gly Val Ser Gly					
	140		145		150
Arg Tyr Phe Gly Asp Cys Lys Glu Glu Glu Leu Leu Pro Lys Ala					
	155		160		165
Met Asp Glu Ser Val Ala Arg Lys Leu Trp Asp Ile Ser Glu Val					
	170		175		180
Met Val Gly Leu Leu Lys					
	185				

<210> 9

<211> 304

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 638419CD1

<400> 9

Met Ala Lys Ile Glu Lys Asn Ala Pro Thr Met Glu Lys Lys Pro					
1	5		10		15
Glu Leu Phe Asn Ile Met Glu Val Asp Gly Val Pro Thr Leu Ile					
	20		25		30
Leu Ser Lys Glu Trp Trp Glu Lys Val Cys Asn Phe Gln Ala Lys					
	35		40		45
Pro Asp Asp Leu Ile Leu Ala Thr Tyr Pro Lys Ser Gly Thr Thr					
	50		55		60
Trp Met His Glu Ile Leu Asp Met Ile Leu Asn Asp Gly Asp Val					
	65		70		75
Glu Lys Cys Lys Arg Ala Gln Thr Leu Asp Arg His Ala Phe Leu					
	80		85		90
Glu Leu Lys Phe Pro His Lys Glu Lys Pro Asp Leu Glu Phe Val					
	95		100		105
Leu Glu Met Ser Ser Pro Gln Leu Ile Lys Thr His Leu Pro Ser					
	110		115		120
His Leu Ile Pro Pro Ser Ile Trp Lys Glu Asn Cys Lys Ile Val					
	125		130		135
Tyr Val Ala Arg Asn Pro Lys Asp Cys Leu Val Ser Tyr Tyr His					
	140		145		150
Phe His Arg Met Ala Ser Phe Met Pro Asp Pro Gln Asn Leu Glu					
	155		160		165
Glu Phe Tyr Glu Lys Phe Met Ser Gly Lys Val Val Gly Arg Ser					
	170		175		180
Trp Phe Asp His Val Lys Gly Trp Trp Ala Ala Lys Asp Thr His					
	185		190		195
Arg Ile Leu Tyr Leu Phe Tyr Glu Asp Ile Lys Lys Asn Pro Lys					
	200		205		210
His Glu Ile His Lys Val Leu Glu Phe Leu Glu Lys Thr Leu Ser					
	215		220		225

```
<210> 10
<211> 629
<212> PRT
<213> Homo sapiens
```

<400> 10

10/39

	305		310		315
Gln Arg Ser Lys	Ala Leu Leu His Leu	Arg Asn Lys Glu Phe	Gln		
	320		325		330
Glu Cys Val Glu	Cys Phe Glu Arg Ser	Val Lys Ile Asn Pro	Met		
	335		340		345
Gln Leu Gly Val	Trp Phe Ser Leu Gly	Cys Ala Tyr Leu Ala	Leu		
	350		355		360
Glu Asp Tyr Gln	Gly Ser Ala Lys Ala	Phe Gln Arg Cys Val	Thr		
	365		370		375
Leu Glu Pro Asp	Asn Ala Glu Ala Trp	Asn Asn Leu Ser Thr	Ser		
	380		385		390
Tyr Ile Arg Leu	Lys Gln Lys Val Lys	Ala Phe Arg Thr Leu	Gln		
	395		400		405
Glu Ala Leu Lys	Cys Asn Tyr Glu His	Trp Gln Ile Trp Lys	Asn		
	410		415		420
Tyr Ile Leu Thr	Ser Thr Asp Val Gly	Glu Phe Ser Glu Ala	Ile		
	425		430		435
Lys Ala Tyr His	Arg Leu Leu Asp Leu	Arg Asp Lys Tyr Lys	Asp		
	440		445		450
Val Gln Val Leu	Lys Ile Leu Val Arg	Ala Val Ile Asp Gly	Met		
	455		460		465
Thr Asp Arg Ser	Gly Asp Val Ala Thr	Gly Leu Lys Gly Lys	Leu		
	470		475		480
Gln Glu Leu Phe	Gly Arg Val Thr Ser	Arg Val Thr Asn Asp	Gly		
	485		490		495
Glu Ile Trp Arg	Leu Tyr Ala His Val	Tyr Gly Asn Gly Gln	Ser		
	500		505		510
Glu Lys Pro Asp	Glu Asn Glu Lys Ala	Phe Gln Cys Leu Ser	Lys		
	515		520		525
Ala Tyr Lys Cys	Asp Thr Gln Ser Asn	Cys Trp Glu Lys Asp	Ile		
	530		535		540
Thr Ser Phe Lys	Glu Val Val Gln Arg	Ala Leu Gly Leu Ala	His		
	545		550		555
Val Ala Ile Lys	Cys Ser Lys Asn Lys	Ser Ser Ser Gln Glu	Ala		
	560		565		570
Val Gln Met Leu	Ser Ser Val Arg Leu	Asn Leu Arg Gly Leu	Leu		
	575		580		585
Ser Lys Ala Lys	Gln Leu Phe Thr Asp	Val Ala Thr Gly Glu	Met		
	590		595		600
Ser Arg Glu Leu	Ala Asp Asp Ile Thr	Ala Met Asp Thr Leu	Val		
	605		610		615
Thr Glu Leu Gln	Asp Leu Ser Asn Gln	Phe Arg Asn Gln Tyr			
	620		625		

<210> 11

<211> 320

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2613056CD1

<400> 11

Met Thr Leu Asp Ser	Ile Met Lys Cys Ala	Phe Ser His Gln Gly	
1	5	10	15
Ser Ile Gln Leu Asp	Ser Thr Leu Asp Ser	Tyr Leu Lys Ala Val	
	20	25	30
Phe Asn Leu Ser Lys	Ile Ser Asn Gln Arg	Met Asn Asn Phe Leu	
	35	40	45
His His Asn Asp Leu	Val Phe Lys Phe Ser	Ser Gln Gly Gln Ile	
	50	55	60
Phe Ser Lys Phe Asn	Gln Glu Leu His Gln	Phe Thr Glu Lys Val	
	65	70	75

Ile	Gln	Asp	Arg	Lys	Glu	Ser	Leu	Lys	Asp	Lys	Leu	Lys	Gln	Asp	
				80					85					90	
Thr	Thr	Gln	Lys	Arg	Arg	Trp	Asp	Phe	Leu	Asp	Ile	Leu	Leu	Ser	
				95					100					105	
Ala	Lys	Ser	Glu	Asn	Thr	Lys	Asp	Phe	Ser	Glu	Ala	Asp	Leu	Gln	
				110					115					120	
Ala	Glu	Val	Lys	Thr	Phe	Met	Phe	Ala	Gly	His	Asp	Thr	Thr	Ser	
				125					130					135	
Ser	Ala	Ile	Ser	Trp	Ile	Leu	Tyr	Cys	Leu	Ala	Lys	Tyr	Pro	Glu	
				140					145					150	
His	Gln	Gln	Arg	Cys	Arg	Asp	Glu	Ile	Arg	Glu	Leu	Leu	Gly	Asp	
				155					160					165	
Gly	Ser	Ser	Ile	Thr	Trp	Glu	His	Leu	Ser	Gln	Met	Pro	Tyr	Thr	
				170					175					180	
Thr	Met	Cys	Ile	Lys	Glu	Cys	Leu	Arg	Leu	Tyr	Ala	Pro	Val	Val	
				185					190					195	
Asn	Ile	Ser	Arg	Leu	Leu	Asp	Lys	Pro	Ile	Thr	Phe	Pro	Asp	Gly	
				200					205					210	
Arg	Ser	Leu	Pro	Ala	Gly	Ile	Thr	Val	Phe	Ile	Asn	Ile	Trp	Ala	
				215					220					225	
Leu	His	His	Asn	Pro	Tyr	Phe	Trp	Glu	Asp	Pro	Gln	Val	Phe	Asn	
				230					235					240	
Pro	Leu	Arg	Phe	Ser	Arg	Glu	Asn	Ser	Glu	Lys	Ile	His	Pro	Tyr	
				245					250					255	
Ala	Phe	Ile	Pro	Phe	Ser	Ala	Gly	Leu	Arg	Asn	Cys	Ile	Gly	Gln	
				260					265					270	
His	Phe	Ala	Ile	Ile	Glu	Cys	Lys	Val	Ala	Val	Ala	Leu	Thr	Leu	
				275					280					285	
Leu	Arg	Phe	Lys	Leu	Ala	Pro	Asp	His	Ser	Arg	Pro	Pro	Gln	Pro	
				290					295					300	
Val	Arg	Gln	Val	Val	Leu	Lys	Ser	Lys	Asn	Gly	Ile	His	Val	Phe	
				305					310					315	
Ala	Lys	Lys	Val	Cys											
				320											

<210> 12

<211> 56

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5053617CD1

<400> 12

Met	Ser	Gly	Cys	Pro	Asn	Cys	Val	Trp	Val	Glu	Tyr	Ala	Asp	Arg	
1				5					10					15	
Leu	Leu	Gln	His	Phe	Gln	Asp	Gly	Gly	Glu	Arg	Ala	Leu	Ala	Ala	
				20					25					30	
Leu	Glu	Glu	His	Val	Ala	Asp	Glu	Asn	Leu	Lys	Ala	Phe	Leu	Arg	
				35					40					45	
Met	Glu	Ile	Arg	Leu	His	Thr	Arg	Cys	Gly	Gly					
				50					55						

<210> 13

<211> 377

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5483256CD1

<400> 13

Met	Asp	Pro	Ala	Ala	Arg	Val	Val	Arg	Ala	Leu	Trp	Pro	Gly	Gly	1	5	10	15
Cys	Ala	Leu	Ala	Trp	Arg	Leu	Gly	Gly	Arg	Pro	Gln	Pro	Leu	Leu	20	25	30	
Pro	Thr	Gln	Ser	Arg	Ala	Gly	Phe	Ala	Gly	Ala	Ala	Gly	Gly	Pro	35	40	45	
Ser	Pro	Val	Ala	Ala	Ala	Arg	Lys	Gly	Ser	Pro	Arg	Leu	Leu	Gly	50	55	60	
Ala	Ala	Ala	Leu	Ala	Leu	Gly	Gly	Ala	Leu	Gly	Leu	Tyr	His	Thr	65	70	75	
Ala	Arg	Trp	His	Leu	Arg	Ala	Gln	Asp	Leu	His	Ala	Glu	Arg	Ser	80	85	90	
Ala	Ala	Gln	Leu	Ser	Leu	Ser	Ser	Arg	Leu	Gln	Leu	Thr	Leu	Tyr	95	100	105	
Gln	Tyr	Lys	Thr	Cys	Pro	Phe	Cys	Ser	Lys	Val	Arg	Ala	Phe	Leu	110	115	120	
Asp	Phe	His	Ala	Leu	Pro	Tyr	Gln	Val	Val	Glu	Val	Asn	Pro	Val	125	130	135	
Arg	Arg	Ala	Glu	Ile	Lys	Phe	Ser	Ser	Tyr	Arg	Lys	Val	Pro	Ile	140	145	150	
Leu	Val	Ala	Gln	Glu	Gly	Glu	Ser	Ser	Gln	Gln	Leu	Asn	Asp	Ser	155	160	165	
Ser	Val	Ile	Ile	Ser	Ala	Leu	Lys	Thr	Tyr	Leu	Val	Ser	Gly	Gln	170	175	180	
Pro	Leu	Glu	Glu	Ile	Ile	Thr	Tyr	Tyr	Pro	Ala	Met	Lys	Ala	Val	185	190	195	
Asn	Glu	Gln	Gly	Lys	Glu	Val	Thr	Glu	Phe	Gly	Asn	Lys	Tyr	Trp	200	205	210	
Leu	Met	Leu	Asn	Glu	Lys	Glu	Ala	Gln	Gln	Val	Tyr	Gly	Gly	Lys	215	220	225	
Glu	Ala	Arg	Thr	Glu	Glu	Met	Lys	Trp	Arg	Gln	Trp	Ala	Asp	Asp	230	235	240	
Trp	Leu	Val	His	Leu	Ile	Ser	Pro	Asn	Val	Tyr	Arg	Thr	Pro	Thr	245	250	255	
Glu	Ala	Leu	Ala	Ser	Phe	Asp	Tyr	Ile	Val	Arg	Glu	Gly	Lys	Phe	260	265	270	
Gly	Ala	Val	Glu	Gly	Ala	Val	Ala	Lys	Tyr	Met	Gly	Ala	Ala	Ala	275	280	285	
Met	Tyr	Leu	Ile	Ser	Lys	Arg	Leu	Lys	Ser	Arg	His	Arg	Leu	Gln	290	295	300	
Asp	Asn	Val	Arg	Glu	Asp	Leu	Tyr	Glu	Ala	Ala	Asp	Lys	Trp	Val	305	310	315	
Ala	Ala	Val	Gly	Lys	Asp	Arg	Pro	Phe	Met	Gly	Gly	Gln	Lys	Pro	320	325	330	
Asn	Leu	Ala	Asp	Leu	Ala	Val	Tyr	Gly	Val	Leu	Arg	Val	Met	Glu	335	340	345	
Gly	Leu	Asp	Ala	Phe	Asp	Asp	Leu	Met	Gln	His	Thr	His	Ile	Gln	350	355	360	
Pro	Trp	Tyr	Leu	Arg	Val	Glu	Arg	Ala	Ile	Thr	Glu	Ala	Ser	Pro	365	370	375	
Ala	His																	

<210> 14
 <211> 501
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5741354CD1

<400> 14
 Met Trp Lys Leu Trp Arg Ala Glu Glu Gly Ala Ala Ala Leu Gly

1	5	10	15
Gly Ala Leu Phe	Leu Leu Phe Ala	Leu Gly Val Arg	Gln Leu
	20	25	30
Leu Lys Gln Arg	Arg Pro Met Gly Phe	Pro Pro Gly Pro	Pro Gly
	35	40	45
Leu Pro Phe Ile	Gly Asn Ile Tyr Ser	Leu Ala Ala Ser	Ser Glu
	50	55	60
Leu Pro His Val	Tyr Met Arg Lys Gln	Ser Gln Val Tyr	Gly Glu
	65	70	75
Ile Phe Ser Leu	Asp Leu Gly Gly Ile	Ser Thr Val Val	Leu Asn
	80	85	90
Gly Tyr Asp Val	Val Lys Glu Cys Leu	Val His Gln Ser	Glu Ile
	95	100	105
Phe Ala Asp Arg	Pro Cys Leu Pro Leu	Phe Met Lys Met	Thr Lys
	110	115	120
Met Gly Gly Leu	Leu Asn Ser Arg Tyr	Gly Arg Gly Trp	Val Asp
	125	130	135
His Arg Arg Leu	Ala Val Asn Ser Phe	Arg Tyr Phe Gly	Tyr Gly
	140	145	150
Gln Lys Ser Phe	Glu Ser Lys Ile Leu	Glu Thr Lys Phe	Phe
	155	160	165
Asn Asp Ala Ile	Glu Thr Tyr Lys Gly	Arg Pro Phe Asp	Phe Lys
	170	175	180
Gln Leu Ile Thr	Asn Ala Val Ser Asn	Ile Thr Asn Leu	Ile Ile
	185	190	195
Phe Gly Glu Arg	Phe Thr Tyr Glu Asp	Thr Asp Phe Gln	His Met
	200	205	210
Ile Glu Leu Phe	Ser Glu Asn Val Glu	Leu Ala Ala Ser	Ala Ser
	215	220	225
Val Phe Leu Tyr	Asn Ala Phe Pro Trp	Ile Gly Ile Leu	Pro Phe
	230	235	240
Gly Lys His Gln	Gln Leu Phe Arg Asn	Ala Ala Val Val	Tyr Asp
	245	250	255
Phe Leu Ser Arg	Leu Ile Glu Lys Ala	Ser Val Asn Arg	Lys Pro
	260	265	270
Gln Leu Pro Gln	His Phe Val Asp Ala	Tyr Leu Asp Glu	Met Asp
	275	280	285
Gln Gly Lys Asn	Asp Pro Ser Ser Thr	Phe Ser Lys Glu	Asn Leu
	290	295	300
Ile Phe Ser Val	Gly Glu Leu Ile Ile	Ala Gly Thr Glu	Thr Thr
	305	310	315
Thr Asn Val Leu	Arg Trp Ala Ile Leu	Phe Met Ala Leu	Tyr Pro
	320	325	330
Asn Ile Gln Gly	Gln Val Gln Lys Glu	Ile Asp Leu Ile	Met Gly
	335	340	345
Pro Asn Gly Lys	Pro Ser Trp Asp Asp	Lys Cys Lys Met	Pro Tyr
	350	355	360
Thr Glu Ala Val	Leu His Glu Val Leu	Arg Phe Cys Asn	Ile Val
	365	370	375
Pro Leu Gly Ile	Phe His Ala Thr Ser	Glu Asp Ala Val	Val Arg
	380	385	390
Gly Tyr Ser Ile	Pro Lys Gly Thr Thr	Val Ile Thr Asn	Leu Tyr
	395	400	405
Ser Val His Phe	Asp Glu Lys Tyr Trp	Arg Asp Pro Glu	Val Phe
	410	415	420
His Pro Glu Arg	Phe Leu Asp Ser Ser	Gly Tyr Phe Ala	Lys Lys
	425	430	435
Glu Ala Leu Val	Pro Phe Ser Leu Gly	Arg Arg His Cys	Leu Gly
	440	445	450
Glu His Leu Ala	Arg Met Glu Met Phe	Leu Phe Phe Thr	Ala Leu
	455	460	465
Leu Gln Arg Phe	His Leu His Phe Pro	His Glu Leu Val	Pro Asp
	470	475	480
Leu Lys Pro Arg	Leu Gly Met Thr Leu	Gln Pro Gln Pro	Tyr Leu

Ile Cys Ala Glu Arg Arg
500

485

490

495

<210> 15
<211> 144
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5872615CD1

<400> 15
Met Arg Lys Ile Asp Leu Cys Leu Ser Ser Glu Gly Ser Glu Val
1 5 10 15
Ile Leu Ala Thr Ser Ser Asp Glu Lys His Pro Pro Glu Asn Ile
20 25 30
Ile Asp Gly Asn Pro Glu Thr Phe Trp Thr Thr Thr Gly Met Phe
35 40 45
Pro Gln Glu Phe Ile Ile Cys Phe His Lys His Val Arg Ile Glu
50 55 60
Arg Leu Val Ile Gln Ser Tyr Phe Val Gln Thr Leu Lys Ile Glu
65 70 75
Lys Ser Thr Ser Lys Glu Pro Val Asp Phe Glu Gln Trp Ile Glu
80 85 90
Lys Asp Leu Val His Thr Glu Gly Gln Leu Gln Asn Glu Glu Ile
95 100 105
Val Ala His Asp Gly Ser Ala Thr Tyr Leu Arg Phe Ile Ile Val
110 115 120
Ser Ala Phe Asp His Phe Ala Ser Val His Ser Val Ser Ala Glu
125 130 135
Gly Thr Val Val Ser Asn Leu Ser Ser
140

<210> 16
<211> 218
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2657543CD1

<400> 16
Met Leu Ser Thr Phe Ala Arg Gln Asn Asp Ile Pro Phe Gln Leu
1 5 10 15
Gln Thr Val Glu Leu Ala Trp Gly Glu His Leu Lys Pro Glu Phe
20 25 30
Leu Lys Val Asn Pro Leu Gly Lys Val Pro Ala Leu Arg Asp Gly
35 40 45
Asp Phe Leu Leu Ala Glu Arg Leu Glu Lys Arg Ser Leu Thr Pro
50 55 60
Pro Ala His Ser Met Val Ile Val Leu Tyr Leu Ser Arg Lys Tyr
65 70 75
Gln Ile Arg Gly His Trp Tyr Pro Pro Glu Leu Gln Ala Arg Thr
80 85 90
Cys Val Asp Glu Tyr Leu Ala Trp Lys His Val Thr Ile Gln Leu
95 100 105
Pro Ala Thr Asn Val Tyr Leu Cys Lys Pro Ala Asp Ala Ala Gln
110 115 120
Leu Glu Arg Leu Leu Gly Arg Leu Thr Pro Ala Leu Gln His Leu
125 130 135
Asp Gly Gly Val Leu Val Ala Arg Pro Phe Leu Ala Met Glu Gln

Ile Ser Leu Glu Asp	140	Leu Val Leu Thr	145	Glu Val Met Gln Val Lys	150
	155		160		165
Leu Ser Tyr Pro Pro	170	Ala Leu Gly Gly Thr	175	Leu Gly Met Gly Leu	180
Ser Pro Asn Pro Ser	185	Cys Pro Val Phe Pro	190	Ala His Cys Arg Trp	195
Leu Arg Pro Leu Pro	200	Arg Leu Ala Leu Ala	205	Gly Ser Val Thr Gly	210
Pro Tyr Glu Gly Cys	215	Pro Trp Tyr			

<210> 17
 <211> 210
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3041639CD1

<400> 17

Met Ala Cys Ile Leu	5	Lys Arg Lys Ser Val	10	Ile Ala Val Ser Phe	15
Ile Ala Ala Phe Leu	20	Phe Leu Leu Val Val	25	Arg Leu Val Asn Glu	30
Val Asn Phe Pro Leu	35	Leu Leu Asn Cys Phe	40	Gly Gln Pro Gly Thr	45
Lys Trp Ile Pro Phe	50	Ser Tyr Thr Tyr Arg	55	Arg Pro Leu Arg Thr	60
His Tyr Gly Tyr Ile	65	Asn Val Lys Thr Gln	70	Glu Pro Leu Gln Leu	75
Asp Cys Asp Leu Cys	80	Ala Ile Val Ser Asn	85	Ser Gly Gln Met Val	90
Gly Gln Lys Val Gly	95	Asn Glu Ile Asp Arg	100	Ser Ser Cys Ile Trp	105
Arg Met Asn Asn Ala	110	Pro Thr Lys Gly Tyr	115	Glu Glu Asp Val Gly	120
Arg Met Thr Met Ile	125	Arg Val Val Ser His	130	Thr Ser Val Pro Leu	135
Leu Leu Lys Asn Pro	140	Asp Tyr Phe Phe Lys	145	Glu Ala Asn Thr Thr	150
Ile Tyr Val Ile Trp	155	Gly Pro Phe Arg Asn	160	Met Arg Lys Asp Gly	165
Asn Gly Ile Val Tyr	170	Asn Met Leu Lys Lys	175	Thr Val Gly Ile Tyr	180
Pro Asn Ala Gln Ile	185	Tyr Val Thr Thr Glu	190	Lys Arg Met Ser Tyr	195
Cys Asp Gly Val Phe	200	Lys Lys Glu Thr Gly	205	Lys Asp Ser Thr Glu	210

<210> 18
 <211> 613
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3595451CD1

<400> 18

Met Cys Cys Trp Pro	5	Leu Leu Leu Leu Trp	10	Gly Leu Leu Pro Gly	15
	1				

Thr	Ala	Ala	Gly	Gly	Ser	Gly	Arg	Thr	Tyr	Pro	His	Arg	Thr	Leu
				20					25					30
Leu	Asp	Ser	Glu	Gly	Lys	Tyr	Trp	Leu	Gly	Trp	Ser	Gln	Arg	Gly
				35					40					45
Ser	Gln	Ile	Ala	Phe	Arg	Leu	Gln	Val	Arg	Thr	Ala	Gly	Tyr	Val
				50					55					60
Gly	Phe	Gly	Phe	Ser	Pro	Thr	Gly	Ala	Met	Ala	Ser	Ala	Asp	Ile
				65					70					75
Val	Val	Gly	Gly	Val	Ala	His	Gly	Arg	Pro	Tyr	Leu	Gln	Asp	Tyr
				80					85					90
Phe	Thr	Asn	Ala	Asn	Arg	Glu	Leu	Lys	Lys	Asp	Ala	Gln	Gln	Asp
				95					100					105
Tyr	His	Leu	Glu	Tyr	Ala	Met	Glu	Asn	Ser	Thr	His	Thr	Ile	Ile
				110					115					120
Glu	Phe	Thr	Arg	Glu	Leu	His	Thr	Cys	Asp	Ile	Asn	Asp	Lys	Ser
				125					130					135
Ile	Thr	Asp	Ser	Thr	Val	Arg	Val	Ile	Trp	Ala	Tyr	His	His	Glu
				140					145					150
Asp	Ala	Gly	Glu	Ala	Gly	Pro	Lys	Tyr	His	Asp	Ser	Asn	Arg	Gly
				155					160					165
Thr	Lys	Ser	Leu	Arg	Leu	Leu	Asn	Pro	Glu	Lys	Thr	Ser	Val	Leu
				170					175					180
Ser	Thr	Ala	Leu	Pro	Tyr	Phe	Asp	Leu	Val	Asn	Gln	Asp	Val	Pro
				185					190					195
Ile	Pro	Asn	Lys	Asp	Thr	Thr	Tyr	Trp	Cys	Gln	Met	Phe	Lys	Ile
				200					205					210
Pro	Val	Phe	Gln	Glu	Lys	His	His	Val	Ile	Lys	Val	Glu	Pro	Val
				215					220					225
Ile	Gln	Arg	Gly	His	Glu	Ser	Leu	Val	His	His	Ile	Leu	Leu	Tyr
				230					235					240
Gln	Cys	Ser	Asn	Asn	Phe	Asn	Asp	Ser	Val	Leu	Glu	Ser	Gly	His
				245					250					255
Glu	Cys	Tyr	His	Pro	Asn	Met	Pro	Asp	Ala	Phe	Leu	Thr	Cys	Glu
				260					265					270
Thr	Val	Ile	Phe	Ala	Trp	Ala	Ile	Gly	Gly	Glu	Gly	Phe	Ser	Tyr
				275					280					285
Pro	Pro	His	Val	Gly	Leu	Ser	Leu	Gly	Thr	Pro	Leu	Asp	Pro	His
				290					295					300
Tyr	Val	Leu	Leu	Glu	Val	His	Tyr	Asp	Asn	Pro	Thr	Tyr	Glu	Glu
				305					310					315
Gly	Leu	Ile	Asp	Asn	Ser	Gly	Leu	Arg	Leu	Phe	Tyr	Thr	Met	Asp
				320					325					330
Ile	Arg	Lys	Tyr	Asp	Ala	Gly	Val	Ile	Glu	Ala	Gly	Leu	Trp	Val
				335					340					345
Ser	Leu	Phe	His	Thr	Ile	Pro	Pro	Gly	Met	Pro	Glu	Phe	Gln	Ser
				350					355					360
Glu	Gly	His	Cys	Thr	Leu	Glu	Cys	Leu	Glu	Glu	Ala	Leu	Glu	Ala
				365					370					375
Glu	Lys	Pro	Ser	Gly	Ile	His	Val	Phe	Ala	Val	Leu	Leu	His	Ala
				380					385					390
His	Leu	Ala	Gly	Arg	Gly	Ile	Arg	Leu	Arg	His	Phe	Arg	Lys	Gly
				395					400					405
Lys	Glu	Met	Lys	Leu	Leu	Ala	Tyr	Asp	Asp	Asp	Phe	Asp	Phe	Asn
				410					415					420
Phe	Gln	Glu	Phe	Gln	Tyr	Leu	Lys	Glu	Glu	Gln	Thr	Ile	Leu	Pro
				425					430					435
Gly	Asp	Asn	Leu	Ile	Thr	Glu	Cys	Arg	Tyr	Asn	Thr	Lys	Asp	Arg
				440					445					450
Ala	Glu	Met	Thr	Trp	Gly	Gly	Leu	Ser	Thr	Arg	Ser	Glu	Met	Cys
				455					460					465
Leu	Ser	Tyr	Leu	Leu	Tyr	Tyr	Pro	Arg	Ile	Asn	Leu	Thr	Arg	Cys
				470					475					480
Ala	Ser	Ile	Pro	Asp	Ile	Met	Glu	Gln	Leu	Gln	Phe	Ile	Gly	Val
				485					490					495

Lys	Glu	Ile	Tyr	Arg	Pro	Val	Thr	Thr	Trp	Pro	Phe	Ile	Ile	Lys
				500					505					510
Ser	Pro	Lys	Gln	Tyr	Lys	Asn	Leu	Ser	Phe	Met	Asp	Ala	Met	Asn
				515					520					525
Lys	Phe	Lys	Trp	Thr	Lys	Lys	Glu	Gly	Leu	Ser	Phe	Asn	Lys	Leu
				530					535					540
Val	Leu	Ser	Leu	Pro	Val	Asn	Val	Arg	Cys	Ser	Lys	Thr	Asp	Asn
				545					550					555
Ala	Glu	Trp	Ser	Ile	Gln	Gly	Met	Thr	Ala	Leu	Pro	Pro	Asp	Ile
				560					565					570
Glu	Arg	Pro	Tyr	Lys	Ala	Glu	Pro	Leu	Val	Cys	Gly	Thr	Ser	Ser
				575					580					585
Ser	Ser	Ser	Leu	His	Arg	Asp	Phe	Ser	Ile	Asn	Leu	Leu	Val	Cys
				590					595					600
Leu	Leu	Leu	Leu	Ser	Cys	Thr	Leu	Ser	Thr	Lys	Ser	Leu		
				605					610					

<210> 19

<211> 741

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4169101CD1

<400> 19

Met	Ala	Val	Leu	Asp	Thr	Asp	Leu	Asp	His	Ile	Leu	Pro	Ser	Ser
1				5					10					15
Val	Leu	Pro	Pro	Phe	Trp	Ala	Lys	Leu	Val	Val	Gly	Ser	Val	Ala
				20					25					30
Ile	Val	Cys	Phe	Ala	Arg	Ser	Tyr	Asp	Gly	Asp	Phe	Val	Phe	Asp
				35					40					45
Asp	Ser	Glu	Ala	Ile	Val	Asn	Asn	Lys	Asp	Leu	Gln	Ala	Glu	Thr
				50					55					60
Pro	Leu	Gly	Asp	Leu	Trp	His	His	Asp	Phe	Trp	Gly	Ser	Arg	Leu
				65					70					75
Ser	Ser	Asn	Thr	Ser	His	Lys	Ser	Tyr	Arg	Pro	Leu	Thr	Val	Leu
				80					85					90
Thr	Phe	Arg	Ile	Asn	Tyr	Tyr	Leu	Ser	Gly	Gly	Phe	His	Pro	Val
				95					100					105
Gly	Phe	His	Val	Val	Asn	Ile	Leu	Leu	His	Ser	Gly	Ile	Ser	Val
				110					115					120
Leu	Met	Val	Asp	Val	Phe	Ser	Val	Leu	Phe	Gly	Gly	Leu	Gln	Tyr
				125					130					135
Thr	Ser	Lys	Gly	Arg	Leu	His	Leu	Ala	Pro	Arg	Ala	Ser	Leu	
				140					145					150
Leu	Ala	Ala	Leu	Leu	Phe	Ala	Val	His	Pro	Val	His	Thr	Glu	Cys
				155					160					165
Val	Ala	Gly	Val	Val	Gly	Arg	Ala	Asp	Leu	Leu	Cys	Ala	Leu	Phe
				170					175					180
Phe	Leu	Leu	Ser	Phe	Leu	Gly	Tyr	Cys	Lys	Ala	Phe	Arg	Glu	Ser
				185					190					195
Asn	Lys	Glu	Gly	Ala	His	Ser	Ser	Thr	Phe	Trp	Val	Leu	Leu	Ser
				200					205					210
Ile	Phe	Leu	Gly	Ala	Val	Ala	Met	Leu	Cys	Lys	Glu	Gln	Gly	Ile
				215					220					225
Thr	Val	Leu	Gly	Leu	Asn	Ala	Val	Phe	Asp	Ile	Leu	Val	Ile	Gly
				230					235					240
Lys	Phe	Asn	Val	Leu	Glu	Ile	Val	Gln	Lys	Val	Leu	His	Lys	Asp
				245					250					255
Lys	Ser	Leu	Glu	Asn	Leu	Gly	Met	Leu	Arg	Asn	Gly	Gly	Leu	Leu
				260					265					270
Phe	Arg	Met	Thr	Leu	Leu	Thr	Ser	Gly	Gly	Ala	Gly	Met	Leu	Tyr

	275		280		285
Val Arg Trp Arg Ile Met Gly Thr Gly Pro Pro Ala Phe Thr Glu					
	290		295		300
Val Asp Asn Pro Ala Ser Phe Ala Asp Ser Met Leu Val Arg Ala					
	305		310		315
Val Asn Tyr Asn Tyr Tyr Tyr Ser Leu Asn Ala Trp Leu Leu Leu					
	320		325		330
Cys Pro Trp Trp Leu Cys Phe Asp Trp Ser Met Gly Cys Ile Pro					
	335		340		345
Leu Ile Lys Ser Ile Ser Asp Trp Arg Val Ile Ala Leu Ala Ala					
	350		355		360
Leu Trp Phe Cys Leu Ile Gly Leu Ile Cys Gln Ala Leu Cys Ser					
	365		370		375
Glu Asp Gly His Lys Arg Arg Ile Leu Thr Leu Gly Leu Gly Phe					
	380		385		390
Leu Val Ile Pro Phe Leu Pro Ala Ser Asn Leu Phe Phe Arg Val					
	395		400		405
Gly Phe Val Val Ala Glu Arg Val Leu Tyr Leu Pro Ser Ile Gly					
	410		415		420
Tyr Cys Val Leu Leu Thr Phe Gly Phe Gly Ala Leu Ser Lys His					
	425		430		435
Thr Lys Lys Lys Lys Leu Ile Ala Ala Val Val Leu Gly Ile Leu					
	440		445		450
Phe Ile Asn Thr Leu Arg Cys Val Leu Arg Ser Gly Glu Trp Arg					
	455		460		465
Ser Glu Glu Gln Leu Phe Arg Ser Ala Leu Ser Val Cys Pro Leu					
	470		475		480
Asn Ala Lys Val His Tyr Asn Ile Gly Lys Asn Leu Ala Asp Lys					
	485		490		495
Gly Asn Gln Thr Ala Ala Ile Arg Tyr Tyr Arg Glu Ala Val Arg					
	500		505		510
Leu Asn Pro Lys Tyr Val His Ala Met Asn Asn Leu Gly Asn Ile					
	515		520		525
Leu Lys Glu Arg Asn Glu Leu Gln Glu Ala Glu Glu Leu Leu Ser					
	530		535		540
Leu Ala Val Gln Ile Gln Pro Asp Phe Ala Ala Ala Trp Met Asn					
	545		550		555
Leu Gly Ile Val Gln Asn Ser Leu Lys Arg Phe Glu Ala Ala Glu					
	560		565		570
Gln Ser Tyr Arg Thr Ala Ile Lys His Arg Arg Lys Tyr Pro Asp					
	575		580		585
Cys Tyr Tyr Asn Leu Gly Arg Leu Tyr Ala Asp Leu Asn Arg His					
	590		595		600
Val Asp Ala Leu Asn Ala Trp Arg Asn Ala Thr Val Leu Lys Pro					
	605		610		615
Glu His Ser Leu Ala Trp Asn Asn Met Ile Ile Leu Leu Asp Asn					
	620		625		630
Thr Gly Asn Leu Ala Gln Ala Glu Ala Val Gly Arg Glu Ala Leu					
	635		640		645
Glu Leu Ile Pro Asn Asp His Ser Leu Met Phe Ser Leu Ala Asn					
	650		655		660
Val Leu Gly Lys Ser Gln Lys Tyr Lys Glu Ser Glu Ala Leu Phe					
	665		670		675
Leu Lys Ala Ile Lys Ala Asn Pro Asn Ala Ala Ser Tyr His Gly					
	680		685		690
Asn Leu Ala Val Leu Tyr His Arg Trp Gly His Leu Asp Leu Ala					
	695		700		705
Lys Lys His Tyr Glu Ile Ser Leu Gln Leu Asp Pro Thr Ala Ser					
	710		715		720
Gly Thr Lys Glu Asn Tyr Gly Leu Leu Arg Arg Lys Leu Glu Leu					
	725		730		735
Met Gln Lys Lys Ala Val					
	740				

<210> 20
 <211> 535
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2925182CD1

<400> 20

Met	Arg	Leu	Arg	Asn	Gly	Thr	Val	Ala	Thr	Ala	Leu	Ala	Phe	Ile	1	5	10	15
Thr	Ser	Phe	Leu	Thr	Leu	Ser	Trp	Tyr	Thr	Thr	Trp	Gln	Asn	Gly	20	25	30	35
Lys	Glu	Lys	Leu	Ile	Ala	Tyr	Gln	Arg	Glu	Phe	Leu	Ala	Leu	Lys	40	45	50	55
Glu	Arg	Leu	Arg	Ile	Ala	Glu	His	Arg	Ile	Ser	Gln	Arg	Ser	Ser	60	65	70	75
Glu	Leu	Asn	Thr	Ile	Val	Gln	Gln	Phe	Lys	Arg	Val	Gly	Ala	Glu	80	85	90	95
Thr	Asn	Gly	Ser	Lys	Asp	Ala	Leu	Asn	Lys	Phe	Ser	Asp	Asn	Thr	100	105	110	115
Leu	Lys	Leu	Leu	Lys	Glu	Leu	Thr	Ser	Lys	Lys	Ser	Leu	Gln	Val	120	125	130	135
Pro	Ser	Ile	Tyr	Tyr	His	Leu	Pro	His	Leu	Leu	Lys	Asn	Glu	Gly	140	145	150	155
Ser	Leu	Gln	Pro	Ala	Val	Gln	Ile	Gly	Asn	Gly	Arg	Thr	Gly	Val	160	165	170	175
Ser	Ile	Val	Met	Gly	Ile	Pro	Thr	Val	Lys	Arg	Glu	Val	Lys	Ser	180	185	190	195
Tyr	Leu	Ile	Glu	Thr	Leu	His	Ser	Leu	Ile	Asp	Asn	Leu	Tyr	Pro	200	205	210	215
Glu	Glu	Lys	Leu	Asp	Cys	Val	Ile	Val	Val	Phe	Ile	Gly	Glu	Thr	220	225	230	235
Asp	Ile	Asp	Tyr	Val	His	Gly	Val	Val	Ala	Asn	Leu	Glu	Lys	Glu	240	245	250	255
Phe	Ser	Lys	Glu	Ile	Ser	Ser	Gly	Leu	Val	Glu	Val	Ile	Ser	Pro	260	265	270	275
Pro	Glu	Ser	Tyr	Tyr	Pro	Asp	Leu	Thr	Asn	Leu	Lys	Glu	Thr	Phe	280	285	290	295
Gly	Asp	Ser	Lys	Glu	Arg	Val	Arg	Trp	Arg	Thr	Lys	Gln	Asn	Leu	300	305	310	315
Asp	Tyr	Cys	Phe	Leu	Met	Met	Tyr	Ala	Gln	Glu	Lys	Gly	Ile	Tyr	320	325	330	335
Tyr	Ile	Gln	Leu	Glu	Asp	Asp	Ile	Ile	Val	Lys	Gln	Asn	Tyr	Phe	340	345	350	355
Asn	Thr	Ile	Lys	Asn	Phe	Ala	Leu	Gln	Leu	Ser	Ser	Glu	Glu	Trp	360	365	370	375
Met	Ile	Leu	Glu	Phe	Ser	Gln	Leu	Gly	Phe	Ile	Gly	Lys	Met	Phe	380	385	390	395
Gln	Ala	Pro	Asp	Leu	Thr	Leu	Ile	Val	Glu	Phe	Ile	Phe	Met	Phe	400			
Tyr	Lys	Glu	Lys	Pro	Ile	Asp	Trp	Leu	Leu	Asp	His	Ile	Leu	Trp				
Val	Lys	Val	Cys	Asn	Pro	Glu	Lys	Asp	Ala	Lys	His	Cys	Asp	Arg				
Gln	Lys	Ala	Asn	Leu	Arg	Ile	Arg	Phe	Arg	Pro	Ser	Leu	Phe	Gln				
His	Val	Gly	Leu	His	Ser	Ser	Leu	Ser	Gly	Lys	Ile	Gln	Lys	Leu				
Thr	Asp	Lys	Asp	Tyr	Met	Lys	Pro	Leu	Leu	Leu	Lys	Ile	His	Val				
Asn	Pro	Pro	Ala	Glu	Val	Ser	Thr	Ser	Leu	Lys	Val	Tyr	Gln	Gly				

His Thr Leu Glu Lys Thr Tyr Met Gly Glu Asp Phe Phe Trp Ala	
410	415 420
Ile Thr Pro Ile Ala Gly Asp Tyr Ile Leu Phe Lys Phe Asp Lys	
425	430 435
Pro Val Asn Val Glu Ser Tyr Leu Phe His Ser Gly Asn Gln Glu	
440	445 450
His Pro Gly Asp Ile Leu Leu Asn Thr Thr Val Glu Val Leu Pro	
455	460 465
Phe Lys Ser Glu Gly Leu Glu Ile Ser Lys Glu Thr Lys Asp Lys	
470	475 480
Arg Leu Glu Asp Gly Tyr Phe Arg Ile Gly Lys Phe Glu Asn Gly	
485	490 495
Val Ala Glu Gly Met Val Asp Pro Ser Leu Asn Pro Ile Ser Ala	
500	505 510
Phe Arg Leu Ser Val Ile Gln Asn Ser Ala Val Trp Ala Ile Leu	
515	520 525
Asn Glu Ile His Ile Lys Lys Ala Thr Asn	
530	535

<210> 21

<211> 522

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3271838CD1

<400> 21

Met Ala Ala Met Ala Val Ala Leu Arg Gly Leu Gly Gly Arg Phe	
1 5	10 15
Arg Trp Arg Thr Gln Ala Val Ala Gly Gly Val Arg Gly Ala Ala	
20	25 30
Arg Gly Ala Ala Ala Gly Gln Arg Asp Tyr Asp Leu Leu Val Val	
35	40 45
Gly Gly Gly Ser Gly Gly Leu Ala Cys Ala Lys Glu Ala Ala Gln	
50	55 60
Leu Gly Arg Lys Val Ser Val Val Asp Tyr Val Glu Pro Ser Pro	
65	70 75
Gln Gly Thr Arg Trp Gly Leu Gly Gly Thr Cys Val Asn Val Gly	
80	85 90
Cys Ile Pro Lys Lys Leu Met His Gln Ala Ala Leu Leu Gly Gly	
95	100 105
Leu Ile Gln Asp Ala Pro Asn Tyr Gly Trp Glu Val Ala Gln Pro	
110	115 120
Val Pro His Asp Trp Arg Lys Met Ala Glu Ala Val Gln Asn His	
125	130 135
Val Lys Ser Leu Asn Trp Gly His Arg Val Gln Leu Gln Asp Arg	
140	145 150
Lys Val Lys Tyr Phe Asn Ile Lys Ala Ser Phe Val Asp Glu His	
155	160 165
Thr Val Cys Gly Val Ala Lys Gly Gly Lys Glu Ile Leu Leu Ser	
170	175 180
Ala Asp His Ile Ile Ile Ala Thr Gly Gly Arg Pro Arg Tyr Pro	
185	190 195
Thr His Ile Glu Gly Ala Leu Glu Tyr Gly Ile Thr Ser Asp Asp	
200	205 210
Ile Phe Trp Leu Lys Glu Ser Pro Gly Lys Thr Leu Val Val Gly	
215	220 225
Ala Ser Tyr Val Ala Leu Glu Cys Ala Gly Phe Leu Thr Gly Ile	
230	235 240
Gly Leu Asp Thr Thr Ile Met Met Arg Ser Ile Pro Leu Arg Gly	
245	250 255
Phe Asp Gln Gln Met Ser Ser Met Val Ile Glu His Met Ala Ser	

His Gly Thr Arg	260	265	270
Phe Leu Arg Gly Cys	275	280	285
Arg Leu Pro Asp Gly Gln Leu Gln Val	290	295	300
Thr Gly Lys Glu Asp Thr Gly Thr Phe	305	310	315
Ile Gly Arg Val Pro Asp Thr Arg Ser	320	325	330
Gly Val Asp Thr Ser Pro Asp Thr Gln	335	340	345
Arg Glu Ala Thr Ser Val Pro His Ile	350	355	360
Val Glu Gly Arg Pro Glu Leu Thr Pro	365	370	375
Arg Leu Leu Val Gln Arg Leu Phe Gly	380	385	390
Asp Tyr Asp Asn Val Pro Thr Thr Val	395	400	405
Gly Cys Val Gly Leu Ser Glu Glu Glu	410	415	420
Gln Glu His Val Glu Val Tyr His Ala	425	430	435
Phe Thr Val Ala Gly Arg Asp Ala Ser	440	445	450
Val Cys Leu Arg Glu Pro Pro Gln Leu	455	460	465
Leu Gly Pro Asn Ala Gly Glu Val Thr	470	475	480
Ile Lys Cys Gly Ala Ser Tyr Ala Gln	485	490	495
Ile His Pro Thr Cys Ser Glu Glu Val	500	505	510
Lys Arg Ser Gly Leu Asp Pro Thr Val	515	520	

<210> 22

<211> 495

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3292871CD1

<400> 22

Met Lys Asn Lys Thr	Cys Val Leu Val	Cys Val Ser Val	Phe Gly
1	5	10	15
Gly Glu Arg Gly Gln	Val Thr Val Pro	Arg Val Gly Val	Arg Arg
	20	25	30
Pro Ser Leu Ala Gly	Pro Leu Gln Lys	Cys Thr Leu Arg	Glu Thr
	35	40	45
Arg Val Trp Leu Pro	Gln Gly Ser Gly	Phe Gln Ser Ser	Arg Arg
	50	55	60
Glu Lys Tyr Gly Asn	Val Phe Lys Thr	His Leu Leu Gly	Arg Pro
	65	70	75
Leu Ile Arg Val Thr	Gly Ala Glu Asn	Val Arg Lys Ile	Leu Met
	80	85	90
Gly Glu His His Leu	Val Ser Thr Glu	Trp Pro Arg Ser	Thr Arg
	95	100	105
Met Leu Leu Gly Pro	Asn Thr Val Ser	Asn Ser Ile Gly	Asp Ile
	110	115	120
His Arg Asn Lys Arg	Lys Val Phe Ser	Lys Ile Phe Ser	His Glu
	125	130	135

Ala	Leu	Glu	Ser	Tyr	Leu	Pro	Lys	Ile	Gln	Leu	Val	Ile	Gln	Asp
				140					145					150
Thr	Leu	Arg	Ala	Trp	Ser	Ser	His	Pro	Glu	Ala	Ile	Asn	Val	Tyr
				155					160					165
Gln	Glu	Ala	Gln	Lys	Leu	Thr	Phe	Arg	Met	Ala	Ile	Arg	Val	Leu
				170					175					180
Leu	Gly	Phe	Ser	Ile	Pro	Glu	Glu	Asp	Leu	Gly	His	Leu	Phe	Glu
				185					190					195
Val	Tyr	Gln	Gln	Phe	Val	Asp	Asn	Val	Phe	Ser	Leu	Pro	Val	Asp
				200					205					210
Leu	Pro	Phe	Ser	Gly	Tyr	Arg	Arg	Gly	Ile	Gln	Ala	Arg	Gln	Ile
				215					220					225
Leu	Gln	Lys	Gly	Leu	Glu	Lys	Ala	Ile	Arg	Glu	Lys	Leu	Gln	Cys
				230					235					240
Thr	Gln	Gly	Lys	Asp	Tyr	Leu	Asp	Ala	Leu	Asp	Leu	Leu	Ile	Glu
				245					250					255
Ser	Ser	Lys	Glu	His	Gly	Lys	Glu	Met	Thr	Met	Gln	Glu	Leu	Lys
				260					265					270
Asp	Gly	Thr	Leu	Glu	Leu	Ile	Phe	Ala	Ala	Tyr	Ala	Thr	Thr	Ala
				275					280					285
Ser	Ala	Ser	Thr	Ser	Leu	Ile	Met	Gln	Leu	Leu	Lys	His	Pro	Thr
				290					295					300
Val	Leu	Glu	Lys	Leu	Arg	Asp	Glu	Leu	Arg	Ala	His	Gly	Ile	Leu
				305					310					315
His	Ser	Gly	Gly	Cys	Pro	Cys	Glu	Gly	Thr	Leu	Arg	Leu	Asp	Thr
				320					325					330
Leu	Ser	Gly	Leu	Arg	Tyr	Leu	Asp	Cys	Val	Ile	Lys	Glu	Val	Met
				335					340					345
Arg	Leu	Phe	Thr	Pro	Ile	Ser	Gly	Gly	Tyr	Arg	Thr	Val	Leu	Gln
				350					355					360
Thr	Phe	Glu	Leu	Asp	Gly	Phe	Gln	Ile	Pro	Lys	Gly	Trp	Ser	Val
				365					370					375
Met	Tyr	Ser	Ile	Arg	Asp	Thr	His	Asp	Thr	Ala	Pro	Val	Phe	Lys
				380					385					390
Asp	Val	Asn	Val	Phe	Asp	Pro	Asp	Arg	Phe	Ser	Gln	Ala	Arg	Ser
				395					400					405
Glu	Asp	Lys	Asp	Gly	Arg	Phe	His	Tyr	Leu	Pro	Phe	Gly	Gly	Gly
				410					415					420
Val	Arg	Thr	Cys	Leu	Gly	Lys	His	Leu	Ala	Lys	Leu	Phe	Leu	Lys
				425					430					435
Val	Leu	Ala	Val	Glu	Leu	Ala	Ser	Thr	Ser	Arg	Phe	Glu	Leu	Ala
				440					445					450
Thr	Arg	Thr	Phe	Pro	Arg	Ile	Thr	Leu	Val	Pro	Val	Leu	His	Pro
				455					460					465
Val	Asp	Gly	Leu	Ser	Val	Lys	Phe	Phe	Gly	Leu	Asp	Ser	Asn	Gln
				470					475					480
Asn	Glu	Ile	Leu	Pro	Glu	Thr	Glu	Ala	Met	Leu	Ser	Ala	Thr	Val
				485					490					495

<210> 23

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4109179CD1

<400> 23

Met	Glu	Glu	Lys	Thr	Ile	Leu	Ser	Cys	Ile	Leu	Arg	His	Phe	Trp
1				5					10					15
Ile	Glu	Ser	Asn	Gln	Lys	Arg	Glu	Glu	Leu	Gly	Leu	Glu	Gly	Gln
				20					25					30

Leu Ile Leu Arg Pro Ser Asn Gly Ile Trp Ile Lys Leu Lys Arg
 35 40 45
 Arg Asn Ala Asp Glu Arg
 50

<210> 24
 <211> 335
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 4780365CD1

<400> 24
 Met Ile Leu Phe Leu Ile Met Leu Val Leu Val Leu Phe Gly Tyr
 1 5 10 15
 Gly Val Leu Ser Pro Arg Ser Leu Met Pro Gly Ser Leu Glu Arg
 20 25 30
 Gly Phe Cys Met Ala Val Arg Glu Pro Asp His Leu Gln Arg Val
 35 40 45
 Ser Leu Pro Arg Met Val Tyr Pro Gln Pro Lys Val Leu Thr Pro
 50 55 60
 Cys Arg Lys Asp Val Leu Val Val Thr Pro Trp Leu Ala Pro Ile
 65 70 75
 Val Trp Glu Gly Thr Phe Asn Ile Asp Ile Leu Asn Glu Gln Phe
 80 85 90
 Arg Leu Gln Asn Thr Thr Ile Gly Leu Thr Val Phe Ala Ile Lys
 95 100 105
 Lys Tyr Val Ala Phe Leu Lys Leu Phe Leu Glu Thr Ala Glu Lys
 110 115 120
 His Phe Met Val Gly His Arg Val His Tyr Tyr Val Phe Thr Asp
 125 130 135
 Gln Pro Ala Ala Val Pro Arg Val Thr Leu Gly Thr Gly Arg Gln
 140 145 150
 Leu Ser Val Leu Glu Val Arg Ala Tyr Lys Arg Trp Gln Asp Val
 155 160 165
 Ser Met Arg Arg Met Glu Met Ile Ser Asp Phe Cys Glu Arg Arg
 170 175 180
 Phe Leu Ser Glu Val Asp Tyr Leu Val Cys Val Asp Val Asp Met
 185 190 195
 Glu Phe Arg Asp His Val Gly Val Glu Ile Leu Thr Pro Leu Phe
 200 205 210
 Gly Thr Leu His Pro Gly Phe Tyr Gly Ser Ser Arg Glu Ala Phe
 215 220 225
 Thr Tyr Glu Arg Arg Pro Gln Ser Gln Ala Tyr Ile Pro Lys Asp
 230 235 240
 Glu Gly Asp Phe Tyr Tyr Leu Gly Gly Phe Phe Gly Gly Ser Val
 245 250 255
 Gln Glu Val Gln Arg Leu Thr Arg Ala Cys His Gln Ala Met Met
 260 265 270
 Val Asp Gln Ala Asn Gly Ile Glu Ala Val Trp His Asp Glu Ser
 275 280 285
 His Leu Asn Lys Tyr Leu Leu Arg His Lys Pro Thr Lys Val Leu
 290 295 300
 Ser Pro Glu Tyr Leu Trp Asp Gln Gln Leu Leu Gly Trp Pro Ala
 305 310 315
 Val Leu Arg Lys Leu Arg Phe Thr Ala Val Pro Lys Asn His Gln
 320 325 330
 Ala Val Arg Asn Pro
 335

<210> 25
 <211> 1269

<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1799250CB1

<400> 25
cgcgggcgcg cgcgggcgcg ggcagccatg tcgccattgt ctgcagcgcg ggcgggccctg 60
cggggtctacg cggttaggcgc cgcgggtgatc ctggcgcgagc tgctgcggcg ctgccgcggg 120
ggcttccttg agccagttct cccccacga cctgaccgtg tcgctatagt gacgggaggg 180
acagatggca ttggctattc tacagcgaag catctggcga gacttggcat gcatgttatc 240
atagctggaa ataataacag caaagccaaa caagttgtaa gcaaaataaa agaagaaacc 300
ttgaacgaca aagtgggaatt tttatactgt gacttggctt ccatgacttc catccggcag 360
tttgtgcaga agttcaagat gaagaagatt cctctccatg tcctgatcaa caatgctggg 420
gtgatgatgg tccctcagag gaaaaccaga gatggattcg aagaacattt cggcctgaac 480
tacctagggc acttcctgct gaccaacctt ctcttgata cgctgaaaga gtctgggtcc 540
cctggccaca gtgcgagggg ggtcacgctc tcctctgcca ccattacgt cgctgagctg 600
aacatggatg accttcagag cagtgcctgc tactacccc acgcagccta cgcccagagc 660
aagctggccc ttgtcctgtt cacctaccac ctccagcggc tgctggcggc tgagggagc 720
cacgtgacgc ccaacgtggt ggaccccggg gtggtcaaca cggacgtcta caagcacgtg 780
ttctggggcca cccgtctggc gaagaagctt ctgggctggt tgcttttcaa gacccccgat 840
gaaggagcgt ggacttccat ctacgcagca gtcacccag agctggaagg agttggtggc 900
cgttacctat acaacaagaa agagaccaag tcctccacg tcacctacaa ccagaaactg 960
cagcagcagc tgtggtctaa gagttgtgag atgactgggg tccttgatgt gacctgtgtg 1020
tatcctgtct caggatagct gctgccccaa gaaacacatt gcacctgcca atagcttgtg 1080
ggtctgtgaa gactgcgggtg tttgagtttc tcacaccac ctgcccacag ggctctgtcc 1140
tctagttttg agacagctgc ctcaacctct gcagaacttc aagaagccaa ataaacattt 1200
tggaggataa tcaccccaag tggctctcaa ccataaactt tgtgattcca aagtgccag 1260
ttgtcacag 1269

<210> 26
<211> 1593
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2242475CB1

<400> 26
cctgcctggt cctctgtgcc tgggtggggtg ggggtgccag gtgtgtccag aggagcccat 60
ttggtagtga ggcaggtatg gggctagaag cactggtgcc cctggccgtg atagtggcca 120
tcttcctgct cctggtggac ctgatgcacc ggcgccaacg ctgggctgca cgctaccac 180
caggccccct gccactgcc gggctgggca acctgctgca tgtggacttc cagaacacac 240
catactgctt cgaccagttg cggcgccgct tcggggacgt gttcagcctg cagctggcct 300
ggacgcgggt ggtcgtgctc aatgggctgg cggccgtgcg cgaggcgctg gtgaccacg 360
gcgaggacac gcgcgaccgc ccgcctgtgc ccatcaccga gatcctgggt ttcgggccc 420
gttcccaagg ggtgttcctg gcgcgctatg gggccgctg gcgcgagcag aggcgcttct 480
ccgtctccac cttgcgcaac ttgggcctgg gcaagaagtc gctggagcag tgggtgaccg 540
aggaggccgc ctgcctttgt gccgccttcg ccaaccactc cggacgcccc tttcgcccca 600
acggtctctt ggacaaagcc gtgagcaacg tgatcgctc cctcacctgc gggcgccgct 660
tcgagtacga cgaccctcgc ttctcaggc tgctggacct agctcaggag ggactgaagg 720
aggagtggg cttcctgcgc gaggtgctga atgctgtccc cgtcctccc ccatcccag 780
cgctggctgg caaggtccta cgcttccaaa aggccttctt gaccagctg gatgagctgc 840
taactgagca caggatgacc tgggacccag ccagccacc ccgagacctg actgagcct 900
tcctggcaaa gaaggagaag gccaaagggg gccctgagag cagcttcaat gatgagaacc 960
tgcgcatagt ggtgggtaac ctgttccttg ccgggatggt gaccacctcg accacactgg 1020
cctgggccct gctgctcatg atcctgcatc cggatgtgca gtgccagta caacaggaaa 1080
tcgatgaggt catagggcag gtgcggcatc cagagatggc agaccaggcc cacatccgt 1140
tcaccaatgc tgtcatccat gaggtgcagc gctttgcaga cattgtccca atgaatttgc 1200
cacacaagac ttctcgtgac attgaagtgc agggcttctt tatccctaag gggacaacc 1260
tcatcccaa cctgtcctca gtgctgaagg atgagactgt ctgggagag cccctccgat 1320
tccacctga acattcctg gatgccagg gcaactttgt gaagcatgag gccttcatgc 1380

```

cattctcagc aggccgcaga gcatgcctgg gggagccctt ggcccgcag gagctcttcc 1440
tcttcttcac ctgcttcctg caacgcttca gcttctcctt gccactgga cagccccggc 1500
ccagcgacta tgggtgtcttt gcctttctcc tttagcccttc cccctaccag ctctgtgcat 1560
tcaaacgtta gaaggaaaga aattctagtc cag 1593

```

<210> 27

<211> 1779

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2706492CB1

<400> 27

```

cagtgcagaga actgagaccc agagagatta agtatcttgc ccaaggtcac acttttagtaa 60
aaggcaaaagt caggatttga atccacacac ttatctagta cactctaaga cacaggggca 120
gatttttagta aacagtagga gatggactct cagaatttgg tgcttgaggga gaggggaagag 180
gagagagatg cctggtgaca agcccagccc ttgctctctc acaggagagt gggaacaatg 240
aggctatctt catggccttg gacttggcca gtctggcctc ggtgcgggcc ttgtccactg 300
cctttctgag ctctgagcca cggttggaca tcctcatcca caatgccggt atcagttcct 360
gtggccggac ccgtgaggcg tttaacctgc tgcttcgggt gaaccatata ggtccctttc 420
tgctgacaca tctgtgtgct ccttgccctga aggcattgtgc ccctagccgc gtggtggtgg 480
tagcctcagc tgcccactgt cggggacgtc ttgacttcaa acgcctggac cgcccagtg 540
tgggctggcg gcaggagctg cgggcatact ctgacactaa gctggctaata gtactgtttg 600
cccgaggact cgccaaccag cttgaggcca ctggcgctcac ctgctatgca gccaccagc 660
ggcctgtgaa ctcgagagctg ttcttgcgcc atgttctctg atggctgcgc ccacttttgc 720
gccattggc ttggctgggtg ctccgggcac caagaggggg tgcccagaca cccctgtatt 780
gtgctctaca agagggcatc gagccctca gtgggagata ttttgccaac tgccatgtgg 840
aagaggtgcc tccagctgcc cgagacgacc gggcagccca tcggctatgg gaggccagca 900
agaggctggc agggcttggg cctggggagg atgctgaacc cgatgaagac cccagttctg 960
aggactcaga ggccccatct tctctaagca cccccaccc tgaggagccc acagtttctc 1020
aaccttacc cagccctcag agctcaccag atttgtctaa gatgacgcac cgaattcagg 1080
ctaaagtga gcctgagatc cagctctcct aacctcagg ccaggatgct tgccatggca 1140
cttcatggtc cttgaaaacc tcggatgtgt gcgaggccat gccttgaca ctgacgggtt 1200
tgtgatcttg acctccgtgg ttactttctg gggccccaag ctgtgccctg gacatctctt 1260
ttcctgggtg aaggaataat ggggtattat ttcttctga gagtgaacag aacccagat 1320
ggagagatag gggatgcta gacactgtgc ttctcggaaa tttggatgta gtattttcag 1380
gccccaccct tattgattct gatcagctct ggagcagagg caggaggttt gcaatgtgat 1440
gcactgcaa cattgagaat tagtgaactg atccctttgc aaccgtctag ctaggtagtt 1500
aaattacccc catgttaatg aagcgggaatt aggtctccga gctaaggagac tcgcctaggg 1560
tctcacagt agtaggagga gggcctggga tctgaaccca agggctctgag gccagggccg 1620
actgccgtaa gatgggtgct gagaagttag tcagggcagg gcagctggta tcgaggtgcc 1680
ccatgggagt aaggggacgc cttccgggcg gatgcagggc tggggtcatc tgtatctgaa 1740
gcccctcgga ataaagcgcg ttgaccgccg aaaaaaaaa 1779

```

<210> 28

<211> 1931

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2766688CB1

<400> 28

```

ggcaacgcgg ctggttctcg cccgtcagtc ctagcccgcc cctgcccctc gcttgcaattt 60
tttccgcgct ggctgagatt caaagagaag tggaggtggg agggagcgac aatggaaaaa 120
tcacctgaaa actgggacag aggaaggaag ctacagttaac gaaggagagc tgcaaaagtt 180
gcagcagaaa ggttgggagt cccgacaggt tccgtagccc acagaaaaga agcaagggac 240
ggcaggactg tttcacactt ttctgcttct ggaagggtgct ggacaaaaac atggaaactaa 300
tttccccaac agtgattata atcctgggtt gccttgctct gttcttactc cttcagcgga 360
agaatttgcg tagacccccg tgcattcaagg gctggattcc ttggattgga gttggatttg 420
agtttgggaa agccccctca gaatttatag agaaagcaag aatcaagtat ggaccaatat 480

```

```

ttacagtctt tgctatggga aaccgaatga cctttgttac tgaagaagaa ggaattaatg 540
tgttttctaaa atccaaaaaa gtagattttg aactagcagt gcaaaatatac gtttatcata 600
cagcatcaat tccaaagaat gtcttttttag cactgcatga aaaactctat attatgttga 660
aagggaaaaat ggggactgtc aatctccatc agtttactgg gcaactgact gaagaattac 720
atgaacaact ggagaattta ggcactcatg ggacaatgga cctgaacaac ttagtaagac 780
atctccttta tccagtcaca gtgaatatgc tctttaataa aagtttgttt tccacaaaca 840
agaaaaaaat caaggagtto catcagtatt ttcaagttta tgatgaagat tttgagtatg 900
gggtccagtt gccagagtgt cttctaagaa actgggtcaaa atccaaaaag tggttcctgg 960
aactgtttga gaaaaacatt ccagatataa aagcatgtaa atctgcaaaa gataattcca 1020
tgacattatt gcaagctacg ctggatattg tagagacgga aacaagtaag gaaaactcac 1080
ccaattatgg gctcttactg ctttgggctt ctctgtctaa tgctgttctt gttgcatttt 1140
ggacacttgc atacgtcctt tctcatcctg atatccacaa ggccattatg gaaggcatat 1200
cttctgtgtt tggcaaaagca ggcaaaagata agattaaagt gtctgaggat gacctggaga 1260
atctccttct aattaaatgg tgtgttttgg aaaccattcg tttaaaagct cctgggtgtca 1320
ttactagaaa agtgggtgaag cctgtggaaa ttttgaatta catcattcct tctgggtgact 1380
tgttgatgtt gtctccattt tggctgcata gaaatccaaa gtattttcct gagcctgaat 1440
tgttcaaacc tgaacgttgg gaaaaaggca aatttagaga agcactcttt cttggactgc 1500
ttcatggcat tggaagcggg aagttccagt gtcctgcaag gtggtttgcct ctgttagagc 1560
ttcagatgtg tattatttta atactttata aatatgactg tagtcttctg gacctattag 1620
ccaaacagag ttatctccat ttgggtgggtg tccccagcc ggaagggcaa tgccgaattg 1680
aatataaaca aagaatatga catctgttgg gcctcacaag gaccagggcc ttctggagga 1740
gtggcactac cccacctggc agcacctaga cctgagctct acaaaaacac actgcttcac 1800
tttgttttag gacttagttc aagaacacat tcaaatggtg catgtgtttg gtatcttcaa 1860
cagtagacca agaattctaac atcactctca gtaatataga gaccggaata catggtttat 1920
aggaaatgat c 1931

```

<210> 29

<211> 1282

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2788823CB1

<400> 29

```

cgcgctgctg cctccgctcg cctgtggctg cgtcgcgcgc tcttctctcg agctaccag 60
gcggctggtg tgcagcaagc tccgcgccga ccccgacgc ctgacgcctg acgcctgtcc 120
ccggcccgcc atgagccgct acctgctgcc gctgtcggcg ctgggcacgg tagcaggcgc 180
cgccgtgctg ctcaaggact atgtcaccgg tggggcttgc ccagcaagg ccaccatccc 240
tggaagacg gtcatcgtga cgggcgcaa cacaggcatc gggaagcaga ccgccttggg 300
actggccagg agaggaggca acatcatcct ggcctgccga gacatggaga agtgtgaggc 360
ggcagcaaag gacatccgcg gggagaccct caatcaccat gtcaacgccc ggcacctgga 420
cttggcttcc ctcaagtcta tccgagagtt tgcagcaaag atcattgaag aggaggagcg 480
agtggacatt ctaatcaaca acgcggtgtg gatgcgttgc cccactgga ccaccgagga 540
cggcttcgag atgcagtttg gcgttaacca cctgggtcac tttctcttga caaacttgct 600
gctggacaag ctgaaagcct cagccccttc cgggatcatc aacctctcgt ccctggccca 660
tgttgctggg cacatagact ttgacgactt gaactggcag acgaggaagt ataacaccaa 720
agccgcctac tgccagagca agctcgccat cgtcctcttc accaaggagc tgagccggcg 780
gctgcaaggc tctggtgtga ctgtcaacgc cctgcacccc ggcgtggcca ggacagagct 840
gggcagacac acgggcatcc atggctccac cttctccagc accacactcg ggcccatctt 900
ctggctgctg gtcaagagcc cggagctggc cgcccagccc agcacatacc tggccgtggc 960
ggaggaactg gcggatgttt ccggaagta cttcgatgga ctcaaacaga aggccccggc 1020
ccccgaggct gaggatgagg aggtggcccg gaggttttgg gctgaaagtg ccgccttgg 1080
gggcttagag gctccctctg tgaggagca gccctcccc agataacctc tggagcagat 1140
ttgaaagcca ggatggcgcc tccagaccga ggacagctgt ccgccatgcc cgcagcttcc 1200
tggcactacc tgagccggga gaccaggac tggcgccgcg catgcccga gtaggttcta 1260
gggggcgggtg ctggccgcag tg 1282

```

<210> 30

<211> 2416

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3348822CB1

<400> 30

```
agcgtgcgcg ctttggtaac cggctagaaa tcccgcacgc ggcctgcct cctctcccca 60
ggcctgagct gccctccca ctgccttcc ttcttccgc gagtcagaag cttcgcgagg 120
gccagagag gcggtgggt gggcgaccct acgcagctc cgggcgggag aaagcccacc 180
ctctcccgcg cccagga aa cgcggcggt tcggcgctgc gcagagccat ggaattctcc 240
tggctggaga cgcgtgggc ggcggccttt tacctggcg tcgtgttctg cctggccctg 300
gggctgctgc aggccattaa gctgtacctg cggaggcagc ggctgctgcg ggacctgcgc 360
cccttcccag cgcggccac ccactgggtc cttgggcacc agaagtttat tcaggatgat 420
aacatggaga agcttgagga aattattgaa aaataccctc gtgccttccc tttctggatt 480
gggccctttc aggcattttt ctgtatctat gaccagact atgcaaagac acttctgagc 540
agaacagatc ccaagtccca gtacctgcag aaattctcac ctccacttct tggaaaagga 600
ctagcggctc tagacggacc caagtgggtc cagcatcgtc gcctactaac tcctggattc 660
cattttaaca tcctgaaagc atacattgag gtgatggctc attctgtgaa aatgatgctg 720
gataagtggg agaagatttg cagcactcag gacacaagcg tggaggtcta tgagcacatc 780
aactcgatgt ctctggatat aatcatgaaa tgcgcttcca gcaaggagac caactgcagc 840
acaacagca cccatgatcc ttatgcaaaa gccatatttg aactcagcaa aatcatattt 900
caccgcttgt acagtttgtt gtatcacagt gacataattt tcaaactcag cctcagggc 960
taccgcttcc agaagttaag ccgagtgttg aatcagtaca cagatacaat aatccaggaa 1020
agaaagaaat cctccaggc tggggtaaaag caggataaca ctccgaagag gaagtaccag 1080
gattttcttg atattgtcct ttctgccaa gtagaaagtg gtagcagctt ctcagatatt 1140
gatgtacact ctgaagtgag cacattcctg ttggcaggac atgacacctt ggcagcaagc 1200
atctcctgga tcctttactg cctggctctg aacctgagc atcaagagag atgcccggag 1260
gaggtcaggg gcacctggg ggatgggtct tctatcactt gggaccagct ggggtgagatg 1320
tcgtacacca caatgtgcat caaggagacg tgccgattga ttcctgcagt cccgtccatt 1380
tccagagatc tcagcaagcc acttaccttc ccagatggat gcacattgcc tgcagggatc 1440
accgtgggtc ttagtatttg gggcttccac cacaaccctg ctgtctggaa aaaccctaaag 1500
gtctttgacc ccttgagggt ctctcaggag aattctgata agagacaccc ctatgcctac 1560
ttaccattct cagctggatc aaggaactgc attgggcagg agtttgccat gattgagtta 1620
aaggtaacca ttgccttgat tctgtccac ttcagagtga ctccagaccc caccaggcct 1680
cttactttcc ccaaccattt tatcctcaag cccaagaatg ggatgtattt gcacctgaag 1740
aaactctctg aatgttagat ctccagggtac aatgattaaa cgtactttgt ttttcgaagt 1800
taaatttaca gtaagtgate caagcagata gaaaggatc aatgtatggt gggaggattg 1860
gaggttggtg gtagatgggt ctctgtgaag gaaacaaa tcatttctag gtacacagtg 1920
tgtcagctag atctgtttct atataacttt gggagatttt cagatctttt ctgttaaaact 1980
ttcactacta ttaatgctgt atacaccaat agactttcat atattttctg ttgtttttaa 2040
aatagttttc agaattatgc aagtaataag tgcattgtat ctactgtca aaaattccca 2100
acactagaaa atcatgtaga ataaaaatt taaatctcac ttcacttagc cgacattcca 2160
tgccctgacc aatcctactg cttttcctaa aaacagaata atttggtgtg cattctttca 2220
gactttttcc tatacatttt atatgtagaa atgtagcaat gtatttgtat agatgtgatc 2280
attcctatat tgttattgat ttttttact taataaaaat tcaccttatt ccttatcatt 2340
gctttatggt attctgtaat atgaatgtac tataatttat ttaactattt tccttattgg 2400
gcatttaagt gatttc 2416
```

<210> 31

<211> 1574

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4290251CB1

<400> 31

```
ggacaacctg agtgctcagt cgtaaagagg aaaggcagaa tttttccttg ctatggctgg 60
aacaacgcga cttttgatgc tggaaaactt catagatgga aaatttttac cttgtagctc 120
atatatagat tcttacgacc catcaacagg ggaagtgtat tgcagagtgc caaatagtgg 180
aaaagacgag atcgaagccg cgggtcaagg cgccagagaa gcctttccca gctggatc 240
ccgcagcccc caggagcgct cacgggtcct gaaccagggt gcggatttgc tggagcagtc 300
cctggaggag tttgcccagg ccgagtctaa agaccaaggg aaaaccttag cactggcaag 360
aaccatggac attccccggt ctgtgcagaa cttcagggtt ttcgcttctc ccagcctgca 420
```

ccacacgtca	gagtgcacgc	agatggaaca	cctgggctgc	atgcactaca	cggtgcgggc	480
cccgggtggga	gtcgtctggc	tgatcagccc	ctggaatttg	ccactctact	tgctgacctg	540
gaagatagct	ccagcgcgatg	ctgcaggga	cactgtgata	gccaagcca	gtgagctgac	600
ttcagtgact	gcgtggatgt	tgtgcaaact	cctggataaa	gcaggtgttc	caccaggtgt	660
ggtcaatatt	gtgtttggaa	ccgggcccag	gggtgggtgag	gccctgggtg	cccaccaga	720
ggtgccccctg	atctccttca	ccgggagcca	gcccacgcct	gagcggatca	cccagctgag	780
cgctcccccac	tgcaaaaagc	tctccctgga	gctggggggc	aagaatcctg	ccatcatctt	840
tgaggacgcc	aacctggatg	agtgcattcc	ggcaaccgtc	aggtccagct	ttgccaacca	900
ggtcagaagt	tacgtcaaga	gagctcttgc	tgaaagtgcc	caaatttggg	gcggtgaagg	960
agtggtgataag	ttgagcctcc	ctgccaggaa	ccaggcaggc	tactttatgc	ttcccacggg	1020
gataacagac	attaaggatg	aatcctgctg	catgacggaa	gagataattg	gtccagtgc	1080
gtgtgtcgtc	ccctttgata	gtgaagagga	gggtattgaa	agagccaaca	acgttaagta	1140
tgggctggcg	gctaccgtgt	ggtccagcaa	tgtggggcgc	gtccacgggg	tggctaagaa	1200
gctgcagtct	ggcttgggtc	ggaccaactg	ctggctcatc	agggagctga	accttccttt	1260
cggggggatg	aagagttctg	gaataggtag	agaggagacc	aaggactctt	acgacttctt	1320
cactgagatc	aaaaccatca	ccgttaaaca	ctgactcttg	ctaattggtg	agccactatg	1380
gccaatgcct	ggctgcaggc	atcagttggt	caatgtggta	gatgaaaatc	atggcatgaa	1440
ttccagctat	gccttgactt	ggcagaaggt	tatctctagc	ttatcctcag	ttcttagtaa	1500
ctttaccac	tagtgaagag	atactgtcta	ttttcaatgt	ggactcggaa	aaaaagactt	1560
ataagtagga	agat					1574

<210> 32

<211> 1227

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4904188CB1

<400> 32

gcaggaccca	gggcgctgaa	ctctcacaac	caatcaggcg	acccccccag	agggaaacta	60
caagtcccg	catgccccac	gcgcaccgtc	aggggcccag	ccgcgcgcgc	ccagcgttct	120
cgcgctacag	gtggtctctt	gggttccgga	agagcctagg	ctggatgtct	tgatcaataa	180
cgcagggatc	ttccagtgcc	cttaccatgaa	gactgaagat	gggtttgaga	tgcatgtccg	240
agtgaacat	ctggggcact	ttctactcac	caatcttctc	cttggactcc	tcaaaagtcc	300
agctcccagc	aggattgtgg	tagtttcttc	caaactttat	aaatacggag	acatcaattt	360
tgatgacttg	aacagtgaac	aaagctataa	taaaagcttt	tgttatagcc	ggagcaact	420
ggctaacatt	ctttttacca	gggaactagc	ccgccgctta	gaaggcaca	atgtcaccgt	480
caatgtgttg	catcctggta	ttgtacggac	aaatctgggg	aggcacatac	acattccact	540
gttgggtcaaa	ccactcttca	atttgggtgc	atgggctttt	ttcaaaaactc	cagtagaagg	600
tgcccagact	tccatttatt	tggcctcttc	acctgaggta	gaaggagtgt	caggaagata	660
ctttggggat	tgtaaagagg	aagaactggt	gcccaaagct	atggatgaat	ctgttgcaag	720
aaaactctgg	gatatcagtg	aagtgatggt	tggcctgcta	aaataggaac	aaggagtaaa	780
agagctgttt	ataaaaactgc	atatcagtta	tatctgtgat	caggaatggt	gtggattgag	840
aacttgttac	ttgaagaaaa	agaattttga	tattggaata	gcctgctaag	aggtacatgt	900
gggtattttg	gagttactga	aaaattattt	ttgggataag	agaatttcag	caaagatgtt	960
ttaaatatat	atagtaagta	taatgaataa	taagtacaat	gaaaaataca	attatattgt	1020
aaaattataa	ctgggcaagc	atggatgaca	tattaatatt	gtcagaatt	aagtactca	1080
aagtgtctatc	gagaggtttt	tcaagtatct	ttgagtttca	tggccaaagt	gttaactagt	1140
tttactacaa	tgtttgggtg	ttgtgtggaa	attatctgcc	tggtgtgtgc	acacaagtct	1200
tacttggaa	aaatttactg	gtacaaa				1227

<210> 33

<211> 1240

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 638419CB1

<400> 33

cttgcttgca cagtgtcctg gagctggacc tggctctggg ttccaggaa gcagtttgac 60

taaaggcagc	aagctgcttc	ctctgctgcc	tgaataacca	gattcccaat	ggcgaagatt	120
gagaaaaacg	ctcccacgat	ggaaaaaaag	ccagaactgt	ttaacatcat	ggaagtagat	180
ggagtcccta	cggtgatatt	atcaaaaagaa	tggtagggaaa	aagtctgtaa	tttccaagcc	240
aagcctgatg	atcttattct	ggcaacttac	ccaaagtcag	gtacaacatg	gatgcatgaa	300
attttagaca	tgattctaaa	tgatggtgat	gtggagaaat	gcaaaagagc	ccagactcta	360
gatagacacg	ctttccttga	actgaaatth	ccccataaag	aaaaaccaga	tttgagagttc	420
gttcttgaaa	tgtcctcacc	acaactgata	aaaacacatc	tcccttcaca	tctgattcca	480
ccatctatct	ggaaagaaaa	ctgcaagatt	gtctatgtgg	ccagaaatcc	caaggattgc	540
ctgggtgtcct	actaccactt	tcacaggatg	gcttccttta	tgcctgatcc	tcagaactta	600
gaggaatttt	atgagaaatt	catgtccgga	aaagttgttg	gcaggtcctg	gtttgacat	660
gtgaaaggat	ggtagggctgc	aaaagacacg	caccggatcc	tctacctctt	ctacgaggat	720
attaaaaaaa	atccaaaaca	tgagatccac	aagtggttg	aattcttgga	gaaaactttg	780
tcagggtgatg	ttataaacia	gattgtccac	catacctcat	ttgatgtaat	gaaggataat	840
cccattggcca	accatactgc	ggtacctgct	cacatattca	atcactccat	ctcaaaattt	900
atgaggaaaag	ggatgcctgg	agactggaag	agccacttta	ctgtggctat	gaatgagaac	960
tttgataaagc	attatgaaaa	gaagatggca	gggtccacac	tgaacttctg	cctggagatc	1020
tgagaggaaac	aacaacaaac	taggtgacag	agactatgcc	aactatttcg	ccttttatte	1080
tgttgagcaa	ggaactgtga	ctgaatgtgg	agcttatgag	cttcagtcca	tctcctatag	1140
tgtggctagt	ttgtctataat	attaaaacat	gatttaaaat	atcaacaaac	cagttactcc	1200
agcaataaaa	ataagagaat	tagagagcag	aaaaaaaaaa			1240

<210> 34

<211> 2275

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1844394CB1

<400> 34

gcaattcagt	gaggttaaag	gactggatgc	atltgttctg	agcctgctca	ctctagatgg	60
tgaatcaatc	tacagcctga	cctcgaagcc	tatactactg	ttattagcac	gcattatcct	120
agtgaatgta	agacataaac	tgacagctat	tcagagcttg	ccatgggtgga	ctttgagatg	180
tgtgaatatt	catcagcatt	tgcttgagga	acgctcacct	ctgcttttta	ctcttgccga	240
aaactgtatt	gatcaagtga	tgaactaca	gaatctgttt	gtagatgatt	caggtcagata	300
tttggtctatt	caattccatc	tggaaatgtgc	atatgtgttt	ttatattatt	atgagtacag	360
aaaagcaaaa	gatcagttgg	atattgctaa	ggacatcagc	caattacaaa	ttgatttgac	420
agggtgctttg	ggaaaaagaa	cacggttcca	ggaaaattat	gtggcacaaac	tgattctaga	480
tgtaagaagg	gaaggggatg	tcctttcaaa	ttgtgaattc	actccagcac	ccactcctca	540
ggaacattta	accaagaatc	ttgagctcaa	tgatgacacc	attctgaatg	acataaagtt	600
agcagattgt	gaacagttcc	agatgccgga	tctgtgtgct	gaagagatcg	ctattattct	660
tggaatctgc	actaattttc	aaaagaataa	cccagtgcac	acattaactg	aagtggagct	720
tctggcatth	acatcatgth	tgctttcaca	accaaagttc	tggggcattc	agacatcagc	780
cttgatcctc	cggacaaaac	ttgagaaagg	aagtactcgc	cgagtggaaac	gtgcaatgag	840
gcagacacag	gctcttgag	accaatttga	agataaaact	acatctgtat	tggaacgcct	900
gaagattttc	tattgctgtc	aagtaccacc	tcactgggccc	attcagcgcc	aacttgcaag	960
tttgctcttt	gagttgggat	gtaccagttc	agcccttcag	atatttgaaa	agctagaaat	1020
gtgggaagat	gttgtcattt	gttatgaaag	agccggggcag	cacggaaagg	cagaagaaat	1080
ccttagacaa	gagctggaga	aaaaagaaac	gcctagttha	tactgcttgc	ttggagatgt	1140
cctcggagac	cattcttgct	atgacaaggc	ctgggagttg	tcccgggtacc	gcagtgtctg	1200
tgctcagcgc	tccaaagccc	tccttcatct	tcggaacaag	gagtttcaag	agtgtgtaga	1260
gtgcttcgaa	cgctcggtha	agattaatcc	catgcagctc	ggggtgtggt	tttctctcgg	1320
ttgtgcctat	ttggccttgg	aagactatca	aggttcagca	aaggcatttc	agcgtgtgtg	1380
gactctagaa	cccataaatg	ctgaagcttg	gaacaatttg	tcaacttcct	atatccgatt	1440
aaaacaaaaa	gtaaaagctt	ttagaacttt	acaagaagct	ctcaagtgtg	actatgaaca	1500
ctggcagatt	tggaaaaact	acatcctcac	cagcactgac	gttgggggaat	tttcagaagc	1560
cattaaagct	tatcaccggc	tcttggactt	acgtgacaaa	tacaaagatg	ttcaggtcct	1620
taaaaattcta	gtcagggcag	tgattgatgg	gatgactgat	cgaagtggag	atgttgcaac	1680
tggcctcaaa	ggaaagctgc	aggagttatt	tggcagagtg	acttcaagag	tgacaaatga	1740
tggagaaatc	tggaggctgt	atgccacgt	atatggaaat	gggcagagtg	aaaagcctga	1800
tgaaaatgaa	aaggcattcc	agtgcctctc	aaaggcatac	aagtgtgaca	ccagtcctca	1860
ttgttgggag	aaagatatta	catcatttaa	ggaagttgtt	caaagagcct	taggacttgc	1920
acatgtggcc	ataaaatgca	gtaaaaacaa	atccagttcc	caagaagctg	tacaaatgct	1980

ttcttctggt	cgactcaatt	tacggggcct	gttatctaaa	gcaaagcaac	tttttacaga	2040
tgtggcaact	ggagaaatgt	ccagggaatt	agctgatgac	ataacagcta	tggacacctt	2100
agtgacagag	ctccaagacc	taagcaacca	gtttcgaaat	cagtattgat	tctgctggaa	2160
gcagattctg	gaaaaaggtgc	tttcacctgc	tggtaaaaga	tacatctgta	tatctgaaat	2220
gcaagatatt	gattttttaa	ataaatttgc	tttatgactt	aaaaaaaaaa	aaaaa	2275

<210> 35

<211> 1586

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2613056CB1

<400> 35

tctaaggcac	agtatcattt	tcagtactga	caagggtgtt	cattttatat	ggttgtcata	60
ataaggcaaa	ttcattttgt	acgctttata	ttttcaaacc	cagcaagctc	taaaaggac	120
ataaaataac	ttagaaattg	ggaaagacgg	gcatgtgtat	gatcatgata	ttcatcccct	180
gccccagaac	aaatgggagg	aacacattgc	ccaaaactca	cgtctggagc	tctttcaaca	240
tgtctccctg	atgaccctgg	acagcatcat	gaagtgtgcc	ttcagccacc	agggcagcat	300
ccagttggac	agtaccctgg	actcatacct	gaaagcagtg	ttcaacctta	gcaaaatctc	360
caaccagcgc	atgaacaatt	ttctacatca	caacgacctg	gttttcaa	tcagctctca	420
aggccaaatc	ttttctaaat	tttaaccaaga	acttcatcag	ttcacagaga	aagtaatcca	480
ggaccggaag	gagtctctta	aggataagct	aaaacaagat	actactcaga	aaaggcgctg	540
ggattttctg	gacatacttt	tgagtgccaa	aagcgaaaac	accaaagatt	tctctgaagc	600
agatctccag	gctgaagtga	aaacgttcat	gtttgcagga	catgacacca	catccagtg	660
tatctcctgg	atcctttact	gcttggcaaa	gtaccctgag	catcagcaga	gatgccgaga	720
tgaatcagg	gaactcctag	gggatgggtc	ttctattacc	tgggaacacc	tgagccagat	780
gccttacacc	acgatgtgca	tcaagggaatg	cctcgcctc	tacgcaccgg	tagtaaacat	840
atccccggtta	ctcgacaaac	ccatcacctt	tccagatgga	cgctccttac	ctgcaggaat	900
aactgtgttt	atcaatattt	gggctcttca	ccacaacccc	tatttctggg	aagaccctca	960
ggtctttaac	cccttgagat	tctccaggga	aaattctgaa	aaaatacatc	cctatgcctt	1020
cataccattc	tcagctggat	taaggaaactg	cattgggcag	cattttgcca	taattgagtg	1080
taagtgggca	gtggcattaa	ctctgctccg	cttcaagctg	gtccagacc	actcaaggcc	1140
tccccagcct	gttcgtcaag	ttgtcctcaa	gtccaagaat	ggaatccatg	tgtttgcaaa	1200
aaaagtttgc	taattttaag	tcctttcgta	taagaattaa	tgagacaatt	ttcctaccaa	1260
aggaagaaca	aaaggataaa	tataatacaa	aatatatgta	tatggttgtt	tgacaaatta	1320
tataaacttag	gatacttctg	actggttttg	acatccatta	acagtaattt	taatttcttt	1380
gctgtatctg	gtgaaaccca	caaaaacacc	tgaaaaaact	caagctgact	tccactgcga	1440
agggaaatta	ttggtttgtg	taactagtgg	tagagtggct	ttcaagcata	gtttgatcaa	1500
aactccactc	agtatctgca	ttacttttat	ctctgcaaat	atctgcatga	tagctttatt	1560
ctcagttatc	tttccccata	ataaaa				1586

<210> 36

<211> 859

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5053617CB1

<400> 36

gtcagagtgc	tccccacccc	cccacatgt	gcttgagtgc	acaccggcg	ccaggccctg	60
atcctggcac	ttcttgtgaa	tcacaccgtg	tcatacccat	gacttccatt	gcacagtggg	120
gaaactgagt	ctagagaggt	gaaataacat	gtctaaagtc	acaggaagtg	aaaaagctga	180
ggacatggag	ccagttgccc	aatgacagga	gagctgaaat	gtcctcactg	ctgggggtag	240
accgggcctc	accagcttcc	tggagagtca	catgtttgtc	tgcactctca	gggggctcgc	300
cggttctcca	gcccggactg	ctgccagagg	cttcctggag	gtggcagctt	tcttcaaagg	360
caccatcccc	gagcgcaagc	ccctgatggg	cgcagaaaat	tcgggacaga	ccacgtagag	420
gtgggctccc	aagcaggtgc	ggacggcacc	aggccgcca	aggcatcgct	gccacctgag	480
ctccagccgc	ccacaaactg	ctgcatgagt	ggctgcccc	actgctgtg	ggtggagtac	540
gcggacaggc	tgctgcagca	cttccaggac	ggtggggagc	gggccctggc	tgccctggag	600

```
gagcacgtgg ctgatgagaa cctcaaggcc ttccctcagga tggagatccg gctgcacacc 660
aggtgcgagg gctgagccat ccctgctgga ctccctaccg caggacggag tccaggacgc 720
agccgcagcc tccttccttc acacccctc acagactcct tgtgtccaac gggaatagga 780
agaattagtt actgacttca cctgagaaaa aaataaatc tctatggtgg tttcaaaaaa 840
aaaaaaaaa aaaaaaaaaa                                     859
```

<210> 37
<211> 2302
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5483256CB1

```
<400> 37
gtttccgggg ctttcagtg cgggaagtc cggcgctgt actgactcta ggaagggtg 60
gagtgttttg aatgggccc cgtaagagag gtgggcaagt acgtgttaca gacggccacg 120
ccgcccttta ggcggtcaag gtggggcgag cagacgttcg ccccccctga gtcggccggg 180
tcactaccga agagcctttg gaggcggaag catggaacgg tctgcaaacg ttcccagcgc 240
ggcctctgcg gctctggcgg gcgtttcgaa cttgggccc gggcacacgc ccagtcccga 300
gagcgctgag gggtccctta gcgtcgccct caccgcggcc aaccgcggg gcgcagagt 360
cctggccctt taaacgcgc gcgtgcctcg gcgtcttcgt ttcgcgcgc ccggccgggc 420
gccggcggag cgaacatgga cccggctgcg cgggtggtgc gggcgctgtg gcctggtggg 480
tgcgcccttg cctggaggct gggaggccgc cccagccgc tgctaccac gcagagccgg 540
gctggcttcg cggggggcgc gggcgggcgc agccccgtg ctgcagctcg taaggggagc 600
ccgcggctgc tgggagctgc ggcgctggcc ctggggggag ccctggggct gtaccacacg 660
gcgcgggtgg acctgcgcgc ccaggacctc cagcagagc gctcagcgc gcagctctcc 720
ctgtccagcc gcctgcagct gaccctgtac cagtacaaga cgtgtccctt ctgcagcaag 780
gtccgagcct tcctcgactt ccatgccctg ccctaccagg tgggtggagg gaacctgtg 840
cgcagggtg agatcaagtt ctctcctac agaaagggtc ccatcctggt ggcccaggaa 900
ggagaaagct cgcaacaact aaatgactcc tctgtcatca tcagcgccct caagacctac 960
ctggtgtcgg ggcagcccct ggaagagatc atcacctact acccagccat gaaggctgtg 1020
aacgagcagg gcaaggagg gaccgagttc ggcaataagt actggctcat gctcaacgag 1080
aaggaggccc agcaagtgt tgggtgggaag gaggccagga cggaggagat gaagtggcgg 1140
cagtggcggg acgactggc ggtgcacctg atctccccc atgtgtaccg cacgcccacc 1200
gaggtctctg cgtcctttga ctacattgtc cgcgagggca agttcggagc cgtggagggt 1260
gccgtggcca agtacatggg tgcagcggcc atgtacctca tcagcaagcg actcaagagc 1320
aggcaccgcc tccaggacaa cgtgcgcgag gacctctatg aggtgctga caagtgggtg 1380
gctgctgttg gcaaggaccg gcccttcatg gggggccaga agccgaatct cgtgatttg 1440
gcggtgtatg gcgtgctgcg tgtgatggag gggctggatg cattcgatga cctgatgcag 1500
cacacgcaca tccagccctg gtacctgcg gtggagagg ccataccga ggcccccac 1560
gcgcactgaa tgtccccgcg cagagcagag ggaaggcagc ggaagacgcc agctgccagg 1620
gcctggggcc actgggcccag cgctggcga tactggttg gggcaggatc attctgcccc 1680
ttgtccacgc acccccacca gccctctcgc ttctaacaca gggcacctgc tggggctcag 1740
ggatgttagg gacgagttcc agccctgcc ctgccctggg gcgacccctc cctgtccctg 1800
cctccctgct ctgccgccc tcttccctga cctcagtg ctgtcccatg gctacatcct 1860
gtgggtgggg gccctcgaca ggacagcagg acggtttgtt ttcagtggaa tcccatccct 1920
gggttccctt gggtccact cttcccaagc ctcccgggac tgggacatgt ttgcaataaa 1980
ggaaaggttt gtggcgctg tcatggcagg catctcatg agctccgtgt ggctgagtgc 2040
tgctggtggc tggcggtcaa gggaggcatc aggtctgggc tgtgccagcc ctgtggttaa 2100
ctaaccgctg gcctggggct tcccaggtgt caggcacggt acggtctcgc aggtttgtg 2160
tggcatcgtc ccaggatcac cactcagggc acacagctgg gccgtggagc ccagcagcca 2220
gagtgcaggt cggggcacc taccacggt ggggctctgc agtgggggtc ctcatcaagc 2280
ctcagtttct tcgtcatgtc cc                                     2302
```

<210> 38
<211> 1653
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5741354CB1

<400> 38

```

ctgggtctca gggctgctgt ggagttcgca cctccagctc gggccgatgt ggaagctttg 60
gagagctgaa gagggcgcg gggcgctcgg cgccgcgctc ttcctgctgc tcttcgcgct 120
aggggtccgc cagctgctga agcagaggcg gccgatgggc tccccccgg gggcccggg 180
gctgccattt atcggcaaca tctattccct ggcagcctca tccgagcttc cccatgtcta 240
catgagaaag cagagccagg tgtaaggaga gatcttcagt ttagatcttg gaggcataac 300
aactgtgggt ctaaatggct atgatgtagt aaaggaatgc cttgttcac aaagcgaaat 360
ttttgcagac agaccatgcc ttcctttatt catgaagatg acaaaaatgg gaggcttact 420
caattccaga tatggccgag gatgggttga tcacagacga ttagctgtaa acagttttcg 480
atatttttga tatggccaaa agtcttttga atctaaaatc ttggaagaaa ccaaattttt 540
caatgatgct attgaaacat acaaaggtag accttttgac tttaaacagt taataacgaa 600
tgctgtttca aacataacca atctgatcat ttttggagaa cgattcactt atgaagacac 660
cgattttcag cacatgattg agttatttag tgaaaatgtg gaactagctg ccagtgcctc 720
agtcttcttg tataatgcct ttccatggat tggcatcctg ccttttggaa aacatcaaca 780
gctgttttag aatgcagctg tagtctatga ttttctctcc agactcattg aaaaagcttc 840
agtcaacaga aagcctcagc tacctcagca ttttgttgat gcttatttag atgagatgga 900
tcaaggtaaa aatgacccat catctacttt ctccaaagaa aacctaattt tctcagtggg 960
tgaactcatc attgctggaa ctgaaactac aaccaatgtg ctacggtggg cgattctttt 1020
catggccctt tatcctaata ttcaaggaca agttcagaaa gagattgatt taattatggg 1080
ccctaattgg aagccttctt gggacgacaa atgcaaaatg ccttatactg aggcagtttt 1140
gcatgaagtt ttaagattct gtaatatagt tccattaggg attttccatg caacctctga 1200
agatgcagtt gtacgtgggt attccattcc taaaggcaca acagtaatta caaatcttta 1260
ttctgtacac ttgatgaaa agtactggag agaccagaa gtgttccatc ctgagcgatt 1320
tctggacagc agtggatatt ttgccaagaa ggaagctttg gttccttttt ccctaggaag 1380
aagacattgt cttggagaac acttggtctg gatggaaatg ttcttgtttt ttacagcatt 1440
gcttcagagg ttctatttgc attttccaca tgaactagtt ccagatctga agcccagggt 1500
aggcatgaca ttgcagcccc aaccctacct catctgtgct gaaagacgct gaaactgcct 1560
gggatgtttt cgggaacaag aatgtatatt tgccttatcc ctgaacttgg tttaatcaaa 1620
tcaatgtgtg tattagaata aaagtcacag cat 1653

```

<210> 39

<211> 683

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5872615CB1

<400> 39

```

cgcgcgaccc cggactccac ggaggccgcg gcgagcaggg ggagctgcgg gtcgggacgc 60
tctgcgtggg gcggggcgca agggaggttt cgagcccgga aggtccggcg cccagagcta 120
acgggagtc cagggttaaac actttaagat gagaaaaatt gatctctgtc tgagctctga 180
aggggtccgaa gtgatttttag ctacatcaag tgatgaaaaa caccacactg aaaatatcat 240
tgatgggaat ccagaaacgt tttggaccac cacaggaatg tttcccaggg aattcattat 300
ttgtttccac aaacatgtaa ggattgaaag gcttgtaatc caaagtactt ttgtacagac 360
cttgaagatt gaaaaaagca cgtctaaaga gccagttgat tttgagcaat ggattgaaaa 420
agatttggtg cacacagagg ggcagcttca aaatgaagaa attgtggcac atgatggctc 480
cgctacttac ttgagattca ttattgtatc agcctttgat cattttgcat ctgtgcatag 540
cgtttctgca gaaggaacag tagtctcaaa tctttcctca taatgataac aaaatgctct 600
tgcatgattt ttttaacaata tatttaaaac ggaagttgtc actgatatac tttattaaaa 660
ggatttttat caaaaaaaaaaaa aaa 683

```

<210> 40

<211> 657

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2657543CB1

<400> 40

```

atgctatcca cttttgccag gcagaatgac atcccttttc agctgcagac agtggagttg 60

```

```

gcttggggggg agcacctgaa gcctgagttc ctgaagggtga accccctggg gaaggtgcct 120
gccctcagag atggcgactt cctactagca gagaggctgg agaaaagatc tctgacacc 180
cctgcccaca gcatggctcat cgttttatac ctgagtcgaa agtaccagat acggggacac 240
tggtacccac ctgagctgca agcccgacac tgcgtggatg agtacttggc gtggaagcat 300
gtcaccatcc agctgcctgc caccaatgtc tacctgtgca agcctgcaga tgctgcacag 360
ctggagcggc tggtggggag gctgacgcca gcctgcagc acctggatgg gggggtcctg 420
gtggccaggc ccttcctggc aatggagcag atctccctgg aagacttggg gctgacggag 480
gtgatgcagg tgaagctttc ctaccacact gccctcgggg ggactctggg catggggctg 540
agccccaacc ccagctgccc tgtcttccca gccactgcc gttggctgcg acctcttcca 600
agactggccc tggtggcag tgtgacaggc ccatatgaag gctgcccttg gtactga 657

```

<210> 41

<211> 1122

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3041639CB1

<400> 41

```

tggatctgcg ggaatgtggg ctggagaggt cctgccgtgg taccagcctc cagcctgccc 60
ccaggactgc ccctgaccca ggcgcgcccc ctgctcgggt gcaggagggc cggcggagcg 120
ccatggcctg catcctgaag agaaagtctg tgattgctgt gagcttcata gcagcgttcc 180
tttctctgct ggttgtgcgt cttgtaaatg aagtgaattt cccattgcta ctaaactgct 240
ttggacaacc tggtaaaag ttgataccat tctcctacac atacaggcgg ccccttcgaa 300
ctcactatgg atacataaat gtgaagacac aagagccttt gcaactggac tgtgaccttt 360
gtgccatagt gtcaaactca ggtcagatgg ttggccagaa ggtgggaaat gagatagatc 420
gatcctcctg catttggaga atgaacaatg cccccaccaa aggttatgaa gaagatgtcg 480
gccgcatgac catgattcga gttgtgtccc ataccagcgt tcctcttttg ctaaaaaacc 540
ctgattatct tttcaaggaa gcgaatacta ctatttatgt tatttgggga cctttccgca 600
atatgaggaa agatggcaat ggcacgtttt acaacatgtt gaaaaagaca gttggtatct 660
atccgaatgc ccaaatatac gtgaccacag agaagcgcgt gagttactgt gatggagttt 720
ttaagaagga aactgggaag gacagtacag agtgaccatg cagtgttgat tgatcgaaca 780
gcaaccacca catacatgtc ctgccccacc acaaaaggaa ggaaggaata aaagaaagaa 840
agaaagaaac aaacaaacaa acaaaacaaa ctaagcaaga caaaacaaat acctatgtca 900
gtggttcaaa gattaagatt gtggctttgt gtaaagtctt ttccctttgt agacttgcgt 960
cataattatt caggtatgat gggtacagtt tttaaaaagg aagggaattt gtggtatgtg 1020
gtatgtaaat attttttaaat gttgtctctc tgttttgatc agtttttgtt ttattcaatt 1080
tgtctttatt aaatcttatc caagccaaaa aaaaaaaaaa ag 1122

```

<210> 42

<211> 2982

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3595451CB1

<400> 42

```

agccgggtacc ggcgggcag aggcgcccga ggatgtgctg ctggccgctg ctctgctgt 60
gggggctgct ccccgggacg gcggcggggg gctcggggcg aacctatccg caccggaccc 120
tcctggactc ggagggcaag tactggctgg gctggagcca gcggggcagc cagatcgct 180
tcgcctcca ggtgcgcact gcaggctacg tgggcttcgg ctctcgccc accggggcca 240
tggcgtccgc cgacatcgct gtgggcgggg tggccacagg gcggccctac ctccaggatt 300
attttacaaa tgcaaataga gagttgaaaa aagatgctca gcaagattac catctagaat 360
atgccatgga aaatagcaca cacacaataa ttgaatttac cagagagctg catacatgtg 420
acataaatga caagagtata acggatagca ctgtgagagt gatctggggc taccaccatg 480
aagatgcagg agaagctggt cccaagtacc atgactccaa taggggcacc aagagtttgc 540
ggttattgaa tcctgagaaa actagtgtgc tatctacagc cttaccatac tttgatctgg 600
taaatcagga cgtcccccac ccaaacaagg atacaacata ttggtgccaa atgtttaaga 660
ttcctgtgtt ccaagaaaag catcatgtaa taaaggttga gccagtgata cagagaggcc 720
atgagagtct ggtgcaccac atcctgctct atcagtgcag caacaacttt aacgacagcg 780

```

ttctggagtc	cggccacgag	tgctatcacc	ccaacatgcc	cgatgcattc	ctcacctgtg	840
aaactgtgat	ttttgcctgg	gctattgggtg	gagagggcct	ttcttatcca	cctcatgttg	900
gattatccct	tggcactcca	ttagatccgc	attatgtgct	cctagaagtc	cattatgata	960
atcccactta	tgaggaaggc	taaatagata	attctggact	gagggtattt	tacacaatgg	1020
atataaggaa	atatgatgct	ggggtgattg	aggctggcct	ctgggtgagc	ctcttcata	1080
ccatccctcc	agggatgcct	gagttccagt	ctgagggcca	ctgcactttg	gagtgccctg	1140
aagaggctct	ggaagccgaa	aagccaagtg	gaattcatgt	gtttgtgtgt	cttctccatg	1200
ctcacctggc	tggcagaggc	atcaggctgc	gtcattttcg	aaaagggag	gaaatgaaat	1260
tacttgccta	tgatgatgat	tttgacttca	atttccagga	gtttcagtat	ctaaaggag	1320
aacaaacaat	cttaccagga	gataacctaa	ttactgagtg	tgcgtacaac	acgaaagata	1380
gagctgagat	gacttgggga	ggactaagca	ccaggagtg	aatgtgtctc	tcataccttc	1440
tttattacc	aagaattaat	cttactcgat	gtgcaagtat	tccagacatt	atggaacaa	1500
ttcagttcat	tggggttaag	gagatctaca	gaccagtcac	gacctggcct	ttcattatca	1560
aaagtcccaa	gcaatataaa	aacctttctt	tcattggatgc	tatgaataag	tttaaattgga	1620
ctaaaaagga	aggtctctcc	ttcaacaagc	tggtcctcag	cctgccagtg	aatgtgagat	1680
gttccaagac	agacaatgct	gagtggctga	ttcaaggaa	gacagcatta	cctccagata	1740
tagaaagacc	ctataaagca	gaacctttgg	tgtgtggcac	gtcttcttcc	tcttccctgc	1800
acagagattt	ctccatcaac	ttgcttggtt	gccttctgct	actcagctgc	acgtgagca	1860
ccaagagctt	gtgatcaaaa	ttctgttgga	cttgacaatg	ttttctatga	tctgaacctg	1920
tcatttgaag	tacagggttaa	agactgtgtc	cactttgggc	atgaagagtg	tgagactttt	1980
tcttccccat	tttccctccc	tcttttttcc	tttccatggt	acatgagaga	catcaatcag	2040
gttctcttct	ctttcttaga	aatatctgat	gttatatata	catggtcaat	aaaataaaac	2100
tggtcctgact	taagataacc	attttaaaaa	attgggctgt	catgtgggaa	taaaagaatt	2160
ctttctttcc	tactacattc	tggttttattt	aaatactcat	tgttgctatt	tcactttttg	2220
acttgacttt	tatatcttct	taaaaaattc	cttcttttta	aaaaatataa	aagggtactac	2280
tggtcattcc	agttttcttc	ttctttgttg	ttcttctagt	gtgacttttc	aagtgtaca	2340
gccattcttc	ctgactttaa	tattgtccag	ttctggtctt	ttctgtgaat	taccactggg	2400
ccccttacct	caatgctttt	tggtgatgcc	cactctgggt	cccttgttta	tctgagtctg	2460
ttggtacccc	aaatgacccc	acaccatct	taaagtactt	ttttcacct	tccctgttta	2520
gtactggcca	gatgagtttt	ttctagagct	ctgtcactat	ctgaaaagaa	agaggctatg	2580
ggaaacatag	aaatgggtatg	tattaataac	tgatcatagg	ctgaggagaa	aaaatgtagc	2640
tggtctgaaa	cccagtgctg	tgaggtgact	tatatgaggt	tccagatcaa	agacaggccg	2700
tgtagagccag	tccaggaggg	tgtaagttct	gaatggttcc	ttgctgactt	tggtgtacac	2760
atgtaccaca	tactggctca	gtttaagtca	tggttctatt	gtagatttat	ttttatatta	2820
gttaataaat	gacttttaaat	tgacccaat	tgaatatctt	gtcactcttt	tggttttctt	2880
tatatagctc	agccaaatct	tgttttatgt	cctgtcctca	tctcttaagc	taaatctgtt	2940
tggtatcatat	taataaacta	aatgaaatta	aaaaaaaaaa	aa		2982

<210> 43

<211> 3517

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4169101CB1

<400> 43

tggtccactat	tacggcgag	tggtgctggaa	aggcggggct	caggctcctt	gcagattcct	60
aaccagcata	atgctggagc	cgggagccac	caacctgcag	ttttcagaat	ggccgtgttg	120
gacactgatt	tggtacacat	tcttccatct	tctgttcttc	ctccattctg	ggctaagtta	180
gtagtgggat	cggttgccat	tggtgtgttt	gcacgcagct	atgatggaga	ctttgtcttt	240
gatgactcag	aagctattgt	taacaataag	gacctccaag	cagaaacgcc	cctggggggac	300
ctgtggcatc	atgacttctg	gggcagtaga	ctgagcagca	acaccagcca	caagtcctac	360
cggcctctca	ccgtcctgac	tttcaggatt	aactactacc	tctcgggagg	cttccacccc	420
gtgggctttc	acgtgggtcaa	catcctcctg	cacagtggca	tctctgtctt	catggtggac	480
gtcttctcgg	ttctgtttgg	cggcctgcag	tacaccagta	aaggccggag	gctgcacctc	540
gccccagggg	cgtccctgct	ggccgcgctg	ctgtttgctg	tccatcctgt	gcacaccgag	600
tggtgtgctg	gtgtgtgctg	ccgtgcagac	ctcctgtgtg	ccctgttctt	cttgttatct	660
ttccttggtc	actgtaaagc	atthagagaa	agtaacaagg	agggagcgca	ttcttccacc	720
ttctgggtgc	tgctgagtat	ctttctggga	gcagtggcca	tgctgtgcaa	agagcaaggg	780
atcactgtgc	tggttttaaa	tgcggtatct	gacatcttgg	tgataggcaa	attcaatgtt	840
ctggaaattg	tccagaaggt	actacataag	gacaagtcac	tagagaatct	cggcatgtct	900
aggaaacgggg	gcctcctctt	cagaatgacc	ctgctcacct	ctggaggggc	tggtgtgtct	960

tacgtgcgct	ggagatcat	gggcacgggc	ccgcccgcct	tcaccgaggt	ggacaacccg	1020
gcctcctttg	ctgacagcat	gctgggtgagg	gccgtaaact	acaattacta	ctattcattg	1080
aatgcctggc	tgctgctgtg	tccctgggtg	ctgtgttttg	attggtcaat	gggctgcac	1140
cccctcatta	agtccatcag	cgactggagg	gtaattgcac	ttgcagcact	ctggttctgc	1200
ctaattggcc	tgatatgcc	agccctgtgc	tctgaagacg	gccacaagag	aaggatcctt	1260
actctggggc	tgggatttct	cgttatccca	tttctccccg	cgagtaacct	gttcttccga	1320
gtgggcttcg	tggtcgcgga	gcgtgtcctc	tacctcccca	gcattgggta	ctgtgtgctg	1380
ctgacttttg	gattcggagc	cctgagcaaa	cataccaaga	aaaagaaact	cattgccgct	1440
gtcgtgctgg	gaatcttatt	catcaacacg	ctgagatgtg	tgctgcgcag	cggcgagtgg	1500
cggagtggag	aacagctttt	cagaagtgtc	ctgtctgtgt	gtcccccaa	tgctaagggt	1560
cactacaaca	ttggcaaaaa	cctggctgat	aaaggcaacc	agacagctgc	catcagatac	1620
taccgggaag	ctgtaagatt	aaatcccaag	tatgttcatg	ccatgaataa	tcttggaaat	1680
atcttaaaag	aaaggaatga	gctacaggaa	gctgaggagc	tgctgtcttt	ggctgttcaa	1740
atacagcag	actttgccgc	tgctgggatg	aatctaggca	tagtgcagaa	tagcctgaaa	1800
cggtttgaag	cagcagagca	aagttaccgg	acagcaatta	aacacagaag	gaaataccca	1860
gactgttact	acaacctcgg	gcgtctgtat	gcagatctca	atcgccacgt	ggatgccttg	1920
aatgcgtgga	gaaatgccac	ctgtctgaaa	ccagagcaca	gcctggcctg	gaacaacatg	1980
attatactcc	tcgacaatac	aggtaattta	gccccagctg	aagcagttgg	aagagaggca	2040
ctgtacattt	tcctaatga	tcactctctc	atgttctcgt	tggtcaaacgt	gctggggaaa	2100
tcccagaaat	acaaggaatc	tgaagcttta	ttcctcaagg	caattaaagc	aatcccaaat	2160
gctgcaagtt	accatggtaa	tttggctgtg	ctttatcatc	gttggggaca	tctagacttg	2220
gccaagaaac	actatgaaat	ctccttgacg	cttgacccca	cggcatcagg	aactaaggag	2280
aattacggtc	tgctgagaag	aaagctagaa	ctaatagcaa	agaaagctgt	ctgatcctgt	2340
ttccttcatg	ttttgagttt	gagtgtgtgt	gtgcatgagg	catatcatta	atagtatgtg	2400
gtttacattt	accattttaa	agtcttagac	atgttatttt	actgattttt	ttctatgaaa	2460
acaaagacat	gcaaaaagat	tatagcacca	gcaatatact	cttgaatgcg	tgatatgatt	2520
tttcattgaa	attgtatttt	ttcagacaac	tcaaatagt	ttctaaaatt	ccaaaaatgt	2580
cttttttaat	taaacagaaa	aagagaaaaa	attatcttga	gcaactttta	gtagaattga	2640
gcttacattt	gggatctgag	ccttgtcgtg	tatggactag	cactattaaa	cttcaattat	2700
gaccaagaaa	ggatacactg	gccccataca	tttgtataaa	tattgaacat	gtctatata	2760
tagcattttt	atttaatgac	aaagcaaat	aagttttttt	atctcttttt	tttaaaacaa	2820
catactgtga	actttgtgag	gaaatatttt	tttgtatttt	tatgttttga	atagggcaaa	2880
taatcgaaat	aggaatggaa	gttttaacat	agtatatcta	tatgcttttc	cccataggaa	2940
gaaattgact	cttgacgttt	ttggatgctc	tgacttgtgc	aattttcaata	cacaggagat	3000
tatgtaatgt	aatatttttt	ataagcgggt	actatcaatt	gaaagttaa	gccatgcttt	3060
aggcaagacc	agcgacgctc	acatctttat	ttttgttaca	tccaagggtga	agagggcaac	3120
acatctgtgt	aagctgcttt	ttagtgtgtt	tatctgaagg	cgtttttcca	ttttgcttaa	3180
tgtaactaca	gacattatcc	agaaaatgca	aaattttcta	tcaaattggag	ccacattcgg	3240
ggaattcgtg	gtatttttaa	gaattgagtt	gttctgtctg	ttttttattt	gatccaaaca	3300
atgttttgtt	ttgttcttct	ctgtatgctg	ttgacctaat	gatttatgca	atctctgtaa	3360
tttcttatgc	agtaaaatta	ctacacaaac	tagcatgaaa	atgtcatatt	gccttcttaa	3420
tcaattattt	tcaagtagtg	aactttgtat	cctcctttac	cttaaaatga	aatcaaaactg	3480
accaaatacat	catttatgtg	gcttctgtgt	gacttgg			3517

<210> 44

<211> 2339

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2925182CB1

<400> 44

ggcagccgcg	ggagcacggc	gacgccagcg	gggtgaaggg	aaaaggccga	ggcatcagcg	60
tgtgaagacc	gcaaagacga	tcccaggtac	agttgtgaac	agcattgctg	ctaggctcct	120
cctgcagatc	atctgaaatg	aacctctctt	attgattttt	attggcctag	agccaggagt	180
actgcattca	gttgactttc	agggtaaaaa	gaaaacagtc	ctgggtgttg	tcatcataaa	240
catatggacc	agtgtgatgg	tgaaatgaga	tgaggctccg	caatggaact	gtagccactg	300
ctttagcatt	tatcacttcc	ttccttactt	tgtcttggtg	tactacatgg	caaaaaggga	360
aagaaaaact	gattgcttat	caacgagaat	tccttgcctt	gaaagaacgt	cttcgaatag	420
ctgaacacag	aatctcacag	cgctcttctg	aattaaatag	gattgtgcaa	cagttcaagc	480
gtgtaggagc	agaaacaaat	ggaagtaagg	atgcgttgaa	taagttttca	gataataccc	540
taaagctgtt	aaaggagtta	acaagcaaaa	aatctcttca	agtgccaaat	atttatttatc	600

```

atttgccctca tttattgaaa aatgaaggaa gtcttcaacc tgctgtacag attggcaacg 660
gaagaacagg agtttcaata gtcattgggca tccccacagt gaagagagaa gttaaatctt 720
acctcataga aactcttcat tcccttattg ataacctgta tcctgaagag aagttggact 780
gtgttatagt agtcttcata ggagagacag atattgatta tgtacatggg gttgttagcca 840
acctggagaa agaattttct aaagaaatca gttctggctt ggtggaagtc atatcacccc 900
ctgaaagcta ttatcctgac ttgacaaacc taaaggagac atttgagagac tccaaagaaa 960
gagtaagatg gagaacaaag caaacctag attactgttt tctaattgat tatgctcaag 1020
aaaagggcat atattacatt cagcttgaag atgataattat tgtcaaacaa aattatttta 1080
ataccataaa aaattttgca cttcaacttt cttctgagga atggatgatt ctagagtttt 1140
cccagctggg cttcattggg aaaatgtttc aagcgccgga tcttactctg attgtagaat 1200
tcataattcat gttttacaag gagaaacca ttgattggct cctggaccat attctctggg 1260
tgaaagtctg caaccttgaa aaagatgcaa aacattgtga tagacagaaa gcaaactctg 1320
gaattcgctt cagaccttcc cttttccaac atgttggctt gcactcatca ctatcaggaa 1380
aaatcaaaaa actcacggat aaagattata tgaaaccatt acttcttaaa atccatgtaa 1440
acccacctgc ggaggatatc acttccctga aggtctacca agggcatacg ctggagaaaa 1500
cttaccatggg agaggatttc ttctgggcta tcacaccgat agctggagac tacatcttgt 1560
ttaaatTTGA taaaccagtc aatgtagaaa gttatttggt ccatagcggc aaccaagaac 1620
atcctggaga tattctgcta aacacaactg tggaagtttt gccttttaag agtgaagggt 1680
tggaataaag caaagaaacc aaagacaaac gattagaaga tggctatttc agaataggaa 1740
aatttgagaa tgggtgttga gaaggatgg tggatccaag tctcaatccc atttcagcct 1800
ttcgactttc agttattcag aattctgctg tttgggccat tcttaattgag attcatatta 1860
aaaaagccac caactgatca tctgagaac caacacattt tttctgtga atttgTTAAT 1920
taaagatagt taagcatgta tctttttttt atttctactt gaacactacc tcttgtgaag 1980
tctactgtag ataagacgat tgtcgtttcc acttggaaa gtaatctccc ataataattg 2040
tatttgtttg aaactaagct gtcctcagat ttttaactga ctcaaacatt tttcaattat 2100
gacagcctgt taatatgact tgtactattt tgggtattat actaataaca taagagtgtg 2160
acatatgttt acattcttta aatttgagaa aaactaatgt tacatacatt ttatgaaggg 2220
gggtactttt gagattcact tattttacta ttatagacc tcttttatag attatcaggg 2280
attatatata taaatatata aatatacata aaaatgttat ggattaattt attagaaca 2339

```

<210> 45

<211> 1955

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3271838CB1

<400> 45

```

gccccagaag cccacagcag atggcggcaa tggcgggtggc gctgcgggga ttaggagggc 60
gcttccgggtg gcggacgcag gccgtggcgg gcgggggtgcg gggcgcgcg cggggcgcg 120
cagcagggtca gcgggactat gatctcctgg tggctggcgg gggatctggt ggcctggctt 180
gtgccaagga gccggtcag ctgggaagga aggtgtccgt ggtggactac gtggaacctt 240
ctccccaagg caccgggtgg ggcttggcg gcacctgcgt caacgtgggc tgcattccca 300
agaagctgat gcaccaggcg gcaactgtgg gaggcctgat ccaagatgcc cccaactatg 360
gctgggaggt gccccagccc gtgccgcag actggaggaa gatggcagaa gctgttcaaa 420
atcacgtgaa atccttgaac tggggccacc gtgtccagct tcaggacaga aaagtcaagt 480
actttaacat caaagccagc tttgttgac agcacacggt ttgcccgtt gccaaagggt 540
ggaaagagat tctgctgtca gccgatcaca tcatattgc tactggaggg cggccgagat 600
acccacgcga catcgaaggt gccttggaa atggaatcac aagtgtgac atcttctggc 660
tgaaggaatc ccctggaaaa acgttgggtg tccgggccag ctatgtggcc ctggagtgtg 720
ctggcttccct caccgggatt ggctggaca ccaccatcat gatgcgcagc atccccctcc 780
gcggcttctga ccagcaaatg tcctccatgg tcataagaca catggcatct catggcacc 840
ggttcctgag gggtgtgccc ccctcggggg tcaggaggct ccctgatggc cagctgcagg 900
tcacctggga ggaccgcacc accggcaagg aggacacggg caccttggac accgtcctgt 960
gggcataggt tcgagtccca gacaccagaa gtctgaattt ggagaaggct ggggtagata 1020
ctagccccga cactcagaag atcctgggtg actccgggga agccacctct gtgccccaca 1080
tctacgccat tgggtgacgtg gtggaggggc ggctgagct gacaccaca gcgatcatgg 1140
ccgggagggt cctggtgcag cggtctcttc gcgggtcctc agatctgatg gactacgaca 1200
atgttcccac agcgtcttc accccgctgg agtatggctg tgtggggctg tccgaggagg 1260
aggcagtggt tccgacggg caggagcatg ttgaggtcta tcacgccat tataaaccac 1320
tggagtccac ggtggctgga cgagatgcat ccagtggtta tgtaaagatg gtgtgcctga 1380
gggagcccc acagctgggt ctgggcctgc atttccctgg cccaacgca ggcgaagtta 1440

```

```

ctcaaggatt tgcctctggg atcaagtgtg gggcttcccta tgcgcagggtg atgcggaccg 1500
tgggtatcca tcccacatgc tctgaggagg tagtcaagct gcgcacatctcc aagcgtctcag 1560
gcctggaccc cacggtgaca ggctgctgag ggtaagcgcc atccctgcag gccagggcac 1620
acggtgcgcc cgccgccagc tcctcgaggg ccagaccagc gatggctgca ggccagggtt 1680
ggggggcctc aacctctctc tggagcgcct gtgagatggc cagcgtggag cgcaagtgtc 1740
ggacaggtgg ccggtgtgcc ccacagggat ggctcagggg actgtccacc tcaccctgc 1800
acctctcagc ctctgccgcc gggcaccccc ccddaggctc ctggtgccag atgatgacga 1860
cctgggtgga aacctaccct gtgggcaccc atgtccgagc cccctggcat ttctgcaatg 1920
caaataaaga gggctactttt tctgaaaata aaaaa 1955

```

<210> 46

<211> 2065

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3292871CB1

<400> 46

```

ctaggcccta cttcgcagtt cttgtgcacg ctatgaaaaa taaaacctgc gtgctcgtct 60
gtgtgagtgt gtttgggtggg gagagggggc aggtgactgt accccgggtt ggggtccgcc 120
gccccctcct cgcgggccct ctgcagaagt gcaccctgag agagaccggg gtgtggctcc 180
cgcaggggtc tggcttccag tcgtcgcgga gggagaagta tggcaacgtg ttcaagacgc 240
atthgttggg gcgccgctg atacgcgtga ccggcgcgga gaacgtgcgc aagatcctca 300
tgggcgagca ccacctcgtg agcacccagt ggcctcgcag caccgcgatg ttgtggggc 360
ccaacacggg gtccaattcc attggcgaca tccaccgcaa caagcgcaag gtcttctcca 420
agatcttcag ccacgagggc ctggagagtt acctgcccaa gatccagctg gtgatccagg 480
acacactgcg cgctggagc agccaccccg agggcatcaa cgtgtaccag gaggcgaga 540
agctgacctt ccgcatggcc atccgggtgc tgcagggtt cagcatccct gaggaggacc 600
ttgggcacct ctttgaggtc taccagcagt ttgtggacaa tgtcttctcc ctgcctgtcg 660
acctgcctt cagtggctac cggcggggca ttcaggctcg gcagatcctg cagaaggggc 720
tggagaaggc catccgggag aagctgcagt gcacacaggg caaggactac ttggacggcc 780
tggacctcct cattgagagc agcaaggagc acgggaagga gatgaccatg caggagctga 840
aggacgggac cctggagctg atctttgcgg cctatgccac cagggccagc gccagcacct 900
cactcatcat gcagctgctg aagcacccca ctgtgctgga gaagctgcgc gatgagctgc 960
gggctcatgg catcctgcac agtggcggct gcccctgcga gggcacactg cgcctggaca 1020
cgctcagtg gctgcgtac ctggactgcg tcatcaagga ggtcatgcgc ctgttcacgc 1080
ccatttccgg cggctaccgc actgtgctgc agaccttcca gcttgatggg ttccagatcc 1140
ccaaaggctg gagtgtcatg tatagcatcc gggacaccca tgacacagcg cccgtgttca 1200
aagacgtgaa cgtgttcgac cccgatcgct tcagccaggc gcggagcgag gacaaggatg 1260
gccgcttcca ttacctcccg ttccgtggcg gtgtccggac ctgcctgggc aagcacctg 1320
ccaagctgtt cctgaagggt ctggcggtgg agctggctag caccagccgc tttgagctgg 1380
ccacacggac cttccccgc atcaccttg tccccgtcct gcaccccggt gatggcctca 1440
gcgtcaagtt ctttggcctg gactccaacc agaacgagat cctgccggag acggaggcca 1500
tgctgagcgc cacagtctaa cccaagacc accgcctca gccagccca ggcagcggg 1560
tgggtcttgt gggaggtaga aacctgtgtg tgggaggggg ccggaacggg gagggcgagt 1620
ggcccccata cttgccctcc cttgtctccc cttcctggca aacctaccc aaagccagt 1680
ggccccatcc ctagggtgg gctccccttc tggctccagc ttcctccag cactcccca 1740
tttaccatca gctcagcccc tgggaagggc gtggcagggg ctctgcatgc ccgtgacagt 1800
gttaggtgtc agcgcgtgct acagtgtttt tgtgatgttc tgaactgtc ccttccctcc 1860
gttcctttcg gacctttta gctggggttg ggggacggga agagccgtgc ccccttgggc 1920
gcactcttca gcgtctctc ctcctgcgcc cccactgcgt ctgccagga acagcctcc 1980
gggtagcaga acaggagtca accttggcgg ggcgggggct gcgtccaacc tggagattgc 2040
ccttccctat gccacggttc ccacc 2065

```

<210> 47

<211> 866

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4109179CB1

<400> 47

```

ttcaaaagag gtttctgggtc actcctaate atcgcagcat aactctgctt ttttaagctat 60
tggtttctgc atttgtaggg gcacgataca actgcagctg caataaactg gtccttatac 120
ctgttgggtt ctaaccacaga agtccagaaa aaagtggatc atgaattgga tgacgtgttt 180
gggaagtctg accgtcccgc tacagtagaa gacctgaaga aacttcggta tctggaatgt 240
gttattaagg agacccttcg ccttttccct tctgttcctt tatttgcccg tagtgtagt 300
gaagattgtg aagtggcagg ttacagagtt ctaaaaggca ctgaagccgt catcattccc 360
tatgcattgc acagagatcc gagatacttc cccaaccccg aggagttcca gcctgagcgg 420
ttcttccccg agaatgcaca agggcgccat ccatatgcct acgtgccctt ctctgctggc 480
cccaggaact gtataggtca aaagtttgct gtgatggaag aaaagaccat tctttcgtgc 540
atcctgaggg acttttggat agaatccaac cagaaaagag aagagcttgg tctagaagga 600
cagttgattc ttctgtccaag taatggcatc tggatcaagt tgaagaggag aaatgcagat 660
gaacgctaac tatattattg ggttgtgcct ttatcatgag aaaggtcttt attttaagag 720
atccttgtca tttacaattt acagatcatg agttcaatat gcttgaatcc cctagaccta 780
atctttccct gatccactg atcttgacat caagtctaac aaagaaaaag ttttgagttt 840
tgtattttct tttttctttt ttcttt 866

```

<210> 48

<211> 1593

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4780365CB1

<400> 48

```

ttacggcgca gtgtgctgga cagcgggtctc ccagggaagg ggggtgctgag tgggaaggagg 60
tcaatgggaa gccgggggtg ctctcagagt cggcaggagc agtcgggctg atgagctggg 120
aggagcagac gcctccctc ttctctgagt gggaggaggg ccagatctgg actgggtttg 180
gagatgctca ggtggggctc agagcatcac ctgtggggca gagggacctt cttggcagat 240
gaaggcccg cgcagggtgt gatgcctgaa ttacaaggcg ggacaggtaa agtggggcag 300
gtgagagaag gaggggtgagt gatgtgattt ttctactcct gttttccagg aaaaccacaa 360
tgccacgcac ttgcacctat gatccttttc ctaataatgc ttgtcttggg cttgtttggg 420
tacgggggtcc taagcccag aagtctaagt ccagggaaggc tggaacgggg gttctgcatg 480
gctgttaggg aacctgacca tctgcagcgc gtctcggttg caaggatggg ctacccccag 540
ccaaagggtg tgacaccgtg taggaaggat gtctctgttg tgacccttg gctggctccc 600
attgtctggg agggcacatt caacatcgac atcctcaacg agcagttcag gctccagaac 660
accaccattg ggttaactgt gtttgccatc aagaaatacg tggctttcct gaagctgttc 720
ctggagacgg cggagaagca ctctcatggt ggcaccgtg tccactacta tgtcttcacc 780
gaccagccgg ccgcggtgcc ccgctgacg ctgggggacc gtcggcagct gtcagtgtcg 840
gaggtgcgcg cctacaagcg ctggcaggac gtgtccatgc gccgcattga gatgatcagt 900
gacttctgcg agcggcgctt cctcagcgag gtggattacc tgggtgtcgt ggacgtggac 960
atggagttcc gcgaccacgt gggcggtggg atcctgactc cgctgttcgg caccctgcac 1020
cccggcttct acggaagcag ccgggaggcc ttacactacg agcgccggcc ccagtcaccg 1080
gcctacatcc ccaaggacga gggcgatttc tactacttgg ggggggttct cgggggtctg 1140
gtgcaagagg tgcagcggct caccagggcc tggccaccag ccatgatggt cgaccaggcc 1200
aacggcatcg aggcctgtg gcacgacgag agccacctga acaagtacct gctgcgccac 1260
aaaccaccca aggtgctctc ccccgagtac ttgtgggacc agcagctgct gggctggccc 1320
gccgtcctga ggaagctgag gttcactgcg gtgcccaga accaccaggc ggtccggaac 1380
ccgtgagcgg ctgccagggg ctctgggagg gctgccggca gcccgtccc cctcccggcc 1440
ttggttttag cagaacgggt aaactctgtt tcctttgtcc gtcctgttgt gagtaactga 1500
agcctaggcc ccgtccccc ctcaaatac acacaccccc tccccaccac agagacacca 1560
ttacatacac agacacacac agaaagacac aca 1593

```

THIS PAGE BLANK (USPTO)

Table 1

AATGATAGGTTTTTTTTATATAGTTGGAGGGCAGGGATAGTGTAAAGGTTTATGATG
TATAAGCACGCTTAGACACACCAGGAGAAAGTATCAGATCTCATTACACATGGTTGTGAG
CCACCATGTGGTTGCTGGGATTTGAACTCGGGACCTCTGGAAGAGCAGTCAGTGCCTTA
TCCACTGAGCCATCTCTATAGCACTTTAAAAAATATTAAGGCATCATACAGCNTTTCT
GCCTCTATGTATGCCCTGCA

Sequence 1104

CGGGCAGGTCCTTGTCTCTCAAACCTTTTATACTGTCATAGTTCATTTTTCTGTACAGAT
GCTCTTTCAACTTTTTTTGAGAGTATATACATAACAATTGCAGTTGAAAGTAGGGTGGGG
TTTAGTCTCCTGGTCACAGTTCAATAAGTACGGACGCGTGGGTGACTCAAGCTAGCTTG
TACACCTN

Sequence 1105

TCGACTNCTATAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACACTTATAGTT
GAGAGCCAAGTCTCCCTTATCATTGGTGAATGAGGATGAGCTACTGAAAACAAAAGAGG
GTCTTCTACTCAGCCTCTACCCCTAATTTTATATCAGAAGCAGAGATTAAGTGTCTTA
CTCATTACACGTTAATGGAAGAGAAGGAAGTTTCCTAGAAAAATCCTCCCGCTCCACCC
TGCAAACTTTATGCTTTTCTGTTACATAATCAGGCAGGGGCAAGACCTAACTATTTTGA
ATTGGTGGTGTGAGGCTAAATTCTCTGCTATTGACAGAATTGAGAATGTGATCAATTTT
AGAGTAGCCATGTTACAAATTTTGTCCCAATTTCAATGGGGGAGGAATTATAACCAAAATC
AAGTAGTGGTTGGGAAGA

Sequence 1106

CCGGGCAGGTACGCGGGGAGTTCTCTCAGGCTCTCCAGAGCTCAGGACCTCTGAGAAGAA
TGGAGCCCTCCTGGCTTCAGGAACCTCATGGCTCACCCCTTCTTGCTGCTGATCCTCCTCT
GCATGTCTCTGCTGCTGTTTCAGGTAATCAGGTTGTACCT

Sequence 1107

TCACTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTACGCGGGGGTAGAT
GGAAGGAAGAACTCGTGTGCTTAGACCTGACGCTGGGAGGAGATGCTGCCACCTAGGTTA
CTTGTAGGACCCTATACGGCAACCTCCTTTGCCAGGAAGTATTTATAACATCCTGCAGG
AAAATGCAGTAAAGTAGAAGAGACAGGGATATCCAGAAGGTTATGCAAAACATCAAGAG
AAGATGAGAGGAGTCTATATGTCAGAATACACATTTCCACCTTGCCCAACAGTAGAAAA
ACATAAGAAGAGAAAAACATTAATAAATGACAAGGAAGTTAATGGAAGTCAGCAATGTGA
TGGTGTGTTGGGAGGTGGAGCCCTTCAGAAAGGTAATTAATGCCCTTGTAAGAAAGAGGCC
AGNAGAGCTTGCCGCACC

Sequence 1108

GGGCAGGTACTTGTCTGATGGGTCATCCAGAAGAGTTTCATGGAGATCAGTTCACAACA
TTGGACAGACTATGAAACAAAGTCTGTAATATCATTATACTCAGTATTGGTAGGCTTTT
TCCTTAATACCCCACTCCAACAAACAGACCTGCCTTCACTTCTCTTGAAAATATTATT
ACCATCAGTAACTGCTTGTCTACTATGTCTCCAAGGCAAGCCACAGGCTATAAGCCAATT
CTGCAAAAGGGAGCAGCAAAAGAAATGCTTAGTGCAATTCCTCTATTTAAAGTTTGCTT
GAGTTTTGATTATTTTGTATTTTG

Sequence 1109

AGGTCACGCGTCCGACCTAGCTTGAGTCGACCCACGCGTCCGATTTCTGGTTTCTTTGGA
GACTCGGTTGTGCCATGTGATGCTTTTCTGGAACTGTCTTATGAGAGGAAGCTTTTGCT
GAAGCAGACACATGGGAGAATGTTTTGTTAAGAACAGACATGTAGTATTTTCTAGAGGC
AGCTTGAATAAAGAGCATGTGGTATTTTGCTAGAGGGGACACTTGAGAGAACATGTGACA
TTTGGAAGGATATATGTATAACCTAAAAGGACAGTGGCCAATGCTGTGTGGTATTTGGG
TGTGCCTTACCATTCTTTGCTGGC

Sequence 1110

TCGTGATCTAGATCCCTATAGTGAGCGGACGCGTGGGTGACTCAAGCTAGGTCGGACGC
GTGGGTGACTCAAGCTAGGTCGGACGCGTGACCTTCCCCAAAATCTTCTTTTTTCAGA

THIS PAGE BLANK (USPTO)

Table 3

TATTTATAAACATCCTGCAGGAAAAATGAGTCTATATGTCAGAATACACAT
TTCCACCTTGCCCAACAGTAGAAAAACATAAGAAGAGAAAAACATTAAA
AAATGACAAGGAAGTTAATGGAAGTCAGCAATGTGATGGTGTGAGGT
GGAGCCTTCAGAAGGTAATTAATGCCCTTGTAAGAAGAGGCCAGAGAGCT
TGCGCACCTTCTTCCTGCCATGTGAGGAGCCAAGAAGCCGGCTGTCTGCA
ACCTGCAAGAGGACCCTCACTAGAAGCTAGCCATACTGGCATCCTCATCT
TGGCTTTCCAACCTCCAGAAGCTGTGAGAAGTATATGTTTGTGGTITAGTC
AATGGTCTATGGTAATTTTTTATAGCAGTCCCAGCCAAGACAGTGCCTC
ATTTACTACATAACCAATTATATTATATAGGCCTCTTTTCAGAAACCC
ATGTTCAAATAAGAGAATAGATACTGAAACACATAACACCTTCACTAGTT
TTTAGTATACAAATATTGAGAAATAGGTTGTTAATAACTATCTCAATCAA
GAAATGCCGAATCATGGTGGTTCTAATTTTTATATATAAATTGACAAAA
TGGAGAACTTAACACCAATTCTAGATTTAACTGCCCAAAGANAAANNAN
AAANNNAAGGGGGGANGGACCTCGGCCGTTTTTA
>Sequence 3369
CCGGGCAGGTACTTTACTCACCTTCTCTGACAGAAAAGGATGAAGTCA
AGGGCCTGGTAGAGGCCACCACTAAGAAAGGCGTCTGAGAGGACCAAAGAG
AGTGACCAGCAAGCANTTTTITGCAAGGCTGAGGAGCTGACAGCTTCATG
AAAGGCTGGACCCCAAGTGGTGAGAAGCATCATCTGGGTTACCTTGTC
TGCCATAAAACACACCACAGACTTGGTGACTTAAACCACAGATATTTATC
TTCTCACAATCCTGGAGGCTGGAAGTCTGCAATCACGGTGCCAGCATGGT
CAGGTTCTGGTGAGGGCCTCTTCTCTCACTGTGTGCTCTTCTTGTC
CATGGAGAGAGAGCATGAACAAGCCCTCACTGTCCC
>Sequence 3370
AGGTACTTTGCCAAGCAGTAAAGGATCCAGGAGATAGCACTGGATGTGGT
GTCATGTCTGCAAACATGAACGTTTTCACTTCAGCCTGGAGATCTGCTT
CAGAGAAATCTTTGGTGTTCGCTTTTGGCACTCAAAAGTATGTCCAGA
AAATCCCAGCGCCTTTCTGAGTAGTATCTTGTITTAGCTTATCCTTAAG
AGACTCCTTCCGGTCTGGATTACTTTCTCTGTGAACTGATGAAGTTCTT
GGTTAAATTTAGAAAAGATTGGCCTTGAGAGCTGAATTTGAAAACCAGG
TCGTTGTGATGTAGAAAATTGTTTCATGCGCTGGTTGGAGATTTTGCTAAG
GTTGAACACTGCTTTCAGGTATGAGTCCAGGGTACCTGCCCGGGCGGCCG
CTC
>Sequence 3371
CCGGGCAGGTACCTGAGTAGTCTGTAACCAAAATAATTCATTTGGCACAT
TTAAGGCATCTGCCCAATAAAATACCTTGTAATAAATCTTTAGGAATT
ATGAACTACTACAAGGAGAAAAATGACAGAAAGAGCTGACTTGGGGGGA
TGGGAGTTGTTTTAATAACCTTTTACCACCCTAGACTTCTGGCCAATC
AAATTGAATCATACCTTGGGAAGGGAAGTGCCTGATGCAGCAGCTGAGC
CAAAGTCAGCAAAATCCTCCGAATAAATCAGCTGATCCTCCTAGAAGTTAA
GAAAAAGTTAAACTGTTAGAACTAGAGAAAAATTGTAAATAATTTCTGG
AGGCCATTTTAGTGCCACACAAAAAGTACCT
>Sequence 3372
TTCTCTTACTGATAGTAGGATATTTCTGCTTTAGTTATTGTCACCTTAAA
TATATTTTCAATGTTGAAATCCTCACAGCATGTTTGATGAAATCTAGTTT
TCAAATTTTCTTAGGTATATTTCTGTACGTTGGCATGATAACAAATGCA
ATAACCCAAAAGACCCCAAAAGCTAGTGTAATCCCITTTGCAATCCAAGC
ATGAGGATTCATCTTCATGTTGACAGTGCGTGAATGTTCCGTTAGGCTTG
TCAAGCTTGCAATACAATAAATTATATATGTCCCTTTTCTTTAGGGTCTC
CTGTTAAAGATGGTCTTCTGAAGGCTAACTGCGGAATGAAAGTTTCTATT
CCAACTAAAGCCTTAAATTTGATGGACATGCAACTTTCAAAGCAGAGCC
TCCCGAGAAGCC
>Sequence 3373
AGGTACTCACCCAGTTCTGACCTTCTGTCTGCATACTCCTTGCTCA
TAAGGGGTTTGAATATGCACTCCAGCTGAACAGATGAGCCACACTCCTGT
CACATATCCTGCAAGGGGTCAGGGAAGTCTCCCATTTCAAGCATGTGTGA

THIS PAGE BLANK (USPTO)

Table 4

TAAAAAATACATAATAATAAATGAATCTATCTATCAGATCTGTATAAAGA
AATAAATAAGAACTTTAGTCTTTCCCTTTATCCTGCTCTACTAGGAAAAA
TAAAAGTGAGCCAACTTCAATATTAACAATCTCATTAATGGAATATATT
TTAAAAATGAATAATGTAGACATTATTTAACTTTGACTATGGGTCAAC
TGTCTTGGGCGTTTTAACTAGTGGATCCCCCGGCTGGAGATTTAATT
AAGCTTTTGATTCCGGCGACCTGAGG

>Sequence 3476

AGGTGCGCGGGTGTGCTGATGATTGATGTGGTGTGAGAACAAAGAAACAA
CAGAGAGTTTTCCCTACACACAGCCCAAAATACTATCTTAAAAAAATTTT
GAAGACAGGTTAACCAGGTTCTGGCCGCCATCCATGTCCAAAAACAAAC
CAAATGTGTTGCCGTAAAAACATTTGCTCTTGAAAAGTAGTCCCTTAGCC
AGGCGCGGTGGCTCACACCTGCAATCCCAGCATTTGGAAGGCCGACGCAG
GTGGATCATCAGGTCAGGAGATCAAGACCATCCTGGCTAACGCAGTAAAA
TCCCATCTCTACTAAAAATACAAAAAGACTAGCCAGGCGTGGTGACACAC
GCCTGTAGTCCCAGCTACTCGGGAGGCTGACGCAGGAGAATCACTTGAAC
CCTGGAAGTGAGGTTGCACTGAGCGGTGATCGTCCACCGCACTCCAGC
CTGGCAACAGAGCGAGACTCCGTCTCAAAAAAACACCGCACCTAGAAGT
TCCTGCCCG

>Sequence 3477

AGGTACCAAATGCTAGTGAGGATGTGGAGCAACAGGAACTTTCATTTCATT
GATGGTGGGAATGCAAAATGGAAACAGCCACTTTGGAATACAATTTCTTAT
AAAACGAAACATACTCTTTAAAAATAAATATACTCTTATCCTACGATCC
AGCAATCTCAATTTCCATGGTATTTATTCAAAGGAGTTGAAATTTATATC
CACACAAAAATCCACACATGGATGTTTGTGGCAGATTTATTCATAATTCT
AAGAAGTAGAAGCAACCAAGATGTCTTTCTGTAAGTGTCTTAATCCATTC
AACCTGATATACCAATGACAAAACCTCATAGATTGCTGGCATTAAACAA
CATAAATTTATTGCTCACAGTCTGGAGGCTGGAAGTCCAAGATCAAGTC
ATGGCACATTCTGCATCTGGTGAGGGCACTTCTGGTTCATAGATGGCTC
CTTTTGTCTGCATCTAAGTGACGAATCTCTTTCATGAGGTTCCACCCTC
ATGACCTCATCACCTCCCCAAAACCTCCAACCTGGGCAACAGAGCAAGCCT
TTGTCTCGAAAAAATGACAANAAAGGTTCTGCCCCGGGCGG
CCGCTCGATGCCCATTTGATGCCTGGTTTATCACAAAAAAGACCCATGCA
CATCCCACTTTGCTCAGGGGAGGCGTTCCCTAAGCAAGCTGGAAAAATA
GTGAAAACCTGGTTTTTTTTTTTTGGGGGCTTGGTTTTTACCCAAAAAT
TTTTCTAGTATAAATGCCCTTTTTTTGAAA

>Sequence 3478

CGGGCAGGTACTGTCCAACCTGGATGCTGCCCTGGTGGCTGAAGGCACACT
TCATGATGCTGTCCAGGTCATCAGGGAGACATGTTGAAAGAGCTCCAGA
CGTGAGTTTTGGGCAATGTGTTCTCCCATTTGTTTCAGCATCATCCGAAC
ACTCTCAGACATCATGGTGATGAATATTTTCAGAATGCTGATGTTGAAGC
CAGGTTTCACAATCTGGCGGTGCTTTTCCA'TT'AGAACCATCCAGGGTC
ACAAGTCTCGACCAACCCAGGATTCAAGGATTTTGTGGCTAACAGCACT
TTTGGGATCTTGTCTTTTCAGGAGAATCTTGGCATAGTCTGGGTCAATGGA
CACTGAAGAACATCGTAAAGGGTCCAACCCACAAGGGAACAGCACATGGG
TATTTTCCATCAGCTTATGATACACCTCAAACCTCTTTACTGGGTAAAA
CTCCTTGTGGCCATAGAACCAGTGGGCAGGGGGTGCAGGAAACAGGTACA
GGGCTCTGATCATCCATCTTCTCCTCTGGTACCTT

>Sequence 3479

AGGTACCAGAAGGGCTCCCGCTCTCCTCTGCCCAAGAAGTGAGCGGTTCC
TCTGCCAGGACGGGGGGAAGGAGGCCAACCTTGTAGGCTTCGTCAATGTT
GGCATTACACAGTGCTGGATCATCTCCTTTACCAGCAGTGGGTGGGGCT
CGTCACAGACCTGGCCAAAGGGAAAGGAAAGCGGTGAGGGGCTAGAAGG
GACAATGTGAGCGGGGAGGCCCAACAGACCGACTTCCAGGCAATCTATG
GNTAAAACCTTCTCAACCTGTTGTTTTCATCAAATCTTCAGCAACCAGGA
TGAGTNTGGGGAATGCTCCTCTCACCATCAAAGAGAAGTGCTTTCCGGCAC
CAAGAAGATAAATTTTCCAAACTTANTACAGATGAACAAGAAAGCCACCA

THIS PAGE BLANK (USPTO)

Table 4

AGCAGCCTCACGCGGGGCTTTCTGGTCTCGGCCGAGAAAGCGAGATGACG
AAGGGAACGTCATCGTTTGGAAAAGCGTCGCAATAAGACGCACACGTTGTG
CCGCCGCTGTGGCTCTAAGGCCTACCACCTTCATAAGTCGACCTGTGGCA
AATGTGGCTACCCTGCCAAGCGCAAGAGAAAGTATAACTGGAGTGCCAAG
GCTAAAAGACTAAATACCACCGGAAGTGGTGAATGAGGCACCTAAAAAT
TGTATACCGCAAATTCAGGCATGGATTCCGTGAAGGAACAACAACCTAAA
CCCAAGAGGGGAGCTGTTGCAGCATCCAATTCATCTTAAGAATGTCAACG
ATTAGTCATGCAATAAATGTTCTGGTTTTGAAGAAAAAAGCATTTAAAAA
AGGTACCTGCCCC

>Sequence 4134

TCCGCCGCCACACAATTGAGGATGTGTGTATCTATATGAATCTNAATTT
CTATCTCTCACTCACACTATATTGATTGTATATGTGTAGATTGAGAGGAG
AATATTACCCATAAGTGAATGATTCTCTTCCCCCTGCTTGAGAGGAGCCC
GGAGATGAACT

>Sequence 4135

AGGTACCTGAGCATCAGCAGAGATGCCGAGATGAAATCAGGGAACCTCT
AGGGGATGGGTCTTCTATTACCTGGGAACACCTGAGCCAGATGCCTTACA
CCAGATGTGCATCAAGGAATGCCTCCGCCCTCTACGCACCGGTAGTAAAC
ATATCCCGGTTACTCGACAAACCCATTACTTTTCCAGATGGACGCTCCTT
ACCTGCAGGAATAACTGTGTTTATCAATATTTGGGCTCTTACCACAACC
CCTATTTCTGGGAAGACCTCAGGTCTTTAACCCCTTGAGATTCTCCAGG
GAAAAATCTGAAAAAATACATCCCTATGCCTTCATACCAATTCTCAGCTGG
ATTAAGGAAGTGCATTGGGCAGCAATTTTCCATAATTGAGTGTAAAGTG
GCAGTGGCATTAACTCTGCTCCGCTTCAAGCTGGCTCCAGACCACTCAA
GGCCTTCCCAGCCTGTTCTGTCAGTTGTCTCAAAGTCCCAAAATGGAAT
CCAATGTGTTTGCAAAAAAAGTTTGCTAATTTTAAGTCCCTTTCTGTT
AAGAATTAATGAGACCATTTTTCTACCAAGGAGAACCAAAAGGGTAAAT
TTATCCAAATTTTTGTTATGGGTGTTGGCAAATTTTACTTTGGATAC
CTTTGACGGGTTTACATCATTAACCAGAATTTTAAATTTTTTGCTGGT
GGGGAACCCCAAAACCCGAAAAAATAAGAGTGTTTTCTTGGGAGGG
GAAATTG

>Sequence 4136

TCCACCGCGGTGGCGGCCGAGGTACCTGACCAGACACCCAAATGCATG
TCATACTGCACAAATTACACATTGCAAAGTGTGCTCTGCACTGTTATG
GAAAACAATTTGCAGAATACTTCTTTTCCCTTCTGTTGTGCCCAACTCT
TTATTATAGGATAGGGATTTAAGGTCAGGGTTACATGGAAGCAGGGTTCC
CTGGGGTGTGTATCAGCCTGATGCCGCCACCTCAGCTGCCCTCCAC
TTTCATCTCCCATTTCTTTATGAGAGCAGAGAGGAGAAGGGAAGACG
TGGCAGAGGAATAAGCAGAGATGGTTACCCTGAGACAGGACTTTGGTCCA
CATATTTACTTGAGAGGTGATCCCAGGAACCATGGGGACAGTGACACAA
GGAAGACAGGAAGCCAATGAAGGGTATGATGACGAGTGGGTGCCTGGCAG
TGAGTGGACAGGCAAGGCTCAGCCTGCTGGGGCCCCCTGAGAGACTGCAG
AACTTCTCCCAAGATTGTCCCAAGTGAAGAGCAAGGGAGTGGGGTTACTGA
TCCACCAACTTGCCTCTGTTGGTTGAGAGTTGCTTTTAACCCAAGGCATC
AACTCCCTGGTACCTGCCCGGCCGCGCTTTAAACTAAGGGAATCCCC
CGGCTTGAGGAATTCATTTAAAGCTTATTGATCCCGTCCACCTCGAGGG
GGGCCCCGGCCCCAACTTTGTTCCCTTAGGGAGGGGTAATGGGCCCTTG
GGGAAAAATGGGAAAAAATTTTCTGCGG

>Sequence 4137

AGGTACCTTAATACACTCCAAACCTCAGACTGGTGATATTGCATTACTTT
CTATAAGATACACACTTATAATTTGCTTAAAGAAGCATTGCACTTTAA
CCCATTTAATGTAATATATAAGGCAGATGGTCTTGACAACATAATCTT
GGAAGAAAACTGAAAAAATCAATTAGGTGTTTGGCAGCACTCAAAAAACA
GCCTAATAAGCTCATTGCCATGCAAATCACCTACAATGTTAAATATATAA
AACTGCTGTATTAAGCTCGGAGAAGGAGGAAAAATTCCTCTTCACTCATG
TGACCGGAGACTAAAAGGAAGGCTCCAGGGGTGCTGCTGGCTGGGAAGAG

THIS PAGE BLANK (USPTO)